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RYAN MICHAEL WHITAKER, Stimulation of Mitochondrial Biogenesis through Modulation 
of cGMP Promotes Recovery of Mitochondrial and Renal Function Following Acute Kidney 
Injury (under the direction of Dr. Rick Schnellmann, PhD) 
 
 Mitochondrial damage and dysfunction are major pathophysiological mechanisms 
underlying acute kidney injury (AKI).  Following various forms of AKI, mitochondrial 
biogenesis, the de novo generation of new, functional mitochondria, is suppressed.  
Pharmacological stimulation of PPARγ-coactivator-1α (PGC-1α), the master regulator of 
mitochondrial biogenesis, promotes recovery of mitochondrial and renal function after AKI.  The 
primary goals of this project were the evaluation of renal cGMP as a modulator of mitochondrial 
biogenesis in AKI, and the assessment of phosphodiesterase (PDE) inhibitors and guanylyl 
cyclase (GC) activators as novel agents to induce mitochondrial biogenesis and promote renal 
recovery. 
 cGMP has been demonstrated to stimulate mitochondrial biogenesis and function.  Both 
cGMP generation through guanylyl cyclase and degradation through PDEs are highly regulated 
processes.  Compounds that regulate cGMP levels, including the PDE3 inhibitors cilostamide and 
trequinsin, and the PDE5 inhibitor sildenafil, increased mitochondrial gene expression, and 
  
elevated mitochondrial respiration in renal proximal tubule cell (RPTC) cultures.  Furthermore, 
these compounds increased renal cortical mitochondrial gene expression and mtDNA copy 
number in naïve mice.  PDE4 inhibitors, which regulate only cAMP levels had no effect.  
Treatment of mice with sildenafil in a folic acid model of AKI promoted recovery of 
mitochondrial gene expression, increased mtDNA content, and reduced expression of the tubular 
injury marker, kidney injury molecule-1 (KIM-1). 
 An occurrence of AKI is a strong risk factor for the development of chronic kidney 
disease (CKD) and end stage renal disease (ESRD).  Following folic acid-induced AKI, mice 
developed renal fibrosis and early signs of CKD.  These changes were associated with a chronic 
suppression of mitochondrial gene expression and mtDNA copy number.  Treatment of mice with 
trequinsin or sildenafil failed to restore mitochondrial gene expression, and failed to prevent the 
progression of fibrosis.  
 Induction of cGMP through activation of guanylyl cyclase by the compound BAY 58-
2667 increased mitochondrial respiration in RPTC, and additionally, increased mitochondrial 
gene and protein expression, and mtDNA copy number in mouse renal cortex.  Daily treatment of 
mice with BAY 58-2667 beginning 24 h after renal ischemia-reperfusion (I/R) injury promoted 
renal functional and morphological recovery at 144 h after reperfusion.  Renal inflammation and 
oxidative stress were also reduced.  Renal recovery was associated with recovery of mitochondrial 
gene and protein expression, and mtDNA content in the renal cortex.   
 Taken together, we have demonstrated that cGMP is a regulator of mitochondrial 
biogenesis in the kidney, and activation of mitochondrial biogenesis through modulators of cGMP 
can promote recovery of renal function following AKI.  PDE inhibitors and guanylyl cyclase 
  
activators represent novel therapeutics that warrant further evaluation as potential interventions to 
treat AKI and other diseases characterized by mitochondrial dysfunction.  To provide a platform 
for clinical evaluation of mitochondrial biogenics in renal disease in humans, we examined 
urinary ATP synthase subunit beta and urinary mtDNA as non-invasive biomarkers of renal 
mitochondrial dysfunction.  These markers were shown to be efficacious as diagnostic and/or 
prognostic biomarkers of renal damage and mitochondrial dysfunction, and will aid in future 
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RENAL ANATOMY AND PHYSIOLOGY 
Overview 
 The kidneys serve a critical role in the maintenance of fluid homeostasis through 
regulation of filtration, reabsorption and secretion of substances in the blood.  The kidney serves 
as the central regulator of body fluid volume, maintains electrolyte balance, including sodium, 
potassium and calcium, and blood pH, and clears the body of harmful metabolic waste products, 
including urea and ammonia, as well as various toxins and xenobiotics.  The kidney also serves 
as a major regulator of blood pressure both through its regulation of fluid volume and through 
secretion of the hormone renin and activation of the renin-angiotensin-aldosterone signaling 
cascade.  The kidney is divided into three distinct zones: the outermost region called the renal 
cortex, the renal medulla (consisting of the outer medulla composed of the outer and inner stripe 
regions and the inner medulla), and innermost renal papilla (Figure 1.1).  These zones differ 
significantly in their morphology, function and extracellular conditions (i.e. pH and oxygen 
tension). 
The nephron 
 The nephron is the basic functional unit of the kidney involved in the process of urine 
generation for excretion (Figure 1.2).  The nephron prepares urine through a complex series of 
processes involving the filtration, secretion and reabsorption of fluid and electrolytes.  The 
nephron is composed of the glomerulus, the site of renal filtration, and the renal tubule 
(comprised of the proximal tubule, the ascending and descending limbs of the loop of Henle, the 
distal tubule and the collecting duct).  The following section will provide a detailed discussion of 
structure and function of the various sections of the nephron. 
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 Blood is supplied to the kidney via the renal artery, a branch of the descending aorta, 
which enters at the renal pelvis.  The renal artery divides into 4-5 segmental branches supplying 
various regions of the kidney.  These further subdivide into the afferent arterioles which supply 
the blood to the capillary bed of the glomerulus.  Efferent arterioles carry blood away from the 
glomerulus.  Regulation of vascular tone in the afferent and efferent arterioles affects renal 
filtration by modulating renal blood flow and hydrostatic pressure.  Afferent and efferent 
arterioles are regulated via the autonomic nervous system as well as a variety of paracrine and 
endocrine signals including angiotensin, ADH, endothelin, adenosine and norepinephrine.  After 
exiting the glomerulus via the efferent arterioles, blood is carried to the peritubular network 
supplying the renal cortex, or the vasa recta supplying the renal medulla.  The renal cortex, 
which is highly dependent on oxidative phosphorylation for energy, receives approximately 90% 
of renal blood flow, while the renal medulla and papilla, which rely primarily on glycolytic 
metabolism receives the remaining 10%.   These capillary networks converge to renal venules 
which combine to form segmental renal veins.  These segmental veins converge to the renal vein 
which carries filtered, deoxygenated blood away from the kidney. 
The glomerulus 
 The glomerulus serves as the site of plasma filtration in the nephron.  Plasma components 
pass through a barrier consisting of the renal capillary endothelium, the vascular basement 
membrane, and the glomerular epithelium made up of cells called podocytes, into a cavity called 
Bowman’s space.  Fluid readily passes across this barrier (normally 20% of renal plasma flow is 
filtered); however, the passage of plasma solutes is restricted in a size- and charge-dependent 
6  
manner.  Generally, small molecules (<60 kDA, or approximately the size of plasma albumin) 
are freely filtered, while larger molecules, i.e. large proteins and polysaccharides, remain in the 
blood due to the pore size created by the direct interaction of podocytes with the glomerular 
endothelium.  Additionally, the movement of highly anionic molecules into the glomerular 
filtrate is limited by electrostatic repulsion with the anionic glomerular basement membrane.  
Glomerular filtration rate (GFR), the rate at which fluid moves from the blood to the renal filtrate 
at the glomerulus, serves as a measure of glomerular functional capacity.  Normal GFR is 
approximately 180 mL/min; however, much of this filtrate is reabsorbed in the renal tubules to 
prevent excessive fluid loss in the urine.   
The proximal tubule 
 The renal filtrate from the glomerulus passes first to the proximal tubule.  The proximal 
tubule is the primary site of reabsorption of both fluid and electrolyte components of the renal 
filtrate.  In fact, >75% of the water filtered at the glomerulus is reabsorbed in the proximal 
tubule.  Additionally, 65% of filtered Na+, as well as other ions including Cl-, Ca2+, PO4
3- and 
HCO3
- are highly reabsorbed back into the blood through various ion transporters.  Furthermore, 
larger molecules including glucose and other carbohydrates, amino acids and oligopeptides are 
reabsorbed through active and facilitated transport.  Activity of these various transporters places 
high oxygen and energy demands on the proximal tubule, the primary consumer of ATP in the 
kidney.  The proximal tubule can be subdivided into 3 structurally and functionally distinct 
regions: S1, S2 and S3.  Structurally the segments can be identified by distinct brush border 
morphology, as well as significant differences in mitochondrial and lyosomal content.  
Furthermore, each section is characterized by differential transporter expression leading to 
distinctions in the reabsorptive capacity for various solutes.  The S1 segment serves as the 
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primary site of HCO3
- transport, as well as small proteins, amino acids and carbohydrates.  Both 
the S1 and S2 segments contain cation active transporters, while the S2 and S3 sections contain 
multiple organic anion transporters involved in the secretion of various endogenous substrates 
including cyclic nucleotides, urate and folate, as well as pharmacological agents, including 
antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).   
Loop of Henle, distal tubule and collecting duct 
 The loop of Henle is comprised of the thin descending and ascending limbs and the thick 
ascending limb.  Much of the remaining water, Na+ and K+ is reabsorbed at this site.  Urine 
filtrate is concentrated in the descending limb due to the reabsorption of water and 
impermeability to ions.  Na+, K+ and Cl- are secreted in the ascending limb through activity of 
the Na+-K+-Cl- co-transporter.  Secretion of ions into the renal medulla creates the osmotic 
gradient required for concentration of urine in the collecting duct.  The distal tubule and 
collecting duct serve as the final sites of solute and water reabsorption for generation of 
concentrated urine.  The distal tubule also directly interacts with a specialized group of cells 
called the juxtaglomerular apparatus composed of juxtaglomerular cells and the macula densa.  
This structure produces renin in response to decreased filtrate pressure causing increased renal 
blood flow and GFR.   
ACUTE KIDNEY INJURY 
Definition 
Acute kidney injury (AKI) is the abrupt (occurring in less than 7 days) loss of renal 
function characterized by reduced urine output and an increase in the serum waste products, 
creatinine and urea [1].  The classical term acute renal failure (ARF), defined by a sudden 
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reduction in GFR, was replaced by AKI to provide a more encompassing definition to include 
renal damage that does not result in changes in GFR.  In 2012, the KDIGO (Kidney Disease 
Improving Global Outcomes) consortium introduced specific guidelines for the diagnosis of AKI 
(Figure 1.3) [2].  AKI can be diagnosed if one of the following is present: an increase in serum 
creatinine (SCr) by ≥0.3 mg/dL within 48 hours, an increase in SCr ≥1.5 times baseline within 7 
days, or a urine output of < 0.5 mL/kg/hr for 6 hours.  The term renal failure is more narrowly 
used to define conditions requiring the application of renal replacement therapy (RRT) or 
dialysis.  Additional classification schemes have been developed including the Acute Kidney 
Injury Network (AKIN) staging system, and the Risk, Injury, Failure, Loss and End-stage renal 
disease (RIFLE) criteria (Figure 1.3).  The RIFLE criteria provides a classification scheme to 
follow the progression from mild, subclinical renal injury to significant, clinical renal 
dysfunction to permanent loss of renal function and need for dialysis.  The RIFLE criteria 
defines Risk as a 1.5-fold increase in SCr or a 25% decrease in GFR, Injury as a 2-fold increase 
in SCr or 50% reduction in GFR, Failure as a 3-fold increase in SCr or a 75% reduction in GFR.  
Loss of kidney function is classified as persistent renal failure, and end-stage renal disease when 
renal replacement therapy is needed.   AKIN classifies AKI in 3 stages similar to KDIGO 
staging.  Use of classification systems has aided in standardization of patient populations 







Figure 1.3: AKI classification schemes.  KDIGO, Kidney Disease Improving Global 
Outcomes, AKIN, Acute Kidney Injury Network, RIFLE, Risk, Injury, Failure, Loss, End Stage 


















Incidence, mortality and cost 
 
 AKI is an under-recognized condition that affects a significant portion of hospitalized 
patients.  AKI is estimated to occur in 3-7% of all hospitalized patients, rising to 25-30% in 
patients admitted to the intensive care unit (ICU) [4-6].  Due to an array of increasing risk factors 
including an aging population, increased use of nephrotoxic medications, and higher rates of 
metabolic and cardiovascular disease, the rates of AKI continue to increase.  AKI is associated 
with high rates of morbidity and mortality [7-9].  Among ICU patients, mortality rates are 
estimated to be as high as 80%.  Patients that recover from AKI are often plagued by an array of 
chronic sequelae, including a highly elevated risk of development of chronic kidney disease 
(CKD) [10, 11].  Due to the need for aggressive treatment and application of renal replacement 
therapy (RRT), the cost of treatment of AKI is high.  Annual U.S expenditures associated with 
the treatment of AKI are estimated to exceed $9 billion per year; however, the exact costs 
associated with AKI are difficult to determine due to the presence of underlying conditions and 
AKI complications.  Stratification of patients by degree of AKI and evaluation of additional 
consequences attributed to incremental increases in severity of AKI has shed some light on the 
overall impact of AKI on patient outcomes and healthcare cost.  Even a moderate, yet clinically 
relevant, increase in serum creatinine levels (0.3-0.4 mg/dL) results in a 70% increase in the risk 
of death, an increase in the length of hospital stay of 3.5 days, and an added cost of $9000 per 
patient [9].  Larger increases in SCr lead to exponential increases in morbidity and mortality, and 
healthcare costs (Figure 1.4A, B).  These results further highlight the importance of standardized 
AKI classification systems, including the RIFLE and AKIN criteria, to provide better data for 
correlation of degree of renal injury with outcomes, and a platform to better compare data across 
clinical studies with diverse patient populations. 
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Figure 1.4A: Mortality associated with change in serum creatinine.  Green bars are 
unadjusted, blue bars are age and gender adjusted, and gray bars are multivariable adjusted.  
Multivariable analyses adjusted for age, gender, diagnosis-related group (DRG), weight, chronic 
kidney disease (CKD) status, and ICD-9-CM codes for respiratory, gastrointestinal, malignant, 




Figure 1.4B: Mean hospital costs associated with change in serum creatinine.  Green bars 
are unadjusted, blue bars are age and gender adjusted, and gray bars are multivariable adjusted.  
Multivariable analyses adjusted for age, gender, diagnosis-related group (DRG), weight, chronic 
kidney disease (CKD) status, and ICD-9-CM codes for respiratory, gastrointestinal, malignant, 
and infectious diseases; n=1564, 885, 246, and 105 for change in SCr 0.3-0.4, 0.5-0.9, 1-1.9, and 




Types of AKI 
 AKI can be subclassified by its origin as prerenal, renal (or instrinsic), or postrenal AKI.  
Prerenal AKI, which accounts for ~60% of cases, occurs due to a reduction or complete loss of 
renal blood, observed in cardiac surgery, septic shock and vascular disease.  Loss of renal blood 
flow causes ischemic injury and cell death in the kidney.  The proximal tubule is heavily affected 
due to its reliance on oxygen for oxidative phosphorylation [12].  Intrinsic renal injury occurs 
when there is direct damage to a component of the nephron, typically as a result of xenobiotic or 
ischemic injury.    Intrinsic AKI accounts for 35-40% of cases observed, and when examined 
together, pre-renal causes with ischemic ATN account for approximately 75% of AKI cases [13].  
Finally, post-renal injury is caused by an obstruction of urinary outflow causing increased 
pressure in the kidney and hydronephrosis.   
Causes of AKI 
 AKI is caused by a diverse array of insults including septic shock, major surgery, 
cardiogenic shock, and drug/toxicant exposure.  Sepsis is the most common cause of AKI in 
critically ill patients accounting for nearly half of all cases [14].  Various pharmalogical agents 
have been identified as nephrotoxicants, including aminoglycoside antibiotics, various 
chemotherapeutic agents, radiocontrast media, and non-steroidal antiflammatory drugs 
(NSAIDs).  Aminoglycosides preferentially accumulate in the renal proximal tubule and mediate 
nephrotoxicity through disruption of phospholipid metabolism and renal perfusion.  Assessment 
in ICU patients demonstrated that administration of aminoglycosides caused renal toxicity in 
~60% of patients [15].  Cisplatin, an effective platinum-based chemotherapeutic agent, is 
associated with high rates of renal toxicity.  Cisplatin causes AKI through direct toxicity to renal 
tubules by disrupting mitochondrial function causing ATP depletion, and increased oxidative and 
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inflammatory tissue damage [16, 17].  Radiocontrast media are commonly used in various forms 
of tissue imaging, but are a frequent cause of AKI in hospitalized patients [18].  Pre-existing 
renal dysfunction sensitizes certain populations to radiocontrast nephrotoxicity.  Radiocontrast 
agents cause renal damage through direct tubular injury, as well as through the reduction of renal 
blood flow and glomerular filtration [19].  Various NSAIDS, including acetaminophen and 
aspirin, are common causes of renal damage, particularly in aged and sensitive populations.  
Acetaminophen induces tubular necrosis through induction of renal oxidative stress and 
depletion of renal anti-oxidative mechanisms [20, 21]. 
Pathophysiology of ischemia/reperfusion-induced AKI 
 Renal ischemia/reperfusion (I/R) is a common cause of AKI.  Ischemia occurs when 
blood flow to the kidney is reduced as a consequence of various insults including drug/toxicant 
exposure, cardiovascular disease, sepsis or surgery [22, 23].  Ischemic AKI is a multi-factorial 
disorder characterized by prominent microvascular and tubular dysfunction (Figure 1.5) [24].  
Following ischemia, renal vessels become constricted reducing microcirculation.  Additionally, 
endothelial damage and leukocyte infiltration are prominently observed [22, 25, 26].  Renal 
tubular damage is marked by breakdown of cytoskeletal components and a loss of renal tubular 
polarity.  Epithelial cells undergo varying degrees of apoptotic and necrotic cell death and are 
sloughed into the renal tubular lumen resulting in tubular obstruction [12, 22, 27].  Each of these 






Figure 1.5: Pathogenesis of ischemic AKI.  The major pathways of GFR impairment in 
ischemic acute tubular injury are caused by ATP depletion in vascular and tubular cells. 
Numerous interactions exist between endothelial cells, WBCs, and epithelial cells in the 
pathophysiology of ischemic AKI. These interactions are bidirectional between the cells 
involved, and result in specific functional and structural alterations. Inflammatory mediators 
released from proximal tubular cells influence endothelial cell processes (e.g. increase 
vasoconstriction and expression of cell adhesion molecules) that in turn influence the interactions 
between WBCs and endothelial cells, leading to reduced microvascular flow and continued 
hypoxia within the local environment. Additional functional changes occur, such as a marked 
reduction in production of erythropoietin and 25-hydroxylation of vitamin D. Electrolyte 
accumulation can rapidly lead to requirement of renal replacement therapy. Metabolic acidosis as 
a consequence of AKI must also be carefully monitored. Abbreviations: AKI, acute kidney 
injury; FENa, fractional excretion of sodium; GFR, glomerular filtration rate; TGF-β, 





Spatial and temporal pattern 
 The acute effects of I/R injury due to disrupted renal perfusion and ATP depletion are 
most prominently observed in the proximal tubule due to high energy demands [12, 22].  
Following reperfusion, the extension phase of I/R is characterized both by renal recovery due to 
restoration of oxygen and nutrients to damaged tissue, but also by further oxidative injury.  
Damage to the vascular endothelium creates pockets of localized ischemia causing further 
progression of injury.  During this phase, injury is observed primarily in the S3 segment of the 
proximal tubule and the medullary thick ascending limb at the border of the cortex and the 
medulla [28].  This region is very sensitive in this period due to a highly developed network of 
small vessels and high oxygen demands of the outer stripe of the medulla [29, 30].  The final, 
maintenance phase of AKI, is also characterized by mixed recovery and further injury.  Further 
cellular injury occurs as the result of chronic inflammation and response to apoptotic stimuli. 
Vascular injury 
 Microvascular injury following I/R is characterized by damage to endothelial cells and 
vascular smooth muscle cells.  Damage is primarily confined to the glomerulus and outer stripe 
of the medulla.  Differential morphology of the renal capillaries in these regions make them 
particularly sensitive.   Autonomic nervous system dysfunction and release of paracrine signals 
promoting vasoconstriction (endothelin, adenosine, angiontensin II and thromboxane), and a 
reduced response to vasodilators (nitric oxide, PGE2, acetylcholine and bradykinin) reduce blood 




Tubular cell death 
 Both apoptotic and necrotic cell death are observed following ischemic AKI.  The degree 
of each type is dependent upon the severity of the injury and the region of the kidney which is 
affected.  Prolonged ischemia leads to depletion of ATP causing necrotic cell death, primarily in 
the renal proximal tubule [31-33].  Furthermore, ATP depletion disrupts cellular ion transport 
and causes disruption of cellular protein structure and function [34-36].  Apoptosis is also 
observed in ischemic injury in both animal models and humans [37-40].  However, the 
contribution of cellular apoptosis to overall renal function is questionable as only a small portion 
of tubular cells undergo apoptosis.   Additionally, apoptosis is primarily observed in the distal 
tubules, while the loss of tubular cells is primarily confined to the proximal tubule.  Furthermore, 
ATP is a requirement for initiation of apoptotic cell death, and is severely depleted during and 
acutely following ischemia.  Expression of apoptotic proteins, including Bax, Bad, Bak and 
various caspases, increases over time following renal ischemia due to the influence of prolonged 
oxidative stress, DNA damage and inflammation, potentially implicating apoptosis in the 
recovery phases of ischemic AKI [41]. 
Sub-lethal tubular injury 
 Renal tubular cells that do not undergo cell death still experience an array of 
morphological and functional changes following ischemia.  The tubular cytoskeleton is severely 
disrupted resulting in loss of epithelial polarity [12, 22, 27].  Disruption of the actin cytoskeleton 
is an early consequence of ischemia.  ATP is required for the dynamic formation and turnover of 
actin, and for the interaction of actin with myosin [42, 43].  Additionally, post-ischemic 
elevations of tubular Ca2+ levels disrupt actin-myosin interactions and microtubule formation 
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[44].  Ca2+ elevation also leads to the activation of the Ca2+-dependent proteases, calpains.  
Calpains degrade actin and various actin binding proteins, as well as integral membrane proteins, 
membrane associated-proteins and cross linking proteins [24, 45-47].  Membrane phospholipids 
interacting with the cytoskeleton, including diacylglycerol and palmitic acid, are also disrupted 
following ischemia [47].  Finally, excessive ROS production leads to cross linking of actin and 
actin-binding proteins, disrupting cytoskeletal integrity [48-50]. 
 Cytoskeletal disruption and subsequent loss of epithelial polarity has profound impacts 
on renal tubular structure and function, including loss of the apical brush border and 
redistribution of membrane proteins.  Microvilli present on the apical membrane are shed into 
the tubular lumen following injury resulting in a reduction in functional renal surface area 
required for water and solute reabsorption [24, 51-53].  The redistribution of membrane proteins 
is best illustrated by the movement of the Na+-K+ ATPase from the basolateral to the apical 
membrane of the renal tubule following injury.  Under physiological conditions, Na+ enters the 
renal tubule via facilitated diffusion at the apical membrane.  Na+ is then pumped out of the cell 
against its concentration gradient across the basolateral membrane via the Na+-K+ ATPase.  
Movement of Na+ out of the cell is required to maintain the gradient for tubular uptake of water 
and solutes.  Relocalization of the Na+-K+ ATPase to the apical membrane inhibits Na+ and 
water reabsorption by establishing a cycle where Na+ is both reabsorbed and secreted into the 
tubular lumen [45, 54-56].   Tubular epithelial cells are held in place by their attachment to the 
extracellular matrix through integrins and to each other by adherens.  Disruption of these 
adhesion complexes following ischemia leads to sloughing of renal tubular cells into the lumen.  
These cells appear as casts in the tubular lumen causing obstruction of flow of the luminal filtrate 
[45, 57].   
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Tubular repair 
 The renal tubular epithelium has an extensive capacity to repair itself following injury.  
Following ischemic injury, a host of renal repair mechanisms are activated.  Renal cell turnover 
is markedly increased due to cell death and enhanced proliferation of renal epithelial cells, 
particularly in the S3 segment of the proximal tubule [58].  The generation of new renal 
epithelial cells replaces the cells lost due to apoptotic and necrotic cell death.  However, the 
source of these cells is still under debate.  Numerous origins have been suggested including bone 
marrow stromal cells [59, 60], a resident renal stem cell population [61], or proliferation of 
surviving renal epithelial cells [12].  Studies have shown that both hematopoietic stem cells 
(HSCs) and mesenchymal stem cells (MSCs), can replace renal epithelial cells following injury 
[61-65].  Additionally, administration of exogenous MSCs has been demonstrated to promote the 
repair of the renal epithelium and enhance renal recovery; however, other studies have 
contradicted these claims [61, 63, 66].  Other studies have demonstrated that surviving renal 
tubular cells do proliferate after ischemic insult [23].  Following injury with loss of renal 
epithelial cells, the surviving cells undergo a process of dedifferentiation [67].  These cells then 
migrate to areas of epithelial cell loss before undergoing proliferation. This proliferating cell 
population expresses various development markers including the proliferation marker PCNA and 
the mesenchymal marker vimentin [68].  The epithelial to mesenchymal transition (EMT) in 
these cells is mediated by signaling through the EGF receptor [69].  These cells lack the 
developed cytoskeleton and polarization of an intact renal epithelium [70-72].   Following 
migration and proliferation, mesenchymal tubular cells re-differentiate and reestablish polarity 
by inactivation of EGF signaling evidenced by regeneration of the actin cytoskeleton and 
localization of the Na+-K+ ATPase to the basolateral membrane (Figure 1.6) [24]. 
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Abnormal repair and progression to CKD. 
 Even with the activation of renal repair processes described above, repair of the renal 
tubular epithelium is often incomplete.  AKI is a major risk factor for the development of CKD, 
and there is increasing evidence that the two diseases are closely linked [10, 73, 74].  
Microvascular damage causing persistent hypoxia, chronic inflammation, persistent oxidative 
stress and proliferation of resident fibroblasts contributing to extracellular matrix deposition 
causing renal fibrosis and failed renal recovery.  The fate of the tubules may lie in the relative 
activation of pro-repair vs. pro-fibrotic signaling cascades; however, the mechanisms underlying 
the regulation of these processes post-ischemic AKI are still poorly understood.  Evidence exists 
for the arrest of renal epithelial cells in the G2/M phase of the cell cycle following ischemia as a 
contributing factor to fibrosis, although further investigation is needed [75].  The source of the 
fibroblasts contributing to renal fibrosis after AKI has been debated.  Some suggest that the 
damaged renal epithelial cells themselves cause fibrosis after undergoing EMT; however, 





Figure 1.6: Effects of sub-lethal injury to tubular cells and their recovery.  Damage to 
epithelial cells occurs early during ischemia and involves alterations to the cytoskeleton and in 
surface membrane polarity. ATP depletion induces rapid disorganization of the actin 
cytoskeleton structure, which disrupts tight junctions and in turn leads to backleak of tubular 
filtrate. Loss of cell–cell contacts and cell adhesion molecules results in flattened nonpolarized 
epithelial cells, denuded basement membranes, and expression of mesenchymal markers. 
Na+/K+-ATPase pumps normally located at the basolateral membrane and tethered by the actin–
spectrin cytoskeleton, redistribute to the apical membrane of the proximal tubular cell and are 
internalized into the cytosol during ischemic injury. Morphologically, proximal tubular cells lose 
their brush borders, undergo swelling, and blebbing of microvilli during injury, leading to cast 
formation. Severely injured proximal tubular cells undergo mesenchymal differentiation and 
subsequent re-epithelization. Recovery of proximal tubular cells begins with integrin 
reattachment, reassembly of the actin cytoskeleton, repolarization of the surface membranes, and 




Animal models of AKI 
 Due to the complex nature of the disease and the lack of availability of human renal 
tissue for study, the use of relevant animal models has been vital to the study of the underlying 
pathophysiology of AKI.  While existing animal models of AKI fail to completely mimic human 
disease, several models have proven reliable to study the underlying mechanisms of renal injury 
and repair, and serve as platform for testing of new therapeutics.   
I/R model of AKI 
Renal I/R can be induced in an array of animal systems; however, rats and mice are most 
commonly used.  Ischemia is induced by unilateral or bilateral clamping of the renal artery or 
renal pedicle to obstruct blood flow to the kidney.  Following clamping for a prescribed period of 
time, the clamps are released allowing blood to reperfuse the ischemic tissue.  Ischemia times 
needed to induce injury vary widely, primarily based on the temperature at which the animals 
were maintained during ischemia [82].  Bilateral clamping of the renal pedicles for 60 min 
followed by 24 h of reperfusion in rats has been previously reported to induce severe AKI [83].  
Unilateral clamping for 45-60 min has also been shown to be sufficient to induce renal failure.  
Mice tend to be relatively more sensitive to ischemia and require shorter ischemic periods to 
induce similar degrees of renal damage [84].  Following experimental I/R, cellular necrosis is 
observed primarily in renal epithelial cells in the outer stripe region of the medulla [85].  Some 
apoptotic cell death is also observed.  Histological evaluation reveals dilated tubules, loss of brush 




Folic acid model of AKI 
 A single bolus overdose of folic acid has been used as a model of AKI in rats and mice 
[86-88].  The doses required to induce renal injury are not clinically relevant in humans; 
however, the model provides a simple, reproducible method of induction of both acute and 
chronic renal disease in animals.  The model is characterized by both direct damage to the renal 
tubular epithelium and tubular obstruction [87].  After acute administration, animals demonstrate 
elevated renal injury biomarkers and reduced urine output.  Folic acid is often used as a method 
of induction of CKD as proliferation of renal interstitial connective tissue (fibrosis) is 
prominently observed late after folic acid overdose [89].  
Biomarkers 
 Serum creatinine and blood urea nitrogen (BUN) have long been the gold standard 
markers of renal function.  However, poor sensitivity and kinetic profiles of these markers has 
created increased interest for the development of new markers of renal injury and dysfunction.  
Over the past 10 years, an array of promising new renal biomarkers have emerged with greater 
sensitivity, site specificity and enhanced diagnostic and prognostic potential (Figure 1.7) [90].  A 
sampling of these biomarkers is discussed below.   
Creatinine and BUN 
Serum creatinine is a standard clinical measure of renal function that has been traditionally 
used in the diagnosis of AKI.  Measurement of creatinine concentration in the urine 
additionally allows for the measurement of creatinine clearance and estimation of GFR.  
Despite its universal usage as a marker of renal function, creatinine has numerous 
limitations.  Baseline serum creatinine levels vary widely depending on population, degree 
of muscle and hydration status.  Therefore, absolute serum creatinine concentrations are 
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difficult to interpret.  Baseline creatinine measurements are needed in order to monitor 
increases, which may correspond to reduced renal function. Additionally, increased serum 
creatinine levels are noted only in patients who have a lost a significant proportion of their 
baseline renal function, making creatinine a poor marker of early and/or mild AKI.  BUN has 
also been used extensively as a renal functional marker and diagnostic tool for the detection of 
AKI.  However, BUN suffers from the same lack of sensitivity and specificity as serum 
creatinine. 
Kim-1 
Kidney injury molecule-1 (Kim-1) is a type 1 transmembrane protein containing a mucin 
and immunoglobulin domain.  Kim-1 was originally identified as a hepatitis A virus receptor 
(HAVCR1, or Tim-1).  Kim-1 was demonstrated to be markedly upregulated in the kidney 
following renal ischemia/reperfusion injury in the rat [91].  Kim-1 has several advantages as a 
biomarker over traditional markers of renal dysfunction.  Kim-1 is not expressed in normal, 
healthy kidney.  Following injury, its expression becomes highly elevated, particularly in the 
apical membrane of renal tubules, and its expression is maintained throughout cellular recovery.  
Following its upregulation, the ectodomain of Kim-1 is shed into the tubular filtrate and excreted 
into the urine simplifying its assessment.  Additionally, this shed domain has been found to be 
very stable in urine even at room temperature.  Assessment of Kim-1 in pre-clinical animal 
models has demonstrated that Kim-1 is an early, sensitive and specific predictor of tubular 
damage that is elevated even in the absence of clinically detectable renal dysfunction by SCr and 
BUN [92-94].  The diagnostic and prognostic potential of Kim-1 has also been demonstrated in 
clinical populations following cardiac surgery, renal transplant, obstructive nephropathy, sepsis, 
chronic kidney disease and other disease states [95-98]. 
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NGAL 
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa protein discovered in 
neutrophils, which plays a role in innate immunity through sequestration of iron.  NGAL is 
expressed at very low levels in normal epithelial tissues including the respiratory tract, prostate 
and kidney.  Following renal injury, NGAL expression is markedly upregulated in damaged 
renal tubular epithelial cells.  NGAL has been demonstrated as a highly effective marker of early 
AKI in multiple animal models and human disease cohorts.  NGAL is rapidly upregulated – less 
than 2 h – following renal I/R [99, 100].  NGAL has also been shown to be an effective predictor 
of patient outcomes, including need for renal replacement therapy, length of hospital stay and 










Figure 1.7. Biomarkers of AKI: Traditionally used markers, such as blood urea nitrogen 
(BUN) and creatinine (CR), are insensitive, nonspecific, and do not adequately 
differentiate between the different stages of AKI. A delay in diagnosis prevents timely 
patient management decisions, including administration of putative therapeutic agents. 
Urinary biomarkers of AKI will facilitate earlier diagnosis and specific preventative and 















Pharmacological treatment of AKI 
 Many drugs been evaluated as prophylactic measures in patients at risk for the 
development of AKI, or as stimulators of renal recovery following injury.  Primary targets of 
investigation include stimulators of naturesis and renal blood flow, or inhibitors of renal 
inflammation and oxidative stress.  Tested therapies that have failed in human trials include the 
vasoactive drugs dopamine [104], fenoldopam [105] and theophylline [106], as well as anti-
inflammatory drugs and antioxidants including aspirin, clonidine [107], dexamethasone [108] 
and N-acetylcysteine [109].  Several studies have shown promise with the use of sodium 
bicarbonate [110], statins [111], erythropoietin [112], naturetic peptides [113], fenoldopam 
[114], nitroprusside sodium [115] and clonidine [116] in various AKI patient cohorts; however, 
all of these drugs require further studies for validation.  Despite the serious nature of AKI, there 
still exists no highly effective therapies that can protect against or promote recovery from AKI.  
The complexity of the pathophysiological mechanisms underlying AKI has made therapeutic 
development difficult.  Multiple mechanisms including apoptotic and necrotic cell death, 
inflammation, oxidative stress and bioenergetic dysfunction occur simultaneously during the 
onset and progression of AKI.  Future successful therapies will likely rely on a multi-targeted 
approach to address these various mechanisms.  Additionally, the use of novel renal biomarkers 
with enhanced sensitivity and prognostic power in future AKI interventional studies to stratify 







MITOCHONDRIAL DYSFUNCTION IN DISEASE 
Mitochondrial homeostasis 
Mitochondria are uniquely situated at a crossroads between multiple cellular processes 
critical to human health.  As the site of aerobic respiration, mitochondria are primarily 
responsible for regulation of cellular energetics.  However, mitochondria also serve as signaling 
organelles that can orchestrate complex cellular responses to both internal and external stimuli 
[117].  The mitochondrion is the only organelle that contains its own DNA (mtDNA) outside the 
nucleus, thus, regulation of mitochondrial function requires coordination of two distinct genomes 
[118]. The complex regulation of mitochondrial assembly and function, as well as the intricate 
nature of the tasks performed by mitochondria, provides myriad opportunities to derail 
mitochondrial homeostasis and facilitate onset of pathology.    
Mitochondria are by nature plastic organelles, existing in a constant state of flux.  This 
plasticity allows mitochondria to adapt to stark changes in cellular energy demands, as well as 
adapt to and mitigate cellular stress.  As the site of oxidative phosphorylation, mitochondria are 
the chief consumers of intracellular oxygen, and thus are also a main source of reactive oxygen 
species (ROS). Under physiological conditions, mitochondrial-derived ROS serve as key second 
messengers to help coordinate cellular responses, including adaptation to hypoxia, cellular 
division, and complex responses to external stimuli, such as regulation of vascular tone [117, 
119].  However, even under normal conditions oxidative damage inevitably occurs.  
Mitochondria mitigate this stress through quality control measures, including balanced 
biogenesis of new mitochondria, autophagic degradation of dysfunctional mitochondria, 
mitochondria-specific protein refolding/turnover pathways and mitochondrial fission/fusion 
events (Figure 1.8) [120].  
28  
Disruption of mitochondrial homeostasis through perturbation of any of these quality 
control processes has been implicated in disease [121-124].    Due to the requirement of 
mitochondrial homeostasis for normal cellular function, mitochondria have received increasing 
attention as a therapeutic target [125].  More specifically, compounds capable of stimulating 
mitochondrial biogenesis (MB) have shown potential as a treatment for a wide range of diseases 

















Figure 1.8: Mitochondrial homeostasis is maintained through balanced biogenesis of new 
mitochondria, mitochondrial fission and fusion, and mitochondrial turnover by mitophagy.  
Mitochondrial biogenesis (MB), the de novo generation of new mitochondria, is a highly 
regulated cellular process controlled by the central mediator and transcriptional coactivator PGC-
1α.  PGC-1α expression and activity is regulated through diverse pathways including receptor 
tyrosine kinases, G-protein coupled receptors, naturetic peptide receptors and nitric oxide 
synthase through cGMP, as well as AMPK activation, and SIRT1-mediated deacetylation.  In 
response to various stimuli, mitochondria can undergo the process of fusion (enlargement by 
combination with other mitochondria) via mitofusin proteins, such as MFN1/2 and OPA1, or 
fission (size reduction by budding off of mitochondrial contents) via fission proteins, such as 
Drp1.  Damaged mitochondria are eliminated by selective degradation in lysosomes.  EGF, 
epidermal growth factor; VEGF, vascular endothelial growth factor; RTKs, receptor tyrosine 
kinases; β2AR, β2-adrenergic receptor; 5HTR, serotonin receptor; GC-A/B, guanylyl cyclase 
A/B; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; sGC, soluble guanylate cyclase; 
cGMP, cyclic guanosine monophosphate; cAMP, cyclic adenosine monophosphate; AMPK, 
AMP-activated kinase; SIRT1, sirtuin 1; PPAR, peroxisome proliferator-activated receptor; 
ERR, estrogen related receptor; NRF1, nuclear respiratory factor-1; PGC-1α, peroxisome 
proliferator-activated receptor gamma coactivator-1 alpha; Ac, acetyl; TCA; tricarboxylic acid 
cycle; OXPHOS, oxidative phosphorylation; TOM, translocase of the outer membrane; TIM, 
translocase of the inner membrane; MFN2, mitofusin 2; OPA1, optic atrophy 1; DRP1, dynamin-







Mitochondrial dysfunction in acute disease 
Mitochondrial dysfunction has been characterized as an important pathophysiological 
mechanism in many acute conditions including drug/toxicant exposure, sepsis, and 
ischemia/reperfusion (I/R) injury (Table 1.1) [126].  Given that the damage caused by tissue 
ischemia is most directly the result of mitochondrial dysfunction and energetic deficits, this 
section will focus on common hallmarks of I/R injury, as well as provide examples of 
mitochondrial directed interventions improving outcomes following I/R in various organ 
systems. 
Acute ischemia most severely affects organs with large ATP requirements and limited 
regenerative potential, such as heart, kidney, and brain.  Ischemia can occur following surgical 
intervention, or as a component of drug/toxicant exposure, systemic infection, or multi-organ 
failure [126].  However, regardless of the cause or site, the mechanisms underlying tissue 
damage and organ dysfunction following ischemia are conserved.  Persistent ischemia causes 
blockade of oxidative phosphorylation, loss of mitochondrial membrane potential, and decreased 
cellular ATP levels.  In addition, acidification of the tissue occurs as glycolytic flux increases 
and the metabolic waste products including protons and lactate accumulate.  As intracellular 
ATP levels decrease, ATP-dependent ion channel function is impaired.  This is critical, as the 
organ systems most severely affected by ischemia also require precise regulation of multiple 
ions, including Na+, Ca2+, Cl- and K+, for proper function, including conduction of action 
potentials in nervous tissue, muscle contraction/relaxation in the heart, and blood filtration in the 
kidney [126-128].  The loss of bioenergetic homeostasis following ischemia thus ultimately 
directly contributes to organ dysfunction. 
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Acute kidney injury3 
Spinal cord injury4 
Ischemia: ↓ATP and ATP-dependent cell functions, 
↑ion imbalance (Na+, K+, Ca2+), ↑reducing equivalents, 
↓tissue pH. 






Drug/toxin induced injuries: 
Nephrotoxicity5 
Acute liver injury6 
↑apoptosis/necrosis, ↑mtDNA release, ↑ oxidative 




Type II diabetes7 
 
↓metabolic capacity, ↓PGC-1α-dependent gene 
expression, and ↑ lipids. Mitochondrial dysfunction 





Alzheimer’s disease (AD)8 
Parkinson’s disease (PD)9 
Huntington’s disease (HD)10 
Amyotrophic Lateral Sclerosis 
(ALS)11 
 
AD: ↓mitochondrial proteostasis, ↓cellular ATP and 
↑oxidative stress result in neuron loss and 
microvascular dysfunction. PD: Defective mitophagy 
and fission/fusion dynamics, ↑oxidative stress, 
↓energetics, and ↑neuron loss. HD: ↓ETC complex 
numbers and activity. Mutant Huntingtin disrupts 
mitochondrial trafficking and ↑mitochondria 
fragmentation. Ca2+ handling is disrupted, ↑ MPTP 
opening and apoptosis.  ALS: ↓ATP from ETC, ↑ROS 





















Following ischemia, restoration of blood flow leads to re-oxygenation and delivery of 
critical nutrients to the damaged tissue.  However, reintroduction of oxygenated blood into the 
ischemic zone causes a secondary complication, termed reperfusion injury, characterized by 
inflammation and oxidative damage [137].  Reperfusion injury primarily affects the peripheral 
regions of an ischemic core, as cells in the central area of ischemia often undergo necrotic cell 
death due to sustained ATP depletion. However, cells in the peripheral zone of the ischemic site 
are not completely dependent upon the occluded vessel, and although hypoxic, are able to 
receive partial perfusion from collateral vessels.  Upon reperfusion of the blocked vessel, the 
spike in oxygen introduced into the hypoxic environment of the peripheral zone causes a host of 
unintended reactions that create tremendous amounts of ROS [128].  A chief source of ROS 
during reperfusion comes from electrons mishandled in the electron transport chain (ETC) of 
dysfunctional mitochondria [127]. The sudden increase in ROS overwhelms endogenous 
antioxidant defenses, and can culminate in opening of the mitochondrial permeability transition 
pore (MPTP) subsequent to Ca2+ overload.   Opening of the MPTP can lead to release of 
mitochondrial cytochrome c and initiate apoptotic cell death [138].  Additionally, leak of 
mitochondrial ROS into the cytosol causes damaging oxidative modifications to proteins and 
lipids, severely affecting cellular function.  Early intervention during this critical period could 
limit damage and promote recovery following ischemia.  Therapies capable of modulating and 
rescuing mitochondrial homeostasis upon reperfusion could restore redox balance, ameliorate 
cellular damage, and prevent initiation of cell death cascades, preserving organ function. 
Efforts to target specific aspects of mitochondrial dysfunction, including oxidative and 
nitrosative stress, have had limited success [138, 139].  Indeed, multiple studies have targeted 
oxidative stress through administration of direct antioxidants, including MitoQ, an antioxidant 
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designed to accumulate in mitochondria [140], or with compounds that fuel endogenous 
antioxidant production, such as N-acetylcysteine, which is converted to cysteine to produce 
glutathione [141].  Although pretreatment strategies have shown efficacy, administration during 
or following organ reperfusion has been relatively ineffective [138].  Despite the deleterious 
effects of ROS following reperfusion, some level of physiological ROS is required for proper 
recovery to occur, and administration of a pan-antioxidant may potentially disrupt the beneficial 
effects of physiological ROS.  In contrast, pharmacological blockade of MPTP using 
cyclosporine A (CSA) has shown some benefit in multiple organ systems, including brain, and 
heart, following I/R injury through prevention of apoptosis and preservation of mitochondrial 
function [142, 143].  CSA is currently in clinical trials for use in treatment of myocardial 
infarction (MI).  Despite the positive effects of CSA on preservation of mitochondrial membrane 
potential, it is also known to induce oxidative stress and contribute to hepatic and renal toxicity, 
limiting its therapeutic application [144].  These studies illustrate that more global therapies 
targeting the restoration of mitochondrial homeostasis through enhanced MB (Figure 1.8) of 
mitochondria could accelerate the restoration of the physiologic balance of ATP and ROS 
production, limiting cell death and tissue loss.   
Multiple studies provide evidence for the benefit of augmented MB in ischemic injury. A 
recent study by Jiang et al found that increased MB induced by exercise was able to attenuate 
adverse left ventricular remodeling and oxidant stress post-MI in rats [145].  Furthermore, 
overexpression of mitochondrial transcription factor A (TFAM), a transcription factor regulating 
mtDNA transcription and replication, in a transgenic mouse model correlated with increased 
survival, and decreased ventricular remodeling following permanent coronary artery ligation 
[146].  In a separate study, TFAM overexpression was also shown to decrease reperfusion injury 
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in a transient ischemic stroke model [147].  Due to the energy dependence of organ repair 
mechanisms, enhancement of MB has potential benefit in accelerating the recovery of organ 
structure and function.  We have previously demonstrated that pharmacological activation of MB 
via 3 distinct pathways following onset of maximal acute ischemic kidney injury in mice 
accelerates recovery of kidney function [148-150], highlighting the critical need for MB to 
improve recovery.  In addition, activation of MB has been demonstrated to block apoptotic cell 
death [151]. Collectively, these data suggest that restoration of mitochondrial homeostasis via 
increased MB could serve as platform for the development of meaningful therapeutics for acute 
organ injury and failure. 
 
Mitochondrial dysfunction in AKI 
 Mitochondrial damage and dysfunction is a major underlying mechanism of lethal and 
sublethal cellular injury in the initiation and progression of AKI [152-156].  Increased production 
of reactive oxygen and nitrogen species, predominantly within the mitochondria, as well as 
compromised antioxidant mechanisms following renal ischemia make the mitochondria 
extremely susceptible [157-159].  Oxidative damage and disruption of the mitochondrial electron 
transport chain, mitochondrial membrane depolarization, ATP depletion, lipid peroxidation, 
activation of the mitochondrial permeability transition and release of apoptotic proteins 
contribute to mitochondrial and cellular injury in AKI [22, 34, 153].  Loss of mitochondrial 
polarity leads to the influx of Ca2+ and other ions into the mitochondria causing swelling.  This 
phenomenon has been clearly demonstrated following hypoxia/reoxygenation via electron 
microscopy (Figure 1.9) [156]. 
 Mitochondria are dynamic organelles and undergo dramatic changes in structure and 
organization following acute insult.  Mitochondria become highly fragmented through the 
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process of mitochondrial fission following multiple forms of AKI [160].  Inhibition of 
fragmentation through the use of a dominant-negative Drp1 prevented mitochondrial 
fragmentation, inhibited the release of apoptotic proteins from the mitochondria, and attenuated 
renal dysfunction following I/R.  Pharmacological inhibition of Drp1 by mdivi-1 before ischemia 
reduced renal morphological changes and renal dysfunction by preserving mitochondrial 
morphology [160].  Despite these results, the role of mitochondrial dynamics, including 
mitochondrial fission and fusion, in the onset, progression and recovery of AKI is still poorly 
understood and warrants further investigation. 
 Mitochondrial biogenesis has been shown to be chronically suppressed in multiple 
models of AKI, including I/R and myoglobinuric renal injury [161].  In both models, 
mitochondrial gene and protein expression is suppressed as early as 24 h after injury, and 
remains suppressed as late as 144 h after injury (Figure 1.10) [162].  The failure to recover 
mitochondrial gene and protein expression mirrored the incomplete recovery of renal glomerular 
and tubular function.  This data indicates that re-activation of mitochondrial biogenesis is vital 







Figure 1.9. Mitochondrial ultrastructural changes. (a) Control. (b) Sixty-minute 
hypoxia. (c and d) Sixty-minute hypoxia followed by 60-min reoxygenation.  Arrowhead, 









Figure 1.10. Sustained depletion of mitochondrial proteins after I/R AKI. A: mRNA from 
sham and I/R mice was analyzed by qRT-PCR for expression of nuclear-encoded respiratory 
genes NDUFB8 and ATP synthase β and the mitochondrial-encoded genes ND6 and COX I at 
24, 72, and 144 h after injury. B: expression of mitochondrial respiratory proteins from kidneys 
of sham and I/R mice was examined by immunoblot analysis. Bars with different superscripts are 
significantly different from one another (P < 0.05). C: immunoblot analysis confirmed reduced 
COX IV protein expression in kidney cortex from mice 24, 72, and 144 h after I/R. D: COX IV 
immunohistochemistry (brown stain) in sham mice (i) or 24 h (ii), 72 h (iii), or 144 h (iv) after 
reperfusion in I/R mice, with hematoxylin counterstain. Low-magnification images were 
captured at ×10 and higher-magnification insets were captured at ×40 [161]. 
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Mitochondrial dysfunction in chronic disease 
Persistent mitochondrial dysfunction has been implicated in the initiation and progression 
of an array of chronic diseases and disorders, including neurodegeneration, type II diabetes 
mellitus, metabolic syndrome, and end stage renal disease (Table 1.1) [132, 134, 163].  As 
disease progresses mitochondria lose their ability to compensate for persistent stressors through 
regeneration and quality control measures leading to the development of tissue injury and 
dysfunction.  Mitochondrial homeostasis (Figure 1.8), which occurs through the balance of 
biogenesis, fission/fusion events, and autophagic degradation of dysfunctional mitochondria, is 
essential to maintain tissue energetics and prevent chronic oxidative stress [164, 165].  Here we 
will highlight Parkinson’s disease (PD) as an example of mitochondrial dysfunction in 
neurodegeneration, and discuss the role of mitochondrial dysfunction in the initiation and 
progression of type II diabetes mellitus and its secondary acute complications. 
 
Parkinson’s Disease 
PD is the second most common neurodegenerative disease, affecting both motor and 
cognitive functions in the brain [166].  Current therapies for PD focus on symptomatic 
management, as there are no effective treatments to limit disease progression [167].  Multiple 
gene defects have been described for both familial and age-related forms of PD, several of which 
converge on pathways regulating mitochondrial homeostasis, implicating mitochondrial 
dysfunction in disease progression [134]. PD primarily affects dopaminergic (DA) neurons, 
which rely heavily on mitochondrial oxidative phosphorylation for energetic homeostasis.  
Additionally, DA neurons within the substantia nigra (SN) have limited antioxidant defense and 
are thus particularly sensitive to oxidative damage from mitochondrial-derived ROS [168].  
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Familial PD is associated with mutations in the proteins Parkin and Pink1, important components 
of mitophagy, leading to failed clearance of damaged and dysfunctional mitochondria.  
Persistence of damaged mitochondria leads to chronically elevated ROS in the SN and ultimately 
DA neuron loss [135].  Maintenance of mitochondrial quality control through the proper balance 
of biogenesis and degradation within the SN, as well as other brain regions, are thus a primary 
concern in preventing the progression of both familial and age-related PD. 
Indeed, increasing evidence suggests enhanced MB is a promising therapeutic target in 
PD [169, 170]. As shown in Figure 1, MB is governed in large part by peroxisome proliferator 
activated receptor coactivator-1α (PGC-1α).  PGC-1α, known as the master regulator on MB, is a 
transcriptional co-activator that interacts with multiple transcription factors and nuclear hormone 
receptors to regulate ~1500 nuclear-encoded mitochondrial genes to coordinate MB and 
oxidative metabolism [171].  Importantly, key PGC-1α-dependent target genes are down-
regulated in PD patients, and restoration of PGC-1α in vitro protects DA neurons [172].  In 
addition, studies in animal models of PD have demonstrated that PGC-1α is down-regulated 
[134], and PGC-1α knockout mice are more susceptible to disease [173]. Subsequent studies 
have shown that pharmacological restoration of PGC-1α expression by treatment with resveratrol 
or AICAR induce functional improvements in animal models of PD [174], suggesting that 
dysfunctional MB is a hallmark of PD and enhancement of PGC-1α expression and function has 
potential as a therapeutic target. 
 
Type II Diabetes 
Though it is well established that mitochondrial dysfunction occurs in patients with Type 
II diabetes, it is currently not known whether mitochondrial dysfunction is a consequence or 
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cause of insulin resistance [175].  Type II diabetes is associated with decreased PGC-1α 
expression, reduced PGC-1α-dependent gene expression, and impaired ability to produce 
mitochondrial ATP [176].  Type II diabetes is also associated with systemic oxidative stress as a 
result of increased ROS production from mishandling of electrons in the ETC and endogenous 
oxidases.  Indeed, oxidized proteins and lipids can be detected in the plasma of diabetic patients, 
suggesting that antioxidant defenses are overwhelmed or impaired [177]. 
Basal mitochondrial dysfunction and persistent oxidative stress, in the presence of 
hyperglycemia, culminates in conditions that exacerbate tissue injury in response to acute 
conditions, including MI, stroke, and acute kidney injury (AKI).  During cerebral ischemia, 
hyperglycemia facilitates greater glycolytic flux than that observed in normoglycemic patients.  
This leads to the accumulation of multiple metabolic byproducts of glycolysis, including lactate, 
protons and NADH.  Upon reperfusion, the spike in molecular oxygen, together with elevated 
levels of NADH, causes hyperpolarization of mitochondria and a rise in mitochondrial-derived 
ROS.  Elevated tissue levels of ROS and increased inflammation contributes to decreased patient 
survival compared to non-diabetic patients [178].  Similar effects of hyperglycemia on patient 
outcomes are also seen in MI [179] and AKI [180], suggesting a conserved mechanism of 
dysfunction across organ systems.  These data suggest that correction of baseline mitochondrial 
function in patients with metabolic disorders could both correct fundamental metabolic 
deficiencies involved in the chronic progression of disease, and could attenuate injury associated 







Definition and overview 
 Mitochondrial biogenesis is an increase in cellular mitochondrial content through the 
growth of existing mitochondria or the generation of new, functional mitochondria [181].  
Mitochondrial biogenesis can occur as a result of de novo synthesis of new mitochondria, the 
formation of mitochondria from other membranous structures, or the growth and/or division of 
existing mitochondria [182].  Mitochondrial biogenesis occurs under normal physiological 
conditions, but can be rapidly and potently induced in response to various stimuli with increased 
energy demands including repair responses to injury, cold exposure and caloric restriction [183-
185].  Mitochondrial biogenesis is primarily regulated by the nuclear transcriptional coactivator 
peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1α) (Figure 1.8).  PGC-1α 
exerts its effects through enhancing transcriptional activity of the nuclear transcription factors 
(NRF1 and NRF1) and the mitochondrial transcription factors TFAM, TFB1M and TFB2M 
[171, 186-188].   
 
Physiological and pathophysiological activation of mitochondrial biogenesis 
 Signaling pathways promoting mitochondrial biogenesis are activated in response to a 
diverse array of physiological stimuli with increased energetic demand (Figure 1.11).  
Mitochondrial biogenic responses to exercise training in muscle cells, cold exposure to brown 
adipose tissue and caloric restriction are described below.  Additionally, mitochondrial 
biogenesis has been shown to be upregulated in response to cellular injury, including renal cells, 





Figure 1.11.  Diverse physiological signals regulate mitochondrial biogenesis in a tissue- 
specific manner. Shown are signaling pathways that induce mitochondrial biogenesis in 
skeletal muscle in response to endurance exercise or caloric restriction, in BAT in response 
to cold exposure, and in macrophages in response to signals promoting alternative 
activation. The signals enhance activity (orange outlines) and/or expression (upward blue 

















 Increased physical activity creates an increased energetic demand that in part is met by 
induction of mitochondrial biogenesis, particularly within the skeletal muscle.  Induction of 
mitochondrial biogenesis in skeletal muscle is triggered by increased cytosolic Ca2+ levels 
occurring during muscle contraction and activation of AMPK in response to an energetic deficit 
[190].  Furthermore, activation of the sympathetic nervous system and subsequent adrenergic 
receptor stimulation activates cAMP signaling, a known inducer of mitochondrial biogenesis.  
Following even a single occurrence of intense exercise, mitochondrial gene expression is 




 PGC-1α expression and activity is induced following cold exposure due to activation of 
the sympathetic nervous system and subsequent stimulation of adrenergic receptors, primarily in 
brown adipose tissue (BAT) [183].  Adrenergic receptor activation leads to increased cAMP 
levels causing activation of the protein kinases PKA and p38 MAPK, and the transcription factor 
cAMP-response element-binding protein (CREB).  Additionally, induction of PGC-1α stimulates 
the activity of uncoupling protein 1 (Ucp1), causing heat generation by uncoupling of the 
mitochondrial proton gradient from ATP generation [183, 196, 197]. 
 
Caloric restriction. 
 Mitochondrial biogenesis is highly induced in animals and humans when caloric intake is 
restricted.  This effect is believed to be mediated primarily through the activation of AMPK and 
44  
sirtuin 1 (SIRT1) [198, 199].  Endothelial nitric oxide synthase (eNOS) has also been 
demonstrated to be induced by caloric restriction and involved in the mitochondrial biogenic 
response [200].  Activation of these pathways regulates PGC-1α activity and expression and 
enhances the efficiency of nutrient utilization by the mitochondria for energy [201-203].  
 
Mitochondrial biogenesis in renal injury.   
 Following acute oxidant exposure in renal proximal tubular cells (RPTC), mitochondrial 
function is severely compromised, evidenced by reductions in cellular ATP levels and 
mitochondrial oxygen consumption [204, 205].  Mitochondrial function recovers in this model 
spontaneously over the course of 6 d after exposure, and this recovery is mirrored by the 
induction of PGC-1α through the Src-EGFR-p38 MAPK signaling pathway (Figure 1.12) [204, 
206].  Furthermore, overexpression of PGC-1α following oxidant injury promoted recovery of 
mitochondrial protein expression, cellular ATP levels and mitochondrial oxygen consumption 
(Figure 1.13) [207].  Finally, stimulation of mitochondrial biogenesis using the β2-adrenergic 
agonist, formoterol accelerated recovery of renal and mitochondrial function after I/R-induced 








Figure 1.12.  Induction of PGC-1α protein (A,B) correlates with recovery of basal (C) 





Figure 1.13.  Overexpression of PGC-1α after oxidant injury restored mitochondrial 
protein expression (A), as well as total cellular ATP (B) and basal (C) and uncoupled 











Figure 1.14. Formoterol stimulates mitochondrial biogenesis and promotes recovery of 
renal and mitochondrial function after I/R.  Mice were subjected to sham surgery or I/R 
surgery and treated daily with saline vehicle or formoterol beginning at 24 h after reperfusion.  
Renal function and damage were assessed by serum creatinine and Kim-1 expression.  
Mitochondrial protein expression was measured by immunoblot [148]. 
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Pharmacological activation of mitochondrial biogenesis 
MB is a tightly controlled cellular process coordinated by several nuclear-encoded 
transcription factors, and a set of transcriptional co-activators and co-repressors [171, 188].  
Identification of stimulators of expression or activity of PGC-1α, a transcriptional co-activator of 
NRF-1 and master regulator of MB, has been a central focus of development of mitochondrial 
therapies.   Modulation of MB has been accomplished through manipulation of an array of 
upstream energy sensing pathways including AMP kinase, sirtuins and cyclic nucleotides (cAMP 
and cGMP), as well as, through direct pharmacological activation of downstream effectors 
including peroxisome proliferator-activated receptors (PPARs) and estrogen-related receptors 















Class Drugs Mitochondrial biogenic effects References 















Formoterol ↑PGC-1α, ↑mtDNA in RPTC, recovery 
of MB following mouse I/R 
[148, 219] 
5HT agonists LY 344,864 
DOI 
↑PGC-1α, ↑mtDNA in RPTC, recovery 
of MB following mouse I/R 
[150, 220] 
CB1 antagonists Rimonabant Activation of eNOS, ↑mtDNA, ↑ mito 
mRNA in mouse adipocytes 
[221] 
Nuclear receptor agonists 
PPARα agonists Fibrates Activation of AMPK and PGC-1α in 
multiple models 
[222-226] 
PPARγ agonists Thiazolidinediones ↑PGC-1α, ↑mtDNA in adipose tissue in 
diabetes  
[227, 228] 
PPARδ agonists GW501516 ↑PGC-1α, ↑FAO in muscle and heart [229] 
Glucocorticoid 
agonists 
Dexamethasone ↑PGC-1 α, ↑Tfam in liver, ↑MB in 
muscle with chronic administration 
[230, 231] 
cGMP modulators 
PDE inhibitors Sildenafil 
Vardenafil 
↑PGC-1α, ↑mtDNA in RPTC, recovery 





DETA-NO ↑PGC-1α, ↑mito mRNA, ↑ respiration in 
culture models 
[233-236] 
GC activators BAY 41-2272 
Cinaciguat 
Riociguat 
↑PGC-1α, ↑mito mRNA, ↑mito function 
in cell models and adipose tissue, 
protective in I/R and LPS models 
 
[233, 237, 238] 
Naturetic peptides ANP 
BNP 
ANP: ↑PGC-1 α , ↑UCP-1 in adipocytes 
BNP: ↑PGC-1α, ↑mito content in muscle 








↑PGC-1α, ↑mtDNA following CsA 
toxicity in kidney 
[242] 
Lipoamide ↑PGC-1α, ↑mtDNA in adipocytes [243] 
Isoflavones SIRT1 activation, ↑PGC-1α, ↑mito 
mRNA in RPTC 
[244] 





Recombinant Tfam ↑MB, ↑respiration in aged mice, LPS 
model 
[247, 248] 
Donor mtDNA ↑MB, ↑respiration in LHON and LS cells [249] 





 AMP kinase (AMPK) is critical metabolic switch which is activated by an increased 
AMP/ATP ratio, indicating low cellular energy status.  Activation of AMPK triggers increased 
glucose uptake, increased oxidative metabolism and MB [250].  AICAR acts as an AMP analog 
and has been used extensively as an AMPK activator and stimulator of MB [208-212].  AICAR 
has been described as an ‘exercise mimetic’ due to its ability to stimulate oxidative metabolism 
gene programs and increase endurance [251].  AICAR has also shown positive effects in both 
acute and chronic disease models characterized by mitochondrial dysfunction.  Pre-conditioning 
of rats with AICAR was protective against cardiac I/R injury through enhancement myocardial 
glucose uptake [252].  AICAR was also shown to limit renal ischemia reperfusion injury in the 
rat kidney [253].  Chronic administration of AICAR prevented the development of 
hyperglycemia and insulin resistance in ZDF rats [254].  Finally, AICAR was shown to protect 
against cisplatin-induced renal injury in mice through SIRT3-mediated enhancement of 
mitochondrial dynamics and function [255]. 
 
Sirtuins 
Sirtuins are a family of protein deacetylases that have been linked to MB and function.  
Of this family, SIRT1 has garnered the most interest due to its positive regulation by the 
oxidized coenzyme NAD+ and its ability to act as a positive transcriptional regulator of PGC-1α 
and other mitochondrial associated genes through promoter deacetylation [211, 256].  
Resveratrol, a stilbenoid found in red wine, has been extensively studied as a SIRT1 activator 
and stimulator of MB.  Resveratrol has been shown to enhance MB and oxidative metabolism, 
and be protective in animal models of cardiovascular disease, neurodegeneration and metabolic 
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syndrome [257-263].  Evaluation of resveratrol in humans has shown positive effects on insulin 
resistance and glycemic control in diabetic patients [264].  Therapeutic application of resveratrol 
is limited by its low potency and poor bioavailability, which has led to the development of a new 
class of synthetic small molecule SIRT1 activators including SRT1720, SRT1460, SRT2104 and 
SRT237.  These compounds have been shown to improve insulin resistance and lower plasma 
glucose in type 2 diabetic animals, while improving mitochondrial oxidative capacity [265].  
SRT1720 significantly increased lifespan in obese mice fed a high fat diet [217].  Additionally, 
SRT1720 has been demonstrated to promote recovery from renal ischemia/reperfusion injury 
through activation of SIRT1/PGC-1α and stimulation of MB [218].  In addition to resveratrol, 
several other natural products including quercetin, a flavonoid found in an array of different 
foods, and daidzein and genistein, isoflavones found in soybeans, can induce SIRT1 and 
positively regulate MB [244, 266]. 
In addition to SIRT1, SIRT3, which acts within the mitochondrial matrix, is critical for 
mitochondrial homeostasis. SIRT3 has been shown to regulate a wide range of mitochondrial 
processes, including ETC efficiency [267], maintenance of mtDNA integrity (30) and 
mitochondrial antioxidant status [121, 267].  Its reduction, at least in part, is thought to 
contribute to increased mitochondrial fission, a necessary event in mitochondrial turnover.  As 
mentioned above, SIRT3 has been shown to be a critical downstream mediator of the protective 
effects of AICAR treatment in renal injury models. These data suggest sirtuins are critical 
mediators of mitochondrial homeostasis, and that direct or indirect pharmacological activation of 




β-adrenergic agonists and cAMP 
 Early work on the transcriptional regulation of PGC-1α demonstrated a response to 
external stimuli including cold temperatures [197].  The transcriptional activation of PGC-1α and 
associated MB was linked to activation of the sympathetic nervous system and subsequent 
release of endogenous adrenergic receptor agonists including norepinephrine.  Release of 
norepinephrine leads to activation of β-adrenergic receptors, stimulation of adenylate cyclase and 
an increase in intracellular cAMP.  Activation of protein kinase A (PKA) by elevated cAMP 
causes the phosphorylation and activation of cAMP response element-binding protein (CREB), 
which serves as a transcriptional activator of PGC-1α.  Thus, modulators of endogenous 
adrenergic ligands or use of pharmacological activators of adrenergic signaling could stimulate 
MB through this canonical pathway.   
Formoterol, a long-acting β2-adrenergic receptor agonist, was shown to stimulate 
mitochondrial respiration and expression of PGC-1α and PGC-1α dependent gene expression in 
primary cultures of renal proximal tubular cells and mouse renal cortex [219].  Administration of 
formoterol 24 h after I/R-induced AKI in mice accelerated the recovery of mitochondrial and 
renal function through enhancement of MB [148].  Interestingly, another β2-adrenergic receptor 
agonist, clenbuterol, was shown to inhibit MB in muscle through activation of the negative 
regulator of MB, RIP140, and suppression of PGC-1α [268].  These data suggest a functional 
selectivity of various β2-adrenergic agonists for activation of MB.  Indeed, in  a 2013 study by 
Peterson et al. a panel of β-adrenergic agonists, endogenous ligands of adrenergic receptors, and 
similar compounds were probed for their ability to stimulate MB in primary cultures of renal 
cells [269].  Three distinct phenotypes were observed: full MB, partial MB, and no MB among 
the panel of compounds.  These data were used to construct pharmacophores for the 
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identification of spatial and chemical characteristics required for activation of MB in this class of 
compounds.  These studies could guide the development of novel pharmacological activators of 
MB with structural similarity to a subset of classical β-agonists.   
 
eNOS, naturetic peptides and cGMP modulators 
 There is increasing evidence for a role of the second messenger cGMP in MB.  Caloric 
restriction was demonstrated to induce MB in mice through the induction of endothelial nitric 
oxide synthase (eNOS) [200].  Furthermore, eNOS-deficient mice demonstrate reduced 
metabolic rates and increased weight gain compared to control mice [270].  Stimulation of eNOS 
leads to generation and release of NO from the endothelium causing the activation of soluble 
guanylate cyclase (sGC) and subsequent production of cGMP.    Activation of the NO/cGMP 
signaling pathway through the use of NO donors, cGMP mimetics or sGC activators stimulates 
PGC-1α associated MB and mitochondrial function in vitro [233].  Furthermore, the sGC 
activator, BAY 41-2272 increased brown fat differentiation through induction of UCP-1, PGC-
1α and other mitochondrial target genes.  The sGC stimulator, cinaciguat (BAY 58-2667) was 
demonstrated to be protective in cardiac I/R injury through protein kinase G (PKG) dependent 
induction of H2S, a known inducer MB [237].   
Natriuretic peptides, including atrial natriuretic peptide (ANP) and brain natriuretic 
peptide (BNP), polypeptide hormones primarily responsible for vascular tone and natriuresis, 
exert their effects through activation of membrane bound guanylate cyclases (NPRA/GC-A and 
NPRB/GC-B) leading to the production of cGMP.  Overexpression of brain natriuretic peptide 
(BNP) in mice fed a high fat diet reduced weight gain and insulin resistance, while partial 
knockdown of GC-A resulted in increased body fat and reduced insulin sensitivity [239].  
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Additionally, exercise induces the expression of NPRA/GC-A which correlates with the 
expression of PGC-1α-dependent genes in muscle [240].  Finally, treatment of myotubes with 
ANP and BNP stimulates MB and mitochondrial respiration.   Levels of cGMP can also be 
modulated by blunting its degradation.   Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, 
which causes the accumulation of cGMP by blocking its conversion to GMP, stimulates PGC-
1α-dependent MB, mitochondrial function and ATP  in renal proximal tubular cells and renal 
cortex of mice.  Furthermore, post-treatment of mice with sildenafil after induction of folic acid-
induced AKI promotes recovery of mitochondrial biogenic signaling, and reduces renal tubular 
injury [149].  While the mechanisms of cGMP-induced MB are still poorly understood, studies 
have implicated both SIRT1 and protein kinase G (PKG) as important downstream mediators of 
PGC-1α expression and activity [271].   
 
Transcription factor agonists 
 An array of nuclear receptors agonists, including peroxisome proliferator-activated 
receptors (PPAR) and estrogen-related receptors (ERR) have been evaluated for their ability to 
regulate cellular metabolism and mitochondrial function.  Modulation of these pathways have 
demonstrated positive effects on MB and mitochondrial function, and disease outcomes in 
multiple animal and cellular models.   Treatment with PPARγ agonists, pioglitazone and 
rosiglitazone, stimulates MB and protects SH-SY5Y neuronal cells from glucose deprivation-
induced cell death [272].  Additionally, the compounds bardoxolone and gallic acid exert a 
protective effect in renal I/R injury through activation of PPARγ-dependent transcriptional 
programs [273, 274].  Finally, agonism of PPARγ using rosiglitazone has shown efficacy in the 
treatment of type II diabetes mellitus, potentially through its effects on MB and oxidative 
metabolism [228].   
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Activation of PPARα using fibrates positively modulates mitochondrial function and 
biogenesis through complex signaling pathways involving several protein kinases, sirtuins and 
interaction with the transcriptional co-activators PGC-1α and PGC-1β .   Despite positive results 
in several model systems, use of these highly active nuclear receptors agonists has been limited 
by safety concerns.  Recent efforts have also been made to directly target the replication of 
mtDNA using a membrane-penetrant recombinant human Tfam protein (rhTfam) designed with 
a mitochondrial targeting sequence.  Treatment of aged mice with rhTfam stimulates MB in 
heart, brain and muscle, and slows the progression of cognitive decline [248].  Additionally, 
rhTfam reduced mortality in mice in an endotoxin-induced sepsis model, which is characterized 
by profound effects on MB signaling [247].  Use of rhTfam provides a highly specific strategy to 
stimulate mtDNA transcription and potentially activate biogenesis of mitochondrial-encoded 
proteins; however, it is unclear how it would exert an effect on the biogenesis of nuclear-encoded 
mitochondrial proteins, and further validation of its role in MB is needed.  
 
Targeting negative regulators of MB 
 MB is a tightly regulated process involving both positive and negative regulators.  
Suppression of MB signaling pathways and reduction in mitochondrial number has been 
observed in various acute and chronic disease states.  In multiple forms of AKI, including I/R 
injury, folic acid nephropathy and sepsis, mitochondrial gene and protein expression is rapidly 
and persistently suppressed [126, 161, 275, 276].  Failure of recovery of MB signaling mirrors 
the incomplete recovery of renal function in these models.  Additionally, MB is suppressed in 
adipose tissue of obese, diabetic mice [277].  MB has also been demonstrated to decline in 
various tissues in an age-dependent manner [278, 279].  Numerous negative regulators of MB 
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have been described, including the transcriptional co-repressor, RIP140, HIF-1α, and several 
kinases including ERK1/2 and p38 MAPK.  However, the upstream mechanisms of suppression 
of MB following injury are still poorly understood.  A link between inflammation and the 
negative regulation of MB has recently been explored.  The pro-inflammatory cytokine, TNF-α 
was shown to reduce PGC-1α expression in the heart through activation of NF-kappaB and p38 
MAPK [280].  Furthermore, TNF-α suppresses eNOS expression and MB in fat and muscle of 
obese mice, which is recovered by administration of NO donors [234].  Interestingly, MB 
signaling has also been linked to the expression of anti-inflammatory genes through dual 
regulation by heme oxygenase-1 [185].   
Damaged mitochondria themselves may provide the signal for the activation of 
inflammation in a diseased tissue.  After tissue injury, damaged mitochondria release various 
proteins and mtDNA, which are recognized by innate immune cells through toll-like receptors 
(TLRs) [281].  Thus, mitochondrial damage leads to a vicious cycle of inflammation that may 
suppress the generation of new, functional mitochondria needed for tissue recovery. These data 
suggest that attenuation of inflammatory signaling in a diseased tissue may support sustained 
MB and cellular recovery.  While significant work is still needed in this area, targeting 
inflammation through the use of anti-inflammatory agents including anti-TNF-α blocking 
antibodies, inhibitors of NF-kappaB, or blockade of specific TLRs may be an effective method to 
re-activate MB in the setting of injury.   
 
Screening and validation of mitochondrial biogenics 
 While significant work has been performed in the identification and evaluation of diverse 
classes of drugs to stimulate MB, many of the identified compounds are limited by 1) poor 
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pathway specificity, 2) off-target toxicities, 3) adverse interactions with existing standard of care 
or morbidities, and/or 4) limited potency and efficacy.  Therefore, continued identification of 
novel compounds targeting canonical and non-canonical pathways to MB is essential.  To 
accomplish this goal, new, high-throughput cellular screening methods are required with outputs 
that accurately reflect increases in mitochondrial content and function that correlates with 
increased bioenergetic capacity of the cell or tissue.  We will discuss the advantages and 
limitations of a high-throughput genetic-based PCR screening procedure for PGC-1α 
transcription, as well as, a physiological-based respirometric screening technique that have both 
led to the identification of positive stimulators of MB.   
 
Gene expression-based screening  
 As discussed above, PGC-1α is a critical transcriptional co-regulator of mitochondrial 
content and oxidative metabolism.  MB is highly dependent upon its expression and activity.  
Therefore, identification of potent stimulators of PGC-1α would likely yield highly active MB 
agents.  Studies performed by the Spiegelman group, used a gene-expression based screening 
technique to identify activators of PGC-1α transcription and mitochondrial metabolism in 
cultured adipocytes and primary skeletal muscle cells [282, 283].  Briefly, cells were cultured in 
384-well plates, treated with compounds of interest and analyzed for PGC-1α mRNA expression 
by real time RT-PCR.  This technique was used to screen ~3000 unique compounds including 
nearly 40% of all FDA-approved drugs.  82 compounds were identified as inducers of PGC-1α in 
cultured myotubes, including glucocorticoids, tubulin inhibitors and protein synthesis inhibitors.  
Screening results from cultured adipocytes identified the CB1 receptor antagonist, AM-251, as a 
potent inducer of PGC-1α mRNA expression.  However, additional CB1 antagonists, SLV319 
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and CAY10505, failed to induce PGC-1α expression.  Examination of alternate targets of AM-
251 led to the identification of antagonism of the Transient Receptor Potential Vanilloid (TRPV) 
family of ion channels as a strategy for induction of PGC-1α.  As PGC-1α mRNA expression 
does not directly indicate increased mitochondrial content and function and changes in PGC-1a 
mRNA and protein over time, confirmatory assays measuring mitochondrial protein expression 
and mitochondrial respiration were performed for hits from both screens.  Evaluation of TRPV4 
antagonism in mouse model of diabetes and metabolic syndrome demonstrated decreased weight, 
improved insulin sensitivity and decreased systemic inflammation.  These results demonstrate 
that gene expression-based screening using PGC-1α can be a simple and efficient technique for 
identification of MB agents in cultured cells that are applicable to more complex models.  While 
the technique is useful as an initial screen, any hits require extensive further evaluation to 
demonstrate if increased PGC-1α expression correlates with increased mitochondrial gene and 
protein expression, and if the compounds tested have direct effects on mitochondrial function 
and homeostasis.  Furthermore, this assay would fail to detect any compounds capable of 
inducing MB through PGC-1α independent mechanisms. 
 
High-throughput respirometry and virtual screening 
 The goal of MB is not merely to increase mitochondrial content, but increase the 
functional mitochondrial capacity of a cell or tissue.  Therefore, measurement of mitochondrial 
respiration may be a useful indicator of MB.  However, application of this technique as a screen 
of compound libraries has been limited by the altered mitochondrial phenotypes of cultured cells 
and lack of instrumentation for high-throughput respirometry.  Our lab developed a culture 
model of renal proximal tubular cells (RPTCs) that exhibit high, physiological levels of aerobic 
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metabolism, and adapted this model to a 96-well plate respirometric assay using the Seahorse 
Bioscience XF96 Extracellular Flux Analyzer (Figure 2).  Assessment of FCCP-uncoupled 
respiration was shown to be a marker of maximal mitochondrial ETC activity and was increased 
in RPTC with increased MB induced by administration of DOI, SRT1720, resveratrol, daidzein, 
and metformin [284].   
Using the assay, we screened a library of ~2000 compounds from the Sigma LOPAC and 
ChemBridge DIVERSet libraries for MB by measuring FCCP-uncoupled mitochondrial 
respiration.  This led to the identification of several new classes of compounds that increase 
mitochondrial function (e.g. β2-adrenergic receptor agonists).  Changes in mitochondrial 
respiration were confirmed to be due to activation of MB by evaluation of the induction of 
mitochondrial gene and protein expression, and mtDNA copy number in cellular and animal 
models.   
 One of the classes of compounds identified were agonists of the 5-hydroxytryptamine 
(serotonin)-1F receptor (5HT-1F), including LY334370 and LY344864 which have no previous 
association with known pathways of MB or mitochondrial function.  Validation studies of the 
agonist LY344864 demonstrated its ability to induce PGC-1α and PGC-1α-dependent gene and 
protein expression both in RPTCs and in vivo.  Furthermore, treatment of mice following I/R-
induced AKI with LY344864 promoted recovery of mitochondrial content and accelerated 
recovery of renal function [150].  Identification of novel stimulators of MB that function in 
disease models demonstrates the efficacy of high-throughput respirometry to screen large 
chemical libraries for the identification of non-canonical regulatory pathways of mitochondrial 
function.  Combining this phenotypic screen with a virtual screening procedure would provide 
the benefit of a physiological readout duplexed with the computational power to evaluate 
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millions of compounds.  Development of pharmacophore models based on the structures of 
known MB agents could be used to screen large virtual libraries for chemical similarity to 
identify novel compounds.  Further analysis of identified hits by clustering based on Tanimoto 
coefficient, determination of root mean square deviation (RMSD) and molecular docking could 
act as screens to identify additional lead compounds for evaluation by respirometry.  In addition 
to identifying MB agents, similar procedures can be used to identify mitochondrial toxicants.  
Use of high-throughput respirometry, high-content imaging for cell viability, and 
chemoinformatic analysis in RPTC allowed for the construction of a mitochondrial toxicophore, 
which could have application in the prediction of mitochondrial toxicity for existing and new 





Figure 1.15: Identification of stimulators of mitochondrial biogenesis with high-throughput 
respirometry and virtual screening.  High-throughput screening for potential mitochondrial 
biogenic agents was performed using a primary rabbit renal proximal tubular cell (RPTC) culture 
model with the Seahorse Bioscience XF96 Extracellular Flux Analyzer.  Screening was 
performed for compounds in the Sigma LOPAC1280 and Chembridge DIVERset chemical 
diversity libraries.  High-throughput screening was duplexed with computational techniques by 
construction of pharmacophores used for screening of the ZINC Clean Leads virtual library 
allowing for the identification of novel chemical hits.  Hits from the high throughput screen were 
validated as mitochondrial biogenic agents by various assays before evaluation in naïve and 
diseased animal models.  Successful agents will proceed into pre-clinical and clinical evaluation 
for safety and efficacy in human disease.  FCCP, Carbonyl cyanide-4 (trifluoromethoxy) 















cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial 










Recent studies demonstrate that mitochondrial dysfunction is a mediator of acute kidney 
injury (AKI).  Consequently, restoration of mitochondrial function after AKI may be key to the 
recovery of renal function.  Mitochondrial function can be restored through the generation of 
new, functional mitochondria in a process called mitochondrial biogenesis (MB).  Despite its 
potential therapeutic significance, very few pharmacological agents have been identified to 
induce MB.  To examine the efficacy of phosphodiesterase (PDE) inhibitors (PDE3: cAMP and 
cGMP activity; and PDE4: cAMP activity) in stimulating MB, primary cultures of renal 
proximal tubular cells (RPTCs) were treated with a panel of inhibitors for 24 hours.  PDE3, but 
not PDE4, inhibitors increased the FCCP-uncoupled oxygen consumption rate (OCR), a marker 
of MB.  Exposure of RPTCs to the PDE3 inhibitors, cilostamide and trequinsin, for 24 hours 
increased peroxisome proliferator-activated receptor γ coactivator-1α, and multiple 
mitochondrial electron transport chain genes.  Cilostamide and trequinsin also increased mRNA 
expression of mitochondrial genes and mitochondrial DNA copy number in mice renal cortex.  
Consistent with these experiments, 8-Br-cGMP increased FCCP-uncoupled OCR and 
mitochondrial gene expression, whereas 8-Br-cAMP had no effect.  The cGMP-specific PDE5 
inhibitor sildenafil also induced MB in RPTCs and in vivo in mouse renal cortex.  Treatment of 
mice with sildenafil after folic acid-induced AKI promoted restoration of MB and renal recovery.  
These data provide strong evidence that specific PDE inhibitors that increase cGMP are inducers 
of MB in vitro and in vivo, and suggest their potential efficacy in AKI and other diseases 




Mitochondrial dysfunction is increasingly recognized as an important pathophysiological 
mediator of a variety of disease states, including neurodegeneration, cardiovascular disease, 
metabolic syndrome and acute organ injury [125, 286-292].  Mitochondrial dysfunction is an 
established component of the pathogenesis of acute kidney injury (AKI) and a cause of renal 
tubular dysfunction and cell death [153-155, 293, 294].   Our group has demonstrated persistent 
disruption of mitochondrial homeostasis and inhibition of mitochondrial biogenesis (MB) after 
ischemia-reperfusion (I/R), rhabdomyolysis-induced AKI, and folic acid (FA)-induced AKI 
[161].   Restoration of mitochondrial number and function is thought to be required for recovery 
from AKI due to the high energy requirements of tissue repair.  These data provide support for 
development of pharmacological agents that induced MB for treatment of AKI and other 
pathologies characterized by mitochondrial dysfunction. 
Mitochondria are dynamic organelles that are continuously regenerated through the 
processes of biogenesis, mitophagy, fission, and fusion [160, 161, 295, 296].  MB is the 
assembly of new mitochondria from existing mitochondria, occurring under basal conditions to 
replace damaged mitochondria, but is rapidly induced in response to both physiological and 
pathophysiological stimuli, including sepsis, exercise, fasting, hypoxia, and cellular injury [197, 
297-299].  The primary regulator of MB is the transcriptional coactivator peroxisome 
proliferator-activated receptor γ coactivator-1α (PGC-1α).  PGC-1α exerts its functions by 
activating the transcription factors, nuclear respiratory factors 1 and 2 (Nrf1 and Nrf2).  Nrf1 
controls the expression of mitochondrial transcription factor A (Tfam), which regulates the 
transcription of mitochondrial DNA (mtDNA) [183, 187, 188, 300].  PGC-1α is enriched in 
tissues with high metabolic demand, including heart, muscle, and kidneys [301].  The ability of 
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PGC-1α to respond to a variety of stimuli and its importance in cellular bioenergetics make it an 
ideal target for pharmacological intervention in disease states characterized by mitochondrial 
disruption.   
Despite the promise of PGC-1α and MB as a therapeutic target, there is a paucity of 
pharmacological agents capable of stimulating PGC-1α expression and activity.  Activators of 
silent mating type information regulation 2 homolog 1 (SIRT1), including isoflavones, 
resveratrol, and N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-
yl]phenyl]quinoxaline-2-carboxamide (SRT1720), have been demonstrated to induce PGC-1α 
and promote increased mitochondrial number and function [162, 214, 244].  Our laboratory also 
identified the 5-hydroxytryptamine type 2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-
aminopropane hydrochloride (DOI), and the β2-adrenergic receptor agonist, formoterol, as 
potent inducers of PGC-1α and MB [219, 220].  Stimulation of MB after injury accelerates 
recovery of cellular morphology and function [162, 207, 220].  These data demonstrate the 
importance of MB in recovery of renal tubular epithelial cells after injury and suggest that agents 
that stimulate MB could serve as viable therapies after AKI. 
Because of the importance the cAMP/protein kinase A (PKA)/cAMP-response element-
binding protein (CREB) axis in PGC-1α regulation, drugs that increase cellular cAMP may 
induce MB.  The β2-adrenergic signaling cascade, which upon activation increases intracellular 
cAMP through Gs-mediated activation of adenylyl cyclase, was shown to regulate oxidative 
metabolism and energy expenditure [302, 303].  Formoterol induces MB in renal proximal 
tubular cells (RPTCs), and mice treated with formoterol demonstrated increased mitochondrial 
gene expression and mtDNA copy number in renal cortex and heart [219].  cGMP levels have 
also been shown to regulate PGC-1α expression and MB.  Pharmacologically induced generation 
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of nitric oxide (NO) via endothelial nitric oxide synthase (eNOS) and subsequent NO-dependent 
activation of guanylyl cyclase led to MB in U937, L6 and PC12 cells [233].   
 Both cAMP and cGMP levels are tightly regulated through cleavage to AMP and GMP, 
respectively, by a class of enzymes called cyclic nucleotide phosphodiesterases (PDEs).  The 
PDE superfamily consists of 11 families differing in tissue distribution, regulation and substrate 
affinity (e.g., cAMP versus cGMP) [304].  Potent, selective inhibitors of nearly all family 
members are available [305].  Inhibition of PDEs could serve as a novel and potentially 
efficacious drug target to induce MB.  As such, we studied inhibitors of PDE3, PDE4, and PDE5 














Cilostamide, trequinsin, (R)-(−)-rolipram, 4-(3-butoxy-4-methoxyphenyl)methyl-2-
imidazolidone (Ro 20-1724), sildenafil, 8-Br-cAMP, and 8-Br-cGMP were purchased from Tocris 
Bioscience (Ellisville, MO).  All other chemicals were obtained from Sigma-Aldrich (St. Louis, 
MO). 
 
Animal Care and Use 
Studies were carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health.  All protocols were 
approved by the Institutional Animal Care and Use Committee at the Medical University of South 
Carolina and all efforts were made to minimize animal suffering. 
 
Isolation and Culture of Proximal Tubules 
Female New Zealand white rabbits (1.5–2.0 kg) were purchased from Charles River 
Laboratories (Wilmington, MA).  RPTCs were isolated using the iron oxide perfusion method 
previously described[306].  For respirometry experiments, cells were plated on 100-mm culture-
grade Petri dishes at 37°C in a 5% CO2/95% air environment.  Dishes were continuously swirled 
on an orbital shaker at 80 rpm. Cell culture media consisted of a 1:1 mixture of Dulbecco’s 
modified Eagle’s essential medium and Ham’s F-12 (lacking glucose, phenol red, and sodium 
pyruvate; Invitrogen, Carlsbad, CA), supplemented with HEPES (15 mM), glutamine (2.5 mM), 
pyridoxine HCl (1 μM), sodium bicarbonate (15 mM), and lactate (6 mM). Hydrocortisone (50 
nM), selenium (5 ng/ml), human transferrin (5 μg/ml), bovine insulin (10 nM), and L-ascorbic 
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acid-2-phosphate (50 μM) were added daily to fresh culture media.  After 3 days of culture, 
dedifferentiated RPTCs were trypsinized and replated on XF-96 polystyrene cell culture 
microplates (Seahorse Bioscience, North Billerica, MA) at a concentration of 18,000 cells per well.  
Cells were maintained at 37°C for an additional 2 days before experimentation [284].  For all other 
RPTC experiments, cells were plated and cultured in 35-mm dishes in the above-described media.  
Experiments were performed on the sixth day after plating when cells had formed a confluent 
monolayer.  RPTCs were treated with various compounds for 24 hours unless otherwise noted. 
 
Oxygen Consumption 
The oxygen consumption rate (OCR) of RPTCs was measured using the Seahorse 
Bioscience XF-96 Extracellular Flux Analyzer according to a previously described protocol[284].  
Each assay plate was treated with vehicle control (dimethylsulfoxide <0.5%), and increasing 
concentrations of the compounds of interest.  Basal OCR was measured before injection of 
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (0.5 μM), allowing for the 
measurement of uncoupled OCR. 
 
Testing of Compounds in C57BL/6 Mice 
Male C57BL/6 mice (aged 6–8 weeks) were obtained from the National Institutes of Health 
National Cancer Institute (Bethesda, MD). Mice were housed individually in a temperature-
controlled room under a 12-hour light/dark cycle.  Mice were randomly assigned to saline control, 
cilostamide (0.3 or 3 mg/kg), trequinsin (0.3 or 3 mg/kg), or sildenafil (0.3 or 3 mg/kg) treatment 
groups. Mice were given a single intraperitoneal injection of saline or compound at the above-
described doses.  Mice were euthanized by CO2 asphyxiation followed by cervical dislocation 24 
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hours after treatment.  Kidneys were removed and preserved by flash-freezing in liquid nitrogen.  
Tissues were stored at −80°C for later analysis. 
 
Folic acid animal model 
Male C57BL/6 mice (aged 8–10 weeks) were given a single intraperitoneal injection of 
250 mg/kg FA dissolved in 250 mM sodium bicarbonate or saline control based on previous 
literature[88].  Mice were injected with sildenafil (0.3 mg/kg) or diluent every 24 hours beginning 
1 day after FA injection. Mice were euthanized at 7 days via isoflurane asphyxiation and cervical 
dislocation.  Kidneys were removed and preserved by flash-freezing. 
 
Quantitative Real-Time Polymerase Chain Reaction 
Total RNA was extracted from RPTCs or renal cortex samples using TRIzol reagent 
(Invitrogen) according to the manufacturer’s protocol.  cDNA was synthesized via reverse 
transcription using the iScript Advanced cDNA synthesis kit (Bio-Rad, Hercules, CA) with 2 μg 
of RNA.  Quantitative real-time polymerase chain reaction (qPCR) analysis was performed with 
cDNA using SsoAdvanced SYBR Green Supermix (Bio-Rad) at a concentration of 1× and primers 
at a concentration of 750 nM (Integrated DNA Technologies, Coralville, IA).  mRNA expression 
of all genes was calculated using the 2-ΔΔCT method normalized to tubulin in RPTCs or β-actin 
in renal cortical tissue.  Primer sequences for PGC-1α, NADH dehydrogenase 6 (ND6), NADH 
dehydrogenase [ubiquinone] 1β subcomplex subunit 8 (NDUFβ8), and tubulin were described 
previously[161]. Primer sequences for NADH dehydrogenase 1 (ND1) and β-actin were as 
follows: ND1, sense 5′-TAGAACGCAAAATCTTAGGG-3′ and antisense 5′-
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TGCTAGTGTGAGTGATAGGG-3′; and β-actin, sense 5′- GGGATGTTTGCTCCAACCAA-3′ 
and antisense 5′-GCGCTTTTGACTCAAGGATTTAA-3′. 
 
mtDNA Content 
Real-time PCR was used to determine the relative quantity of mtDNA in both RPTC and 
mouse renal cortical tissue samples.  After treatment, DNA was extracted from cells or tissue using 
the DNeasy Blood and Tissue Kit (QIAGEN, Valencia, CA) and 5 ng of cellular DNA was used 
for qPCR. For RPTC samples, mitochondrial-encoded ND6 was used to measure mitochondrial 
copy number and was normalized to nuclear-encoded tubulin expression.  For renal cortex, ND1 
was used as the mitochondrial gene and expression was normalized to nuclear-encoded β-actin 
expression. 
 
cAMP and cGMP Enzyme-Linked Immunosorbent Assay 
RPTCs in 35-mm dishes were treated with vehicle control (dimethylsulfoxide) or the 
compound of interest for 20 minutes.  RPTCs were then harvested according to the 
manufacturer’s protocol and cAMP or cGMP levels were measured using a commercially 
available enzyme-linked immunosorbent assay kit (Cayman Chemical, Ann Arbor, MI). 
 
Tissue ATP Levels 
ATP was isolated from renal cortical tissue via phenol-Tris-EDTA extraction as previously 
described[307].  In brief, freshly prepared tissue was homogenized in 3.0 ml ice-cold Tris-EDTA 
saturated phenol.  One milliliter of the homogenate was combined with 200 μl chloroform and 
150 μl of deionized water and vortexed and centrifuged at 10,000g for 5 minutes at 4°C.  An aliquot 
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from the supernatant was diluted 200-fold in deionized water, and ATP levels were measured using 
a luciferin-luciferase–based ATP determination kit (Invitrogen). 
 
Data and Statistical Analysis 
Data are presented as the mean ± S.E.M. Single comparisons were performed using 
the t test.  Multiple comparisons were subjected to one-way analysis of variance followed by the 
Newman–Keuls test, with P < 0.05 considered to be a statistically significant difference between 
means.  RPTCs isolated from a single rabbit represented an individual experiment (n = 1) and were 

















PDE3 Inhibitors, but not PDE4 Inhibitors, Increase FCCP-Uncoupled OCR in RPTCs. 
We treated RPTCs in XF-96 culture plates with the PDE3 inhibitors cilostamide or 
trequinsin, the PDE4 inhibitors (R)-(−)-rolipram or Ro 20-1724, or vehicle control for 24 hours.  
PDE3 hydrolyzes both cAMP and cGMP to their noncyclic forms, AMP and GMP, whereas 
PDE4 specifically hydrolyzes cAMP to AMP [304].  FCCP-OCR increased in RPTCs compared 
with vehicle control after 24-hour exposure to cilostamide (25–100 nM) and trequinsin (30–100 
nM) (Figure 2.1A, 2.1B), but no significant changes were observed in FCCP-OCR after 
treatment with (R)-(−)-rolipram (0.5–50 µM) or Ro 20-1724 (5–20 µM) (Figure 2.1C, 2.1D).  
These data suggest a functional selectivity for the MB response between PDE3 and PDE4 
inhibition in RPTCs. 
PDE3 Inhibitors Induce MB in RPTCs. 
To validate that the increased FCCP-OCR observed in RPTCs after treatment with PDE3 
inhibitors was due to MB, mRNA levels for PGC-1α, the mitochondrial-encoded complex I 
protein ND6, and the nuclear-encoded complex I protein NDUFβ8 were measured via qPCR.  
Gene expression was normalized to tubulin. PGC-1α levels increased versus control after 
treatment with cilostamide (1.8-fold) or trequinsin (2.5-fold) (Figure 2.2).  In addition, mRNA 
expression of mitochondrial-encoded ND6 and the nuclear-encoded NDUFβ8 mitochondrial 
proteins were increased versus control with cilostamide (1.5- and 2.2-fold, respectively) and 
trequinsin (1.8- and 2.4-fold, respectively).  These data provide strong evidence that inhibition of 





Figure 2.1: PDE3 inhibitors, but not PDE4 inhibitors, increase FCCP-induced uncoupled 
mitochondrial respiration in RPTCs.  RPTCs were treated with cilostamide (A), trequinsin 
(B), (R)-(−)-rolipram (C), or Ro 20-1724 (D) for 24 hours.  FCCP-uncoupled mitochondrial 
respiration was measured using the Seahorse XF-96 instrument.  Data are presented as the mean 






Figure 2.2: PDE3 inhibitors, cilostamide or trequinsin, induce mitochondrial gene 
expression in RPTCs.  RPTCs were exposed to cilostamide (25 nM) or trequinsin (30 nM) for 
24 hours and evaluated for changes in mRNA expression of PGC-1α, ND6, and NDUFβ8 
relative to dimethylsulfoxide controls.  Data are presented as the mean 6 S.E.M. (n ≥ 4). *p < 










Increased cGMP, but Not cAMP, Induces MB in RPTCs. 
To examine the functional selectivity of PDE3 and PDE4 inhibitors under conditions that 
induce MB, RPTCs were treated with the PDE3 inhibitors cilostamide and trequinsin, the PDE4 
inhibitor (R)-(−)-rolipram, or vehicle control for a period of 20 minutes.  Sildenafil, a specific 
inhibitor of PDE5 (cGMP-specific PDE), was included as a control.  Both cAMP and cGMP 
levels increased in response to cilostamide and trequinsin compared with vehicle control, 
whereas cAMP only increased in RPTCs treated with rolipram (Figure 2.3A, 2.3B).  RPTCs 
treated with sildenafil resulted in increased cGMP, but not cAMP.  These data agree with the 
classic mechanisms of PDE3 (hydrolyzes both cAMP and cGMP), PDE4 (hydrolyzes only 
cAMP), and PDE5 (hydrolyzes only cGMP) [305].  The inability of rolipram and other PDE4 
inhibitors tested to induce MB suggests that cGMP may be the primary mediator of MB in 
RPTCs. 
To test this hypothesis, we treated RPTCs with the cell-permeable cyclic nucleotide 
analogs, 8-Br-cAMP and 8-Br-cGMP for a 24-hour period.  RPTCs treated with 8-Br-cGMP 
(10–300 μM) showed an approximately 20% increase in FCCP-uncoupled OCR at all 
concentrations tested, whereas treatment with 8-Br-cAMP resulted in no change (Figure 2.3C).  
To validate that this increase in FCCP-OCR is due to stimulation of MB, mRNA expression of 
PGC-1α, ND6, and NDUFB8 was measured by qPCR. RPTCs treated with 8-Br-cGMP had 
elevated mRNA levels of PGC-1α (2.2-fold), ND6 (1.7-fold), and NDUFB8 (1.9-fold).  8-Br-
cAMP had no effect on mitochondrial gene expression (Figure 2.3D).  
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Figure 2.3: PDE inhibitor–induced increases in cGMP, but not cAMP, stimulate MB in 
RPTCs.  cAMP (A) and cGMP (B) levels were measured in RPTCs by enzyme-linked 
immunosorbent assay 20 minutes after treatment with dimethylsulfoxide, cilostamide (25 nM), 
trequinsin (30 nM), rolipram (0.5 μM), or sildenafil (10 nM).  (C) FCCP-uncoupled 
mitochondrial respiration was measured using the Seahorse XF-96 instrument after 24-hour 
treatment with 8-Br-cAMP or 8-Br-cGMP.  (D) RPTCs were exposed to 8-Br-cAMP (10 μM) or 
8-Br-cGMP (10 μM) for 24 hours and evaluated for changes in mRNA expression of PGC-1α, 
ND6, and NDUFβ8 relative to dimethylsulfoxide controls.  Data are presented as the mean ± 







Furthermore, to test the ability of a PDE5 inhibitor to induce MB in vitro, RPTCs were treated 
with sildenafil for 24 hours (1 nM–1 μM) and FCCP-OCR was measured using the Seahorse 
XF96. RPTCs treated with sildenafil showed an approximately 20% increase in FCCP-uncoupled 
OCR versus controls (Figure 2.4A) at 10 and 100 nM.  To validate that the increase in respiration 
was due to MB, mRNA levels of PGC-1α, ND6, and NDUFB8 were measured and were found to 
increase 1.8-, 2.0-, and 1.5-fold, respectively (Figure 2.4B). 
PDE3 Inhibitors Induce MB in Mouse Renal Cortex. 
In kidneys of cilostamide-treated mice, PGC-1α was induced 2- and 2.7-fold at doses of 
0.3 and 3 mg/kg, respectively.  Trequinsin induced PGC-1α 2.7- and 2.8- fold in the kidney at 
doses of 0.3 and 3 mg/kg.  mRNA expression of the nuclear-encoded mitochondrial genes 
NDUFB8 and ATPSβ both increased greater than 2-fold in kidneys of mice treated with either 
cilostamide or trequinsin at 0.3 or 3 mg/kg (Figure 2.5A, 2.5B).  The mitochondrial-encoded 
mitochondrial genes ND1 and cytochrome c oxidase subunit I (COX1) increased in the kidneys 
of these mice.  The mtDNA copy number was also increased in the kidneys of mice treated with 
cilostamide at 0.3 mg/kg, whereas mice treated with 3 mg/kg cilostamide had no effect (Figure 
2.5C).  Trequinsin increased mtDNA copy number in the kidneys 1.6- and 2-fold at doses of 0.3 
and 3 mg/kg, respectively (Figure 5D).  These data provide strong evidence that pharmacological 








Figure 2.4: The PDE5 inhibitor sildenafil stimulates MB in RPTCs.  Sildenafil increases 
FCCP-uncoupled mitochondrial respiration at various doses (A) and mitochondrial gene 
expression at 10 nM (B) in RPTCs.  mRNA expression of PGC-1α, ND6, and NDUFβ8 is 



















Figure 2.5: PDE3 inhibitors, cilostamide and trequinsin, induce mitochondrial gene 
expression and mtDNA copy number in mouse renal cortex.  mRNA expression and mtDNA 
copy number were evaluated in the renal cortex of mice 24 hours after a single intraperitoneal 
injection of cilostamide (A and C) or trequinsin (B and D).  Values indicate fold change relative 










Sildenafil Induces MB in Mouse Renal Cortex. 
The selectivity of the MB response for cGMP in RPTCs indicates that inhibitors of 
cGMP-specific PDEs, such as PDE5, may in fact be a better therapeutic target and could 
eliminate off-target effects due to the accumulation of cAMP.  PDE5 inhibitors also have a much 
more favorable safety protocol than PDE3 inhibitors, particularly for extended administration 
[308]. 
To determine whether PDE5 inhibition is capable of inducing MB in the kidney in vivo, 
mice were given a single intraperitoneal injection of sildenafil (0.3 or 3 mg/kg) or saline control.  
Mice were euthanized and kidneys were harvested 24 hours after treatment.  mRNA levels of 
PGC-1α, NDUFB8, ND1, ATPβ, and COX1 were measured by qPCR.  All mitochondrial genes, 
except for COX1 and ATPSβ, were increased in mice treated with 3 mg/kg sildenafil versus 
saline-treated animals (Figure 2.6A).  mtDNA copy number was assessed by qPCR in kidneys of 
sildenafil-treated mice and was found to increase 1.6-fold in mice treated with 0.3 mg/kg 
sildenafil.  No change in mtDNA copy number was observed in mice treated with 3 mg/kg 
sildenafil (Figure 2.6B). 
To assess whether sildenafil-induced MB increased mitochondrial function in the kidney 
cortex, we measured ATP levels.  ATP levels increased 32% in mice treated with 0.3 mg/kg 
sildenafil compared with control mice (Figure 2.6C).  These data strongly support our hypothesis 








Figure 2.6: Sildenafil induces mitochondrial gene expression, mtDNA copy number, and 
ATP levels in mouse renal cortex.  mRNA expression (A), mtDNA copy number (B), and ATP 
levels (C) were evaluated in the renal cortex of mice 24 hours after a single intraperitoneal 
injection of sildenafil.  Values indicate fold change relative to dimethylsulfoxide controls.  Data 









Sildenafil Promotes Recovery of MB and Renal Function after FA-Induced AKI. 
To test the hypothesis that sildenafil-induced MB will accelerate recovery of 
mitochondrial and renal function after AKI, we induced AKI by injecting FA and then treated 
these mice with sildenafil or vehicle once daily starting at 24 hours after injury for 6 days.  
mRNA expression of COX1 and Tfam were reduced to 27 and 36% of control, respectively, in 
FA-treated mice receiving vehicle control at 6 days.  Sildenafil-treated FA mice demonstrated a 
1.6-fold increase in mRNA COX1 expression to 43% of control mice, and a 1.4-fold increase in 
Tfam expression to 50% of control (Figure 2.7A).  mtDNA copy number was reduced to 36% of 
animals receiving FA alone, and treatment with sildenafil caused an approximately 2-fold 
induction to 63% of control (Figure 2.7B).  These data demonstrate that sildenafil can induce 
MB in a model of AKI. 
To examine whether MB promoted renal recovery, kidney injury molecule-1 (KIM-1), a 
specific marker of tubular injury, was measured in renal cortex.  KIM-1 levels were markedly 
increased (approximately 6-fold) in FA-treated animals compared with control animals and 
treatment of FA mice with sildenafil restored KIM-1 expression to control levels (Figure 2.7C, 
2.7D).  These data demonstrate that sildenafil promotes renal recovery with its induction of 







Figure 2.7: Sildenafil stimulates MB after FA-induced AKI.  AKI was induced in C57BL/6 
by a single intraperitoneal injection of FA.  Mice received daily injections of sildenafil (0.3 
mg/kg) or saline vehicle beginning 24 hours after FA.  Mice were killed and kidneys were 
collected 7 days after FA administration.  mRNA expression (A) and mtDNA copy number (B) 
were evaluated in the renal cortex.  Immunoblotting was performed for renal cortical assessment 
of KIM-1 expression (C) and quantified via densitometry (D).  Data are presented as the mean ± 











Mitochondria are highly regulated organelles whose function is tightly linked to the 
metabolic demands and health of a cell [160, 161, 295, 296].  Mitochondrial function is 
necessary for normal cell and tissue function, and is critical in energy-dependent repair 
processes.  A wide array of disease states are characterized by mitochondrial dysfunction, 
including diabetes, neurodegenerative disease, traumatic brain injury, and acute organ injury 
[287, 289, 291, 292, 309].  I/R and drug/toxicant-induced renal injury demonstrate mitochondrial 
dysfunction and suppression of MB, and recovery of renal function is tightly linked to the 
restoration of mitochondrial number and function [161].  This suggests that development of 
therapies capable of inducing MB may have great potential in the treatment of a broad range of 
disease states. 
Despite strong evidence supporting mitochondria as a therapeutic target, there are very 
few drugs/chemicals available that promote mitochondrial function or MB.  Many of the agents 
that are available suffer from lack of specificity, low potency, or poor toxicity profiles.  There is 
a clinical need to develop new pharmacological agents or identify existing therapeutics that 
induce MB.  Because of the role of cyclic nucleotides as regulators of PGC-1α, in this study, we 
sought to determine the efficacy of various classes of PDE inhibitors at stimulating MB. 
The cAMP/PKA/CREB signaling cascade is a well characterized regulator of PGC-
1α expression and activity [310].  Increases in intracellular cAMP levels cause activation of PKA 
and subsequent phosphorylation and activation of CREB, an important transcriptional regulator 
of PGC-1α.  Induction of cAMP levels in the cell occurs after activation of various G protein-
coupled receptors.  Our laboratory recently identified the β2-adrenergic agonist, formoterol, as a 
potent inducer of MB in the kidney and heart [219].   β-agonism was previously shown to induce 
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PGC-1α in skeletal muscle of treated mice [311].  In addition, exercise-induced MB can be 
blocked by treatment with β-receptor antagonists, propranolol and ICI-118,551.  cAMP levels in 
the cell are controlled both by the rate of synthesis and the rate of turnover by cyclic nucleotide 
PDEs.  Therefore, inhibition of PDEs that hydrolyze cAMP may serve as a viable intervention to 
induce MB. 
To test this hypothesis, we screened a panel of PDE3, PDE4, and PDE5 inhibitors using a 
phenotypic respirometric assay.  FCCP-uncoupled OCR was used as a marker of increased 
energetic capacity and MB.  Interestingly, PDE3 and PDE5 inhibitors increased FCCP-
uncoupled OCR in RPTCs, whereas none of the PDE4 inhibitors tested caused an increase 
(Figures 2.1 and 2.4).  To further probe the functional selectivity of PDE3, PDE4, and PDE5 
inhibition in promoting MB, cAMP and cGMP levels were measured in RPTCs after treatment 
with the PDE3 inhibitors cilostamide and trequinsin, the PDE4 inhibitor rolipram, or the PDE5 
inhibitor sildenafil.  PDE3 inhibition led to increases in levels of both cAMP and cGMP in 
RPTCs, whereas rolipram increased only cAMP levels and sildenafil increased only cGMP 
levels (Figure 2.3).  These data correspond with the classic substrate affinities of the various 
PDE family members: PDE3 hydrolyzes both cAMP and cGMP with nearly equal affinity, PDE4 
specifically hydrolyzes cAMP, and PDE5 specifically hydrolyzes cGMP [304, 305].  Finally, 8-
Br-cGMP increased FCCP-uncoupled OCR in the respirometric assay and increased mRNA 
expression of mitochondrial genes after 24-hour treatment. 8-Br-cAMP had no effect on 
respiration of mitochondrial gene expression in RPTCs.  This multipronged approach strongly 
supports our hypothesis that cGMP, rather than cAMP, is important for regulation of MB in renal 
tubules. 
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cGMP was previously demonstrated to induce MB through the eNOS/NO soluble 
guanylate cyclase/cGMP signaling cascade.  In 2004, Nisoli et al. [233] showed that long-term 
administration of NO mimetics, guanylyl cyclase activators, or 8-Br-cGMP increased mRNA 
expression of mitochondrial genes, mtDNA copy number, mitochondrial respiration, and ATP 
levels in multiple cell lines.  eNOS-deficient mice have a reduction in metabolic rate and 
accelerated weight gain, which has been correlated with reduced mitochondrial content and 
function [270]. 
Both the PDE3 inhibitors cilostamide or trequinsin (0.3–3 mg/kg) and the PDE5 inhibitor 
sildenafil (0.3–3 mg/kg) when administered to naïve mice induced renal cortical mRNA 
expression of PGC-1α, nuclear-encoded mitochondrial genes (NDUFB8 and ATPSβ), and 
mitochondrial-encoded mitochondrial genes (ND1 and COX1).  mtDNA copy number was also 
increased in the renal cortex of these mice (Figures 2.5 and 2.6).  Sildenafil increased the number 
of functional mitochondria in the renal cortex as evidenced by a significant increase in tissue 
ATP levels (Figure 6).  These data confirm that PDE3 and PDE5 inhibitors are capable of 
inducing MB both in vitro in RPTCs and in vivo in mouse kidney. 
Cyclic nucleotides including both cAMP and cGMP were shown to be activators of 
signaling pathways promoting MB in various model system s[233, 270, 302, 303].  Acute ex 
vivo administration of the PDE5 inhibitor vardenafil to human skeletal muscle stimulated MB as 
evidenced by increases in mitochondrial gene expression and mtDNA copy number [232].  This 
is the first report of pharmacological induction of MB in vivo by inhibition of either PDE3 or 
PDE5, and could represent a novel use for these classes of compounds.  Despite the evidence of 
their role in MB, these compounds have yet to be evaluated as potential therapies for 
mitochondrial damage and dysfunction. 
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Previous studies reported the ability of various classes of PDE inhibitors to protect 
against AKI.  Pretreatment with rolipram, a specific PDE4 inhibitor, blunted I/R-induced renal 
dysfunction in rat kidney and reduced oxidative damage [312].  Sildenafil was shown to be 
protective in cisplatin-induced AKI, whereas tadalafil, a long-acting PDE5 inhibitor, protected 
against early I/R injury in rats[313, 314]  However, limitations of these studies have been the 
lack of a clear mechanism for the renoprotective effects and the use of pretreatment protocols.  
To address these issues, we examined the ability of sildenafil to promote recovery from FA-
induced AKI by administering the drug 24 hours after induction of injury, and examined the 
effects of FA and sildenafil on both renal and mitochondrial function.  Sildenafil promoted 
recovery mitochondrial gene expression (i.e., COX1 and Tfam) and mtDNA copy number.  In 
addition, renal KIM-1 expression was reduced in sildenafil-treated mice, indicating an enhanced 
recovery from the renal injury.  These results demonstrate that sildenafil accelerates recovery 
from AKI by activating MB pathways. 
Our results indicate that PDE inhibitors that are capable of increasing tissue levels of 
cGMP, including sildenafil, are promising treatments for diseases characterized by mitochondrial 














Evaluation of phosphodiesterase inhibitors in a model of acute-to-chronic 











Acute kidney injury (AKI) is a disease with mitochondrial dysfunction and a newly 
established risk factor for the development of chronic kidney disease (CKD) and fibrosis.  We 
examined mitochondrial homeostasis in the folic acid (FA)-induced AKI model that develops 
early fibrosis over a rapid time course.  Mice given a single dose of FA had elevated serum 
creatinine (3-fold) and urine glucose (2.2-fold) 1 and 2 d after injection that resolved by 4d. In 
contrast, peroxisome proliferator gamma coactivator 1α (PGC-1α) and mitochondrial 
transcription factor A (TFAM), critical transcriptional regulators of mitochondrial biogenesis 
(MB), were down-regulated ∼80% 1d after FA injection and remained depressed through 14 d.  
Multiple electron transport chain and ATP synthesis genes were also down-regulated from 1 to 
14 d after FA, including NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 (NDUFβ8), 
ATP synthase subunit β (ATPSβ), and cytochrome C oxidase subunit I (COXI).  Mitochondrial 
DNA copy number was reduced ∼50% from 2 to 14 d after FA injection.  Protein levels of early 
fibrosis markers α-smooth muscle actin and transforming growth factor β1 were elevated at 6 
and 14 d after FA.  Picrosirius red staining and collagen 1A2 (COL1A2) IHC revealed staining 
for mature collagen deposition at 14 d.  We propose that mitochondrial dysfunction induced by 
AKI is a persistent cellular injury that promotes progression to fibrosis and CKD.   Treatment of 
mice for 1 week following FA administration with the PDE5 inhibitor sildenafil failed to recover 






Acute kidney injury (AKI) is defined as a rapid and reversible decline in renal function. 
AKI affects 40–60% of intensive-care unit patients and incidence rates remain unchanged [23, 
315].  Drugs, toxicants, ischemia/reperfusion (I/R), and sepsis are common causes of AKI and 
lead to reduced glomerular filtration and tubular necrosis.  One mechanism of drug and toxicant-
induced renal injury is crystal formation in the lumen, as observed with uric acid, acyclovir, and 
calcium oxalate, the molecule responsible for renal toxicity of ethylene glycol [23].  When given 
intraperitoneally at high doses (e.g. 250 mg/kg), folic acid (FA) causes AKI in rodents [316, 
317].   The mechanism of FA nephropathy may be due to the formation of luminal crystals at 
these doses [318]; however, FA also has direct toxicity on the tubular epithelium at high doses 
[87].  The Reference Daily Intake for adult humans provided by the Food and Drug 
Administration is 400 μg.  While renal toxicity of FA has not been reported in humans, FA-
induced nephrotoxicity has been used as a model of AKI. 
CKD is defined as a consistent reduction in the glomerular filtration rate and typically 
progresses to end stage renal disease (ESRD) [319].  CKD affects over 750,000 people in the US 
and the incidence is rising due to increasing rates of diabetes and hypertension [319].  
Tubulointerstitial fibrosis (TIF) is the best predictive marker of progression to ESRD [320] and 
development of TIF is observed following I/R- and toxicant-induced AKI [75, 321].   Fibrotic 
lesions damage the peritubular vasculature, and lead to a state of chronic hypoxia in the nephron, 
promoting sustained oxidative stress [321, 322]. 
Recent advances in nephrology research demonstrate a causal role for AKI in CKD 
development.  For example, AKI is a major risk factor for CKD, increasing the risk of 
progression to CKD as much as 28-fold [323].   In addition, the severity of injury in the acute 
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phase of AKI is a highly effective indicator of progression to CKD [10].   In mice, CKD and 
fibrosis have been shown to follow AKI caused by FA, I/R, and aristolichic acid [75, 324].  CKD 
progression in the models is dependent upon the extent of AKI[75] and preventable with 
therapeutic intervention during the acute phase [325].  These studies form the basis of our 
analysis of mitochondrial dysfunction in the AKI to CKD continuum. 
Mitochondrial dysfunction is a recognized pathogenic element of AKI and cause of 
tubular cell dysfunction and death.  Increased reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) production, decreased ATP production, and cytochrome c release are 
frequently associated with epithelial cell injury in AKI [157, 326, 327].  Our group recently 
reported persistent disruption of mitochondrial homeostasis and suppression of mitochondrial 
biogenesis (MB) following I/R- and glycerol-induced AKI [161].  In both models, renal 
mitochondrial proteins cytochrome c oxidase subunit I (COXI), ATP synthase subunit β 
(ATPSβ) and NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 (NDUFβ8) were 
depleted, indicative of mitochondrial damage and suppressed MB [161].  Over-expression of 
PGC-1α, the master regulator or MB, in renal proximal tubule cells restored mitochondrial and 
cellular functions after oxidant exposure, demonstrating the importance of MB in recovery from 
cellular injury [207].  While the mechanisms of maladaptive repair of the tubular epithelium after 
AKI are still unclear, it can lead to TIF through paracrine activation of resident fibroblasts and 
epithelial-mesenchymal transition (EMT) of renal epithelial cells [78, 328].  Interestingly, 
mitochondrial-derived ROS can induce EMT in renal tubular cells in vitro, and restoration of 
functional mitochondria and antioxidant mechanisms by induction of PGC-1α attenuates this 
transition [67, 329].  However, little is known about the role of mitochondrial function in renal 
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fibrosis. Here we report that persistent mitochondrial dysfunction is linked to early renal fibrosis 




















This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health.  The protocol 
was approved by the Institutional Animal Care and Use Committee at the Medical University of 
South Carolina and all efforts were made to minimize animal suffering.  Male CD-1 mice (8–10 
weeks of age, Harlan Laboratories) were injected with a single intraperitoneal dose of 250 mg/kg 
FA (Sigma) dissolved in 300 mM NaHCO3 as previously described [330].   At 0, 1, 2, 4, 6, 10, 
and 14 d after treatment, serum and urine samples were collected.  Urine was collected overnight 
from mice housed in metabolic cages (18 h collection period).  Serum and urine creatinine, blood 
urea nitrogen (BUN), and urine glucose levels were measured using Quantichrom Assay Kits 
(BioAssay Sytems).  Urine glucose was normalized to urine creatinine. Urine osmolality was 
measured using the 5004 Micro-Osmette (Precision Systems).  Mice were euthanized 0, 1, 2, 6, 
and 14 d after treatment by CO2 asphyxiation.  These time points were chosen to capture the 
acute, recovery and chronic phases of FA-induced AKI.  Kidneys were removed and preserved 
either by snap freezing or formalin fixation and paraffin embedding.  For drug studies with 
sildenafil, male C57BL/6 mice aged 8-10 weeks were used.  Mice received daily injections of 
saline vehicle or sildenafil (0.3 mg/kg) beginning at 1 d after induction of FA nephropathy until 




Kidneys were sectioned and stained with Periodic Acid Schiff (PAS) for the evaluation of 
histology.  Fibrillar collagen content was evaluated using picro-sirius red staining.  Briefly, slides 
were deparaffinized and rehydrated, stained with Weigert’s Iron hematoxylin for 10 min, and 
washed with water for 10 min.  Slides were then stained with picro-sirius red (0.1% direct red 80 
CI#35780 in saturated aqueous picric acid) for 1 h, washed twice in 1% glacial acetic acid, 
dehydrated, cleared with xylene, mounted with Permount and examined under plane polarized 
light.  Immunohistochemistry was performed as previously described using the collagen 1A2 
(COL1A2) antibody (Santa Cruz) [331]. 
mRNA Analysis 
Total RNA was isolated from renal cortex with Trizol (Invitrogen) and reverse 
transcription was performed using the iScript Advanced cDNA Synthesis Kit (Bio-Rad) with 2 
μg RNA.  qPCR was performed using SsoAdvanced SYBR Green Supermix (Bio-Rad). mRNA 
expression of all genes was calculated using the 2-ΔΔCT method normalized to β-actin.  Primer 
sequences for PGC-1α, TFAM, NDUFβ8, COX1, and ATPS-β were described previously [161]. 
Additional primer sequences were as follows: COL1A2: sense 5′-
TGTTGGCCCATCTGGTAAAGA-3′, antisense 5′-CAGGGAATCCGATGTTGCC-3′; β-actin: 




Protein lysates were isolated from renal cortex using RIPA buffer containing mammalian 
protease inhibitor cocktail, 1 mM sodium orthovanadate, and 10 mM sodium fluoride (Sigma). 
Proteins were separated on a 4–15% SDS-PAGE gel and transferred to a nitrocellulose 
membrane before blocking in 2.5% BSA.  Membranes were incubated with primary antibody at 
4°C overnight.  Primary antibodies used were α-smooth muscle actin (α-SMA) (1:1000, Sigma), 
transforming growth factor β1 (TGF-β1) (1:1000, Abcam), neutrophil gelatinase-associated 
lipocalin 2 (NGAL) (1:1000, Abcam) and β-actin (1:500, Santa Cruz).  Membranes were then 
incubated with an appropriate horseradish peroxidase (HRP)-conjugated secondary antibody for 
1 h.  Bound antibody was imaged following chemiluminescent visualization using a GE 
ImageQuant LAS4000 standalone imaging system.  Densitometry of Western blots was 
performed using NIH Image J software. 
Mitochondrial DNA Content 
qPCR was used to determine relative quantities of mitochondrial DNA content in renal 
cortex as previously described[162].  Briefly, the DNeasy Blood and Tissue kit (QIAGEN, 
Valencia, CA) was used for genomic DNA extraction and 5 ng of total DNA was used for qPCR.  
Mitochondrially encoded NADH dehydrogenase 1 (ND1) was used to measure mitochondrial 
copy number and was normalized to nuclear β-actin.  Primer sequences were as follows: ND1: 
sense 5′-TAGAACGCAAAATCTTAGGG-3′, antisense 5′-TGCTAGTGTGAGTGATAGGG-3′; 
β-actin: sense 5′-GGGATGTTTGCTCCAACCAA-3′, antisense 5′-
GCGCTTTTGACTCAAGGATTTAA-3′. 
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Data and Statistical Analysis 
Data are presented as means ± SEM and were subjected to one-way analysis of variance 
(ANOVA).  Multiple means were compared using Student-Newman-Keuls test with p<0.05 

















FA Induces AKI with Rapid Functional Recovery 
FA decreased glomerular function as serum creatinine levels increased ~3-fold versus 
controls 1–2 d after FA injection and returned to control levels at 4 d (Figure 3.1A).  BUN 
concentrations increased ~8-fold versus controls 1–2 d after FA injection, and did not return to 
control levels until 10 d (Figure 3.1B).  Over 90% of mice developed AKI, defined as a doubling 
of serum creatinine or BUN levels at 2 d.  As an indicator of tubular function we measured 
urinary glucose concentrations, which increased 2-fold over controls 1–2 d after FA injection 
(Figure 3.1C).  Urinary glucose concentrations returned to control levels at 4 d. Renal NGAL 
protein levels also increased ~4-fold 1–2 d after FA injection and returned to control levels at 6 d 
(Figure 3.1D). 
Renal histopathology was examined using PAS staining at 2, 6, and 14 d.  At 2 d the 
renal cortex displayed tubular dilatation, brush border loss, cast formation, and accumulation of 
debris in the lumen.  At 6 d there was a partial restoration of normal renal architecture 
characterized by repopulation of the tubular epithelial cells, but brush border restoration 
remained incomplete at 14 d (Figure 3.2). 
In summary, peak renal dysfunction occurred 2 d after FA administration, as indicated by 
maximal levels of serum creatinine, BUN, urine glucose, and the injury marker NGAL.  All 
markers returned to control levels by 4 d except BUN, which gradually decreased over time and 
returned to control levels at 10 d.  In contrast to the recovery of glomerular and tubular function, 
persistent disruption of normal tubular morphology was observed in PAS-stained kidneys 
through 14 d, revealing incomplete recovery. 
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Figure 3.1: Folic acid (FA) causes AKI.  Two days after a 250 mg/kg intraperitoneal dose of 
FA, serum creatinine (A), BUN (B), and urine glucose (C) levels were maximally elevated.  Both 
serum creatinine and urine glucose concentrations returned to control levels at 4 d.  BUN 
concentrations returned to control levels at 10 d.  Protein levels of renal NGAL increased at 1 
and 2 d but returned to control levels at 6 and 14 d (D).  Data are represented as mean ± SEM. *, 









Figure 3.2: Histopathology of progressive FA nephropathy.  Kidneys display massive tubular 
dilatation and brush border loss at 2 d via PAS staining (top row) that partially recovered at 6 and 
14 d.  Picro-sirius red staining showed deposition of fibrillar collagen at 14 d using brightfield 
(second row) and polarized (third row) light microscopy.  Immunohistochemical detection of 
COL1A2 (bottom row) showed strong staining only at 14 d after FA injection.  Representative 







FA-Induced AKI Suppresses Mitochondrial Homeostasis and Biogenesis Rapidly and 
Persistently 
To determine if FA nephrotoxicity disrupts mitochondrial homeostasis and biogenesis, 
transcript levels of mitochondrial markers of homeostasis and biogenesis were measured in renal 
cortex over time.  mRNA levels of the transcription factor coactivator PGC-1α and 
mitochondrial transcription factor A (TFAM) decreased by ~80% 1 d after FA treatment (Figure 
3.3A, 3.3B).  PGC-1α levels remained reduced throughout the 14 d experiment while TFAM 
levels partially recovered to ~60% of controls at 2 d and remained depressed at 6 and 14 d.  One 
day after FA injection, transcript levels of NDUFβ8, ATPSβ, and COXI decreased 85%, 83%, 
and 72%, respectively (Figure 3.3C-E).  NDUFβ8 levels partially recovered at 6 d but remained 
depressed at 14 d.  COXI and ATPSβ transcript levels remained depressed throughout the 14 d of 
the experiment.  Finally, we measured mitochondrial DNA copy number as an indicator of 
mitochondrial content.  Mitochondrial DNA copy number was reduced ~50% 2 d after FA 
injection and remained depressed through 14 d (Figure 3.3F).  To control for possible variation 
in expression of the mitochondrial markers over the course of the study, a separate experiment 
was performed using time-matched controls.  Over 14 d mRNA expression did not change in 







Figure 3.3: Mitochondrial biogenesis is persistently down-regulated during FA 
nephropathy.  mRNA levels of PGC-1α (A) and TFAM (B) were reduced 1 d after FA 
injection.  PGC-1α remained depressed while TFAM mRNA partially recovered at 2 d and did 
not increase further through 14 d.  Expression of mitochondrial homeostasis markers NDUFβ8 
(C), COX1 (D), and ATPSβ (E) was also strongly suppressed at 1 d, and only NDUFβ8 reached 
a partial recovery at 6 and 14 d.  Mitochondrial copy number was reduced by ~50% 2 d after FA 
injection and remained persistently depressed at 6 and 14 d (F).  Data are represented as mean ± 





Figure 3.4: Time-matched control study.  mRNA levels of mitochondrial genes PGC-1α, 
ATPSβ, and COXI were equivalent in control mice at day 0 and day 14, and decreased in FA 
mice at day 14.  The fibrosis marker COL1A2 increased 14 d after FA (B).  Data are represented 











In summary, numerous markers of mitochondrial homeostasis were strongly suppressed 
at 1 d and remained suppressed through 14 d.  It should be noted that TFAM and NDUFβ8 
partially recovered to 50% and 60% of control, respectively.  Importantly, mitochondrial DNA 
copy number, an indirect marker of mitochondrial content was also decreased from 2–14 d.  
These data reveal that the disruption of mitochondrial homeostasis and content begins with the 
onset of AKI and persists, consistent with the disruption of tubular morphology.  The persistent 
loss of mitochondrial homeostasis in this model is similar to that reported in AKI caused by I/R 
and myoglobulinuria [161].  Furthermore, it is interesting that the early recovery of glomerular 
and tubular function is not dependent on the up-regulation of these genes. 
FA-Induced AKI and Mitochondrial Dysfunction is Followed by Fibrosis 
Protein levels of early fibrosis markers TGF-β1 and α-SMA increased at 6 and 14 d after 
FA injection with a maximum induction of ~4- and ~9-fold, respectively (Figure 3.5A).  
Transcript levels of COL1A2 (Figure 3.5B), a primary transcriptional target of TGF-β1 and 
pathological molecule in fibrosis, increased at 6 and 14 d, in concert with the increases in TGF-
β1.  COL1A2 mRNA also increased versus 14 d controls in the separate time-matched study 
(Figure 3.4).   We measured urine output and osmolality as indicators of CKD.  Urine output was 
similar to controls from 1–6 d after FA injection but increased at 10 and 14 d. (Figure 3.5C). 
Urine osmolality decreased 14 d after FA injection (Figure 3.5D). 
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Figure 3.5: Early fibrosis and CKD in FA nephropathy.  TGF-β1 and α-SMA protein 
remained at control levels through 2 d but increased at 6 and 14 d (A).  COL1A2 mRNA was 
significantly increased in renal cortex 6 and 14 d after FA treatment (B).  Urine volume 
increased 10 and 14 d after FA injection (C), while urine osmolality decreased at 14 d (D).  Data 







Kidney sections were stained with picro-sirius red to examine the development of TIF.  
When examined using bright-field microscopy, the red staining is indicative of general ECM 
deposition (Figure 3.2).  We observed very low levels of red staining in control kidneys and in 
kidneys 2 and 6 d after FA injection.  However, at 14 d there was a marked increase in red 
staining in the tubulointerstitium.  We also examined the picro-sirius red staining under polarized 
light, which allows specific visualization of fibrillar collagen [332].  There was no detectable 
kidney collagen staining in controls or at 2–6 d following FA treatment, but there was an intense 
tubulointerstitial staining pattern at 14 d (Figure 3.2).  We used immunohistochemistry to 
examine the levels of COL1A2. Low levels of staining were observed through 6 d after FA 
injection, but at 14 d there was a strong increase in the COL1A2 positive staining in the renal 
cortex (Figure 3.2). 
In conclusion, while glomerular and tubular function recovered, early fibrosis occurred at 
6 d and continued through 14 d following FA treatment.  Molecular markers of fibrosis including 
TGF-β1 and α-SMA increased 6 and 14 d after FA, and picro-sirius red staining and IHC for 
COL1A2 showed increases in staining 14 d after FA injection.  The changes in these markers are 
consistent with the persistent disruption of tubular morphology.  Additionally, increases in urine 
volume were observed at 6 and 14 d, and urine osmolality decreased at 14 d.  Decreased ability 
to concentrate the urine is seen in CKD patients [333].  CKD has been characterized in the FA 
model, with decreased glomerular function and microalbuminuria at 2 and 12 weeks [324, 334].  
We did not detect increases in urinary albumin or total protein in FA-treated mice at 14 d (Figure 
3.6).  This finding could be due to the early stage of fibrosis at 14 d in this study. In summary, 
the FA model under these conditions represents early AKI with recovery of multiple functions 
within 4 d that is followed by early fibrosis and CKD. 
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Figure 3.6: Measurement of Urinary Albumin and Protein in FA Nephropathy.  There was 
no statistical change in the albumin:creatinine ratio (A) or protein:creatinine ratio (B) in the urine 













Sildenafil failed to stimulate mitochondrial biogenesis and prevent fibrosis in folic acid-
induced CKD 
 To test whether stimulation of mitochondrial biogenesis can promote renal recovery and 
prevent development of renal fibrosis, mice received daily injection of sildenafil at a dose of 0.3 
mg/kg beginning at 1 d after folic acid administration for a period of 1 wk.  Mice were then 
sacrificed at 14 d after folic acid administration and kidneys were collected.  Expression of the 
mitochondrial genes COX, NDUFβ8, PGC-1α and Tfam remained suppressed in mice treated 
with folic acid at 14 d compared to control animals.  Treatment with sildenafil failed to promote 
recovery of mitochondrial gene expression in these mice (Figure 3.7A-C).  Furthermore, 
sildenafil treatment did not decrease COL1A2 expression in folic acid treated mice (Figure 
3.7D).  These data indicate that sildenafil may not be an effective therapy for limiting the 











Figure 3.7: Sildenafil does not promote recovery of mitochondrial biogenesis or limit 
fibrosis in FA-induced CKD.  Renal damage was induced by bolus injection of folic acid in 
C57BL/6 mice.  Mice received daily treatment with saline vehicle or sildenafil (0.3 mg/kg) 
beginning at day 1 after FA until day 7.  mRNA levels of PGC-1α (A), Tfam (B), COX1 (C) and 
COL1A2 (D) were measured at 14 d after FA by real time PCR.  Data are represented as mean ± 







The above studies provide the first evidence of a link between suppression of the MB 
program and the AKI to CKD continuum.  However, while the sustained suppression of MB is 
correlated with development of early fibrosis and CKD, it is not clear if early fibrosis and CKD 
are dependent on MB suppression.  Hickey et al., in 2011, reported increased PGC-1α protein in 
a unilateral ureteral obstruction (UUO) model of renal fibrosis [335].  However, the authors did 
not measure any PGC-1α targets or functional mitochondrial parameters in vivo.  In skeletal 
muscle, it has been shown that tissue-specific over-expression of PGC-1α slows the age-
dependent development of fibrosis [336].  In addition, the severe cardiomyopathy induced by 
anthracycline, which includes fibrosis as a hallmark, is associated with decreased cardiac MB 
and increased oxidative stress [337].  These studies support our findings that the suppression of 
MB by AKI is involved in the development of renal fibrosis. 
The AKI-CKD continuum is recently established and many questions remain regarding 
clinical progression and pathophysiological mechanisms.  A single episode of AKI is known to 
increase the risk of CKD [338, 339], and the severity of the acute injury is predictive of 
progression to CKD [10].  TIF, a pathological hallmark of CKD, is an effective predictor of 
declining renal function [340], and work in animal models has addressed mechanisms of 
fibrogenesis after AKI.  Inhibition of prolyl-4-hydroxylase domain (PHD)-containing 
dioxygenases, which promote degradation of hypoxia inducible factors (HIF) 1 and 2, reduces 
I/R-induced AKI and subsequent fibrogenesis [325].  The effect was only observed when PHD 
inhibitors were administered before I/R [325] and suggests that the well-known activity of HIF in 
regulating cellular metabolism could be a critical factor in the early response to AKI and the 
maladaptive repair and fibrogenesis that develop afterwards.  In addition, repeated, selective 
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injury of renal epithelial cells was sufficient to cause fibrosis using a genetically engineered 
model expressing the diphtheria toxin (DT) receptor in the renal epithelium [341].  This suggests 
a key role for epithelia in renal fibrogenesis.  Finally, hyper-methylation of the promoter 
for RASAL1, an inhibitor of the RAS oncoprotein, was also found to promote renal fibrosis after 
FA-induced AKI and was attenuated by 5-azacytidine or DNA methytransferase 1 
haploinsufficiency [342].  We did not examine promoter methylation in this study, but these 
findings raise the possibility that epigenetic mechanisms could play a role in silencing expression 





















The guanylyl cyclase activator BAY 58-2667 stimulates mitochondrial 










 Mitochondrial dysfunction is an important pathophysiological component of acute kidney 
injury (AKI).  Following AKI, reduced mitochondrial function can impair energy-dependent 
renal repair processes.  Thus, stimulation of mitochondrial biogenesis (MB), the generation of 
new, functional mitochondria, could promote renal recovery.  We explored the ability of the 
guanylyl cyclase activator, BAY 58-2667, to induce MB and promote renal recovery following 
I/R-induced AKI.  Treatment of renal proximal tubular cells (RPTCs) with BAY 58-2667 
increased FCCP-uncoupled OCR.  Furthermore, BAY 58-2667 increased mitochondrial gene and 
protein expression, and mtDNA content in the renal cortex of naïve mice.  Beginning 24 h after 
I/R injury, daily treatment with BAY 58-2667 accelerated recovery of renal function evidenced 
by reduced BUN levels at 6 d.  Additionally, renal expression of the tubular injury markers 
NGAL and Kim-1 were also decreased.  Histological examination demonstrated reduced renal 
tubular necrosis in BAY 58-2667 treated mice.  BAY 58-2667 blunted the progression of renal 
fibrosis evidenced by reduced COL1A2 and αSMA expression.  Furthermore, BAY 58-2667 
decreased renal expression of the inflammatory cytokines, TNF-α and IL-1β, and reduced 
oxidative DNA damage.  Finally, BAY 58-2667 promoted the recovery of renal mitochondrial 
biogeneic signaling after I/R.  Renal mRNA expression of PGC-1α, NRF1, ND1, COX1 and 
ATPSβ were all increased over I/R+vehicle levels.  mtDNA content and protein expression of 
PGC-1α and COX1 were also induced.  Finally, mitochondrial function was recovered evidenced 
by a return of ATP levels to sham control levels.   These data demonstrate that activation of 
guanylyl cyclase by BAY 58-2667 promotes recovery from AKI by stimulation of mitochondrial 




Acute kidney injury (AKI) is a rapid loss of renal function characterized by reduced 
urinary output and increased serum biomarkers, including creatinine and urea.  AKI is caused by 
a diverse array of insults including inflammatory renal disease, sepsis, obstruction, ischemia-
reperfusion (I/R) injury, and drug or toxicant exposure [14, 45, 343].  AKI causes a host of 
systemic complications including disrupted acid-base and electrolyte homeostasis, and other 
organ damage [344].  AKI has a poor prognosis, particularly in intensive care patients, with 
mortality rates up to 80% [7].  Survivors of AKI are at a highly increased risk of development of 
chronic kidney disease (CKD) and ultimately progression to end stage renal disease (ESRD) 
requiring dialysis [10, 74].  Increased utilization of nephrotoxic agents, higher rates of metabolic 
syndrome and cardiovascular disease, and an aging population have led to an increased incidence 
of AKI.  AKI also substantially increases healthcare costs due to extended hospital stays, 
increased ICU admissions and utilization of renal replacement therapy (RRT) [9].  Despite the 
serious nature of the disease and an increasing array of risk factors, there are still no highly 
effective therapies to prevent or promote recovery from AKI.  Thus, the need exists to identify 
new targets and develop new pharmacological agents for its treatment. 
The pathogenesis of AKI is complicated and multifactorial, which has made development 
of new therapies difficult.  Following an acute insult, the renal tubular epithelium undergoes 
apoptotic and necrotic cell death with the shedding of damaged cells into the tubular lumen [22, 
27].  Restoration of renal morphology and function requires the regeneration of functional 
tubules through the proliferation and differentiation of new renal epithelial cells.  This process 
requires rapid and sustained activation of critical tissue repair mechanisms, which are highly 
energy dependent.  The requirement of ATP for renal repair has highlighted mitochondrial 
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integrity and function as important factors in AKI pathogenesis and recovery.  Following 
ischemia-reperfusion (I/R) injury, cells of the renal tubular epithelium experience profound 
mitochondrial dysfunction characterized by activation of the mitochondrial permeability 
transition, loss of membrane potential and swelling caused by uptake of cytosolic calcium [45, 
153, 156, 345].  Loss of mitochondrial polarity impairs electron transport chain function causing 
depletion of renal ATP levels and increased production of reactive oxygen and nitrogen species.  
Furthermore, in the recovery phase following I/R-induced AKI, mitochondrial biogenesis (MB), 
the generation of new mitochondria, is persistently suppressed, and is associated with a failed 
recovery of renal tubular function [161].  Therefore, reactivation of the signaling cascades that 
induce MB could promote recovery of mitochondrial function and enhance renal repair.  Use of 
various pharmacological activators of PGC-1α-dependent MB has shown the efficacy of this 
therapeutic strategy.  Treatment with the SIRT1 activator SRT1720, the 5HT-1F receptor agonist 
LY 344-864, or the β2-adrenergic agonist formoterol, following renal I/R, accelerated recovery 
of MB and renal function [148, 150, 218].  Additionally, the PDE5 inhibitor sildenafil, 
stimulated MB and reduced renal cortical Kim-1 levels after folic acid-induced AKI [149].  
These data highlight a potential for renal cGMP as a modulator of MB following AKI. 
The cyclic nucleotide, cGMP, acts as an important signaling molecule linking membrane 
receptor activation to activation of intracellular kinases and other proteins, much like cAMP.  
cGMP levels are regulated both by their generation by guanylyl cyclases (GC), as well as their 
degradation by phosphodiesterases (PDE), providing two potential targets for therapeutic 
modulation.  Previous studies have shown that cGMP regulates MB in a variety of model 
systems [271, 346].  Nisoli et al. in 2004, demonstrated that cGMP induction by nitric oxide or 
direct activation of GC stimulated MB and mitochondrial function in vitro [233].  Furthermore, 
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eNOS-/- mice showed reduced tissue mitochondrial gene expression, mtDNA content, ATP levels 
and mitochondrial respiration.  Transgenic mice overexpressing the naturetic peptide, BNP, 
which signals through activation of GC, were protected against diet-induced obesity and 
metabolic dysfunction through effects on MB [239].  PDE5 inhibition has also been shown to 
induce mitochondrial biogenesis in renal tissue and fat [149, 232].   
 Recently, novel, potent, NO-independent inducers of GC activity have been identified.  
Screening for more potent and specific GC activators based on the imidazole scaffold of the GC 
inducer YC-1, led to the identification of the compounds BAY 41-2272 and BAY 41-8543 [347, 
348].  Further work has led to the identification of a number of other compounds in this class and 
has led to the division of these compounds into 2 subclasses: GC stimulators and GC activators, 
which target 2 different redox states of GC.  GC stimulators act upon GC containing a reduced 
heme moiety which is NO-sensitive.  GC activators, however, can activate GC when this heme 
becomes oxidized and is no longer responsive to NO [349].  Several of these compounds have 
shown promise in the treatment of pulmonary arterial hypertension and cardiovascular disease; 
however, no studies have examined their effects on mitochondrial biogenesis in disease models 
[350-352].   For these studies, we sought to evaluate the efficacy of the small molecule GC 
stimulator, BAY 41-2272, and the GC activator, BAY 58-2667, to stimulate mitochondrial 







Isolation and culture of RPTCs. 
Female New Zealand white rabbits (1.5 – 2.0 kg) were obtained from Charles River 
Laboratories (Wilmington, MA).  RPTCs were isolated using the iron oxide perfusion method as 
previously described.  Cells were incubated at 37 oC in a 5% CO2/95% air environment with 
continuous swirling.  Cells were cultured using 100 mm dishes in a 1:1 mixture of Dulbecco’s 
modified Eagle’s essential medium and Ham’s F-12 without glucose, phenol red or sodium 
pyruvate (Mediatech, Manassas, VA) supplemented with HEPES (15 mM), glutamine (2.5 mM), 
pyridoxine HCl (1 µM), sodium bicarbonate (15 mM), and lactate (6 mM).  Further supplements 
including hydrocortisone (50 nM), selenium (5 ng/mL), human transferrin (5 µg/mL), bovine 
insulin (10 nM) and L-ascorbic acid-2-phosphate (50 µM) were added fresh daily to culture 
media.  Following 3 days in culture, RPTCs were trypsinized and replated in XF-96 polystyrene 
cell culture microplates (Seahorse Bioscience, North Billerica, MA) at a density of 18,000 cells 
per well.  Cells were maintained in culture for an additional 2 days before treatment with vehicle 
or compounds of interest.   
Measure of oxygen consumption rate. 
The oxygen consumption rate (OCR) of RPTCs was measured using the Seahorse 
Bioscience XF-96 Extracellular Flux Analyzer as previously described.  Plates were treated with 
vehicle control (DMSO < 0.5% v/v), or increasing concentrations of BAY 41-2272 or BAY 58-
2667.  Basal OCR was measured before injection of 0.5 µM carbonyl cyanide 4-
(trifluormethoxy)phenylhydrazone (FCCP) for measurement of uncoupled (maximal) OCR. 
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Animal care and use. 
Studies were carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals from the National Institutes of Health.  All protocols 
were approved by the Institutional Animal Care and Use Committee at the Medical University of 
South Carolina.  All efforts were made to minimize animal pain and suffering.  
Testing of compounds in naïve mice. 
Male C57BL/6 mice (8-10 weeks old) were obtained from the Charles River Laboratories 
(Wilmington, MA).  Mice were housed individually in a temperature controlled room under a 12-
hour light/dark cycle.  Mice were given a single intraperitoneal injection of BAY 41-2272 (100 
µg/kg or 1 mg/kg), BAY 58-2667 (10 µg/kg or 100 µg/kg), or saline vehicle.  Mice were 
euthanized 24 h after treatment by isoflurane inhalation and cervical dislocation.  Kidneys were 
removed, preserved by flash-freezing in liquid nitrogen and stored at -80 oC for later analysis. 
Ischemia-reperfusion (I/R)-induced AKI mouse model. 
For the I/R model of AKI, mice were subjected to bilateral renal pedicle ligation as 
described previously [148, 353]. In brief, renal artery and vein were isolated and blood flow was 
occluded with a vascular clamp for 19 minutes. Mice were maintained at 37°C throughout the 
procedure using a homeothermic heating system. Sham surgery mice received all manipulations 
with the exception of clamping of the renal pedicles. Mice were treated once daily beginning at 
24 hours after reperfusion with saline vehicle, sildenafil (1 mg/kg) or BAY 58-2667 (0.1 mg/kg).  
Blood was collected from mice via retro-orbital bleed at 24 and 144 hours after surgery. Blood 
urea nitrogen (BUN) levels were measured using a QuantiChrom Urea Assay Kit (BioAssay 
Systems, Hayward, CA) according to the manufacturer's protocol.  Urine was collected at 72 h 
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and 144 h after surgery using metabolism cages for monitoring of urine volume.   Mice were 
euthanized at 144 hours after the procedure, at which time kidneys were harvested for molecular 
analyses.  
Renal histology. 
Formalin-fixed kidney sections approximately 5–6 microns from mice at 144 hours after 
I/R or sham surgery were stained with hematoxylin and eosin, and the degree of morphologic 
changes was determined by light microscopy in a blinded fashion.  Degree of tubular necrosis 
was evaluated on a scale from 0 to 4, which ranged from not present (0), mild (1), moderate (2), 
severe (3), and very severe (4). 
Quantitative real-time PCR for mRNA and mtDNA expression. 
Total RNA was extracted from renal cortical samples using Trizol reagent (Life 
Technologies, Carlsbad, CA).  cDNA was synthesized via revere transcription using the iScript 
Advanced cDNA synthesis kit (Bio-Rad, Hercules, CA) with an input of 2 µg of RNA.  qPCR 
was performed using SSoAdvanced SYBR Green Supermix (Bio-Rad) at a concentration of 1x 
and primers at a final concentration of 750 nM (Integrated DNA Technologies, Coralville, IA).  
mRNA expression was calculated using the 2-ΔΔCT method normalized to β-actin.  Primer 
sequences for COL1A2 [275], PGC-1α, NRF-1, COX1, ND1, ATPSβ, Kim-1, NGAL, TNF-α, 
IL-1β, and β-actin were previously described [276].  Additional primer sequences used were as 
follows: MCP-1: F: 5’- ACCACAGTCCATGCCATCAC-3’, R: 5’- 
TTGAGGTGGTTGTGGAAAAG-3’; F4/80: F: 5’- CTTTGGCTATGGGCTTCCAGTC-3’, R: 
5’- GCAAGGAGGACAGAGTTTATCGTG-3’; Catalase: F: 5’- 
GCAGATACCTGTGAACTGTC-3’, R: 5’- GTAGAATGTCCGCACCTGAG-3’; MnSOD: F: 
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5’- ACACATTAACGCGCAGATCA-3’, R: 5’- AGCCTCCAGCAACTCTCCTT-3’; eNOS: F: 
5’- TCTGCGGCGATGTCACTATG-3’, R: 5’- CATGCCGCCCTCTGTTG-3’. qPCR was used 
to determine the relative quantity of mtDNA in mouse renal cortical tissue. DNA was extracted 
from tissue using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA).  qPCR was 
performed as described above using 5 ng of cellular DNA.  The mitochondrial gene ND1 was 
used as an indicator of mtDNA content and was normalized to nuclear-encoded β-actin 
expression.  
Immunoblotting for protein expression. 
  Renal lysates were prepared via homogenization and sonication in RIPA buffer.  
Samples were centrifuged at 10,000 x g for 10 min. to clear insoluble material.  Protein 
concentrations were quantified via BCA assay (Life Technologies).  Equal amounts of protein 
(10 μg) were separated on 4%–20% gradient SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes. Membranes were blocked with 2.5% BSA in TBST and incubated 
with anti-PGC-1α (Calbiochem, 1:1000), anti-COX1 (Santa Cruz, 1:1000), anti-β actin (Santa 
Cruz, 1:1000), anti-Kim-1 (R&D Systems, 1:1000), anti-NGAL (Abcam, 1:1000), anti-αSMA 
(Sigma, 1:5000), or anti-GAPDH (Santa Cruz, 1:5000) overnight at 4°C. After incubation for 2 h 
at room temperature with secondary antibodies (1:5000) conjugated with horseradish peroxidase, 
membrane proteins were detected via chemiluminescence. Renal proteins were quantified via 
densitometry using NIH ImageJ. 
Renal ATP levels. 
ATP was isolated from fresh kidneys as described previously [307]. Briefly, renal cortical 
tissue was homogenized in phenol-TE. DEPC water and chloroform were added and the 
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suspension was vortexed. Samples were centrifuged at 10,000 × g for 5 min at 4°C. The upper 
layer was diluted 1:100 in DEPC water and ATP was measured using the ATP Determination Kit 
(Invitrogen, Carlsbad, CA). ATP levels were normalized to tissue wet weight. 
8-OH-dG and cGMP ELISA. 
 cGMP was isolated from flash frozen tissue via TCA extraction.  Briefly, renal tissue was 
homogenized in 10 volumes (uL/mg tissue) 5% TCA.  Samples were centrifuged for 10 min at 
1,500 x g and the supernatant was collected.  TCA was extracted 3x in water-saturated ether.  
Samples were heated at 70 oC to remove residual ether.  cGMP levels were then measured using 
a commercially available ELISA kit according to manufacturer’s instructions (Cayman 
Chemical).   
 To prepare samples for measurement of 8-OH-dG, flash frozen tissue samples were 
homogenized in Homogenization buffer (PBS + 1 mM EDTA).  Samples were centrifuged at 
1,000 x g to remove insoluble material.  DNA was then purified using the DNeasy Blood and 
Tissue kit (Qiagen).  Resultant DNA was digested with nuclease P1 (Sigma) according to 
manufacturer instructions.  pH of the sample was then adjusted to 7.5-8.5 using 1 M Tris.  
Samples were incubated with alkaline phosphatase (1 U/100 µg DNA) at 37 oC for 30 min.  
Samples were then boiled for 10 min and placed on ice.  8-OH-dG levels were measured using a 
commercially available kit according to manufacturer’s instructions (Cayman Chemical). 
Data and statistical analysis. 
Data are expressed as means ± SEM for parametric data, or median ± IQR for non-parametric data. 
Multiple comparisons of normally distributed data were analyzed by one-way ANOVA and group 
means were compared using Fisher’s LSD post-test.  Non-parametric data were analyzed using a 
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Kruskal-Wallis test followed by a Dunn’s test for multiple comparisons.  The criterion for 



















BAY 58-2667 and BAY 41-2272 stimulate mitochondrial respiration in RPTC. 
 To evaluate the ability of GC activators and stimulators to stimulate mitochondrial 
biogenesis and increase mitochondrial function, RPTC were treated for 24 h with the GC 
stimulator, BAY 41-2272 (10 nM – 10 µM) or the GC activator, BAY 58-2667 (10 nM – 10 
µM).  Basal and FCCP-uncoupled (maximal) oxygen consumption rate (OCR) were determined 
using the Seahorse XF96 Extracellular Flux analyzer.  Basal OCR was unchanged at any 
concentration tested for either BAY 41-2272 or BAY 58-2667 (Figure 4.1A-B).  BAY 41-2272 
increased FCCP-uncoupled OCR 25% and 30% at concentrations of 1 and 10 µM, respectively.   
BAY 58-2667 significantly increased FCCP-uncoupled OCR at all concentrations tested from 
21-26% above vehicle controls (Figure 4.1C-D).  These data demonstrate that either GC 
activators or stimulators can increase maximal mitochondrial function, which could be due to 
activation of mitochondrial biogenic signaling. 
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Figure 4.1: BAY 41-2272 and BAY 58-2667 increase FCCP-uncoupled OCR in RPTC.    
RPTC were treated with BAY 41-2272 (10 nM – 10 µM) or BAY 58-2667 (10 nM – 10 µM) for 
24 h.  Basal (A, B) and FCCP-uncoupled (C, D)  OCR were measured using the Seahorse XF96 
Extracellular Flux Analyzer.  Data are expressed as % of vehicle control. * indicates significant 










BAY 58-2667, but not BAY 41-2272 stimulates mitochondrial biogenesis in mouse renal 
cortex. 
 To examine activation of pathways of mitochondrial biogenesis, BAY 41-2272 and BAY 
58-2667 were evaluated in mouse renal cortex.  Mice were administered BAY 41-2272 (100 
µg/kg or 1 mg/kg), BAY 58-2667 (10 µg/kg or 100 µg/kg), or saline vehicle by intraperitoneal 
injection.  Mice were sacrificed and kidneys were collected for biochemical analyses 24 h after 
dosing.  mRNA expression of the mitochondrial-encoded mitochondrial genes COX1 and ND1 
were evaluated by quantitative PCR (qPCR).  COX1 and ND1 mRNA expression increased to 
1.90 and 1.75-fold of control mice, respectively, in mice that were treated with BAY 58-2667 at 
100 µg/kg (Figure 4.2A-B).  No changes were observed in COX1 and ND1 expression for either 
dose of BAY 41-2272 or BAY 58-2667 at 10 µg/kg vs. vehicle control.  Renal cortical 
mitochondrial DNA (mtDNA) copy number, an indicator of mitochondrial number, was 
increased to 1.35-fold of vehicle control in mice treated with BAY 58-2667 at 100 µg/kg (Figure 
4.2C).  No changes were observed in any of the other treatment groups vs. control.  Finally, 
protein expression of PGC-1α and COX1 were assessed by immunoblot (Figure 4.2D-F).  PGC-
1α and COX1 protein were significantly increased in mice treated with either 10 µg/kg BAY 58-
2667 (1.44- and 1.35-fold) or 100 µg/kg BAY 58-2667 (1.53- and 1.37-fold) vs. control.  No 
changes were observed in PGC-1α or COX1 protein expression with either dose of BAY 41-
2272.  These results indicate that the GC activator BAY 58-2667, but not the GC stimulator 





Figure 4.2: BAY 58-2667, but not BAY 41-2272 stimulates mitochondrial biogenesis in 
mouse renal cortex.    Male C57BL/6 mice (8-10 weeks old) were administered BAY 41-2272 
(100 µg/kg or 1 mg/kg), BAY 58-2667 (10 µg/kg or 100 µg/kg) or saline vehicle by 
intraperitoneal injection.  Mice were sacrificed 24 h after injection and kidneys were collected.  
Renal cortical mRNA expression of COX1 (A) and ND1 (B), and mtDNA copy number (C) were 
assessed by qPCR.  Protein expression of PGC-1α and COX1 were assessed by immunoblot (D).  
Blots were quantified by densitometry and corrected to β-actin (E-F).  * indicates significant 








BAY 58-2667 promotes recovery of renal function and renal tubular damage markers 
following I/R-induced AKI.     
 In order to evaluate the efficacy of BAY 58-2667 in the setting of renal injury, AKI was 
induced in C57BL/6 mice by bilateral clamping of the renal pedicle for 19 minutes followed by 
reperfusion.  Mice undergoing sham surgery served as controls.  24 h after I/R injury, mice 
displayed significant renal dysfunction evidenced by a ~4-fold increase (sham: ~25 mg/dL; I/R 
~100 mg/dL) in blood urea nitrogen (BUN) levels. Beginning 24 h after reperfusion mice 
received daily injections with BAY 58-2667 (100 µg/kg) or saline control.  Additionally, a group 
of mice were treated with sildenafil, a PDE5 inhibitor, at 1 mg/kg, as a positive control.  
Sildenafil has previously been demonstrated to induce mitochondrial biogenesis, and be 
protective and/or promote recovery in multiple models of AKI [149, 313, 354, 355].  BUN levels 
remained elevated at 6 d after I/R in mice treated with saline vehicle; however, treatment with 
either sildenafil or BAY 58-2667 reduced BUN levels indicating an acceleration of recovery of 
renal function (Figure 4.3A).  We then assessed renal tubular damage by measuring renal cortical 
Kim-1 and NGAL mRNA and protein expression at 6 d after I/R.  Renal Kim-1 and NGAL 
mRNA levels were increased to 150-fold and 25-fold of sham surgical levels, respectively 
(Figure 4.3B,C).  Treatment with sildenafil or BAY 58-2667 significantly reduced renal Kim-1 
levels, but had no effect on renal NGAL expression.  Kim-1 and NGAL protein levels were 
measured by immunoblot in the renal cortex, and were increased to 120-fold and 23-fold of sham 
surgical levels, respectively (Figure 4.3D-F).  BAY 58-2667, but not sildenafil significantly 
reduced renal Kim-1 levels.  Both sildenafil and BAY 58-2667 reduced renal NGAL protein 
levels back to near sham surgical levels.  These data indicate that induction of cGMP through 
either inhibition of PDE5 or activation of GC promotes recovery of renal function and reduces 
tubular damage markers after I/R-induced AKI. 
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Figure 4.3: BAY 58-2667 promotes recovery from ischemia-reperfusion (I/R)-induced AKI.    
Male C57BL/6 mice (8-10 weeks old) underwent sham surgery or 19 minutes of ischemia by 
bilateral clamping of the renal pedicle followed by reperfusion.  Mice were treated with saline 
vehicle, the PDE5 inhibitor sildenafil (1 mg/kg), or BAY 58-2667 (100 µg/kg) daily beginning at 
24 h after surgery.  Blood was collected via retroorbital bleed at 1 and 6 d after surgery.  Urine 
was collected using metabolism cages at 3 and 6 d after surgery.  Mice were sacrificed 6 d after 
surgery for tissue collection.  Renal function was monitored by assessment of BUN (A) and urine 
output (B). Renal damage was assessed biochemically by measurement of renal cortical KIM-1 
and NGAL mRNA (C,D) and protein levels (E).* indicates significant difference from sham 
(p<0.05), # indicates significant difference from I/R+vehicle (p<0.05), n = 5-17 per group 






BAY 58-2667 reduces renal morphological damage following I/R-induced AKI. 
 Formalin-fixed renal sections were stained with hematoxylin-eosin (H&E) for 
histological evaluation and were scored by a pathologist.  At 6 d after I/R, kidneys continued to 
demonstrate severe morphological disruption characterized by tubular dilation, degeneration and 
necrosis, loss of tubular brush borders and inflammatory cell infiltration (Figure 4.4A).  Mice 
treated with BAY 58-2667 showed a partial recovery of renal morphology evidenced by reduced 












Figure 4.4: BAY 58-2667 reduces renal tubular necrosis following I/R-induced AKI.  
Kidneys were stained for morphological assessment with hematoxylin & eosin (H&E) (A).  
Kidneys were scored in a blinded fashion by pathologist for tubular necrosis on a scale from 0-4 
(0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe) (B).  * indicates significant difference 













BAY 58-2667 stimulates mitochondrial biogenesis and promotes recovery of renal function 
following I/R-induced AKI. 
 Due to the importance of mitochondrial energetics in tissue repair and recovery, and our 
data demonstrating the efficacy of BAY 58-2667 in naïve mice as an inducer of MB, we 
examined mitochondrial biogenic signaling and its outcomes in the kidney after renal I/R.  
Previous studies have demonstrated that MB is potently and persistently suppressed in the kidney 
after various forms of AKI including I/R [161].  Our results concur with these previous data as 
mRNA expression of PGC-1α, NRF-1, COX1, ND1 and ATPSβ were also suppressed to 30-50% 
of sham controls at 6 d after I/R injury (Figure 4.5A-E).  Furthermore, mtDNA copy number was 
reduced to 34% of control levels (Figure 4.5F).  Treatment with BAY 58-2667 promoted the 
recovery of PGC-1α and NRF-1 back to control levels.  Additionally, mRNA expression of 
COX1, ND1 and ATPSβ were also significantly increased.  Finally, mtDNA content was 
restored back to near sham control levels.  To examine whether these transcriptional changes 
manifested as increases in mitochondrial protein levels, we measured PGC-1α and COX1 
expression via immunoblot (Figure 4.6A-C).  At 6 d after I/R injury, PGC-1α protein expression 
was unchanged vs. sham controls.  However, treatment with sildenafil or BAY 58-2667 
increased PGC-1α expression to ~1.8-fold of sham levels, indicating that MB is being driven 
above levels observed in healthy controls.  COX1 expression was reduced to 34% of control 
levels in I/R mice, and treatment with either sildenafil or BAY 58-2667 restored expression to 
normal levels.  Finally, as an assessment of renal mitochondrial function, we measured renal 
cortical ATP levels using a luminescence based assay (Figure 4.6D).  Renal ATP levels were 
reduced to 39% of normal levels in I/R mice.  Both sildenafil and BAY 58-2667 restored renal 
ATP levels back to control levels suggesting a restoration of mitochondrial content and/or 
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Figure 4.5: BAY 58-2667 stimulates recovery of mitochondrial gene expression and mtDNA 
copy number following renal I/R. .  Renal cortical mRNA expression of PGC-1α (A), NRF1 
(B), ND1 (C), COX1 (D), ATPSβ (E) and mtDNA copy number (F) were assessed by qPCR. * 
indicates significant difference from sham (p<0.05), # indicates significant difference from 







Figure 4.6: BAY 58-2667 promotes recovery of renal mitochondrial protein expression and 
ATP levels. .  Renal cortical protein expression of PGC-1α and COX1 were assessed by 
immunoblot (A) and quantified by densitometry (B,C).  ATP levels (D) were quantified using the 
ATP Determination Kit (Life Technologies) * indicates significant difference from sham 
(p<0.05), # indicates significant difference from I/R+vehicle (p<0.05), n = 7-12 for qPCR, n=7-8 






BAY 58-2667 reduces development of renal fibrosis after I/R. 
 Increasing evidence points to AKI as a major risk factor for the development of chronic 
kidney disease (CKD) and end stage renal disease (ESRD) [10, 74, 356].  The failed repair of the 
renal tubular epithelium and chronic inflammation and oxidative stress may contribute to the 
development of fibrosis and chronic renal disease [27].  Furthermore, collagen deposition and 
fibrotic signaling have been prominently observed in animal models of I/R-induced renal injury 
[75, 357, 358].  In our model, early fibrotic development was observed following I/R, evidenced 
by a 5-fold induction in COL1A2 gene expression, and a 7.2-fold induction in renal cortical 
αSMA protein expression at 6 d after I/R (Figure 4.7A-C).  Treatment with BAY 58-2667 
reduced COL1A2 expression to 2.6-fold of sham controls, and αSMA to 3.7-fold of controls.  As 
polyuria is often observed in patients with early CKD, we monitored urinary output in these mice 
following I/R.  Urine output was significantly increased in I/R mice vs. sham controls at 6 d after 









Figure 4.7: BAY 58-2667 reduces renal fibrotic development following I/R.  Renal cortical 
mRNA expression COL1A2 (A) was assessed by qPCR. Renal cortical protein expression of 
αSMA was assessed by immunoblot and quantified by denistrometry (B,C). Urine output was 
monitored by 18-h collection in metabolism cages (D).   * indicates significant difference from 





BAY 58-2667 reduces renal inflammatory cytokines and oxidative damage. 
 Inflammation and oxidative stress are key mediators of the initiation and progression of 
renal damage and dysfunction following I/R injury [359].  Additionally, inflammation and 
oxidative stress have been demonstrated to affect mitochondrial function [360].  We examined 
the effects of treatment with BAY 58-2667 on expression of inflammatory cytokines and 
chemokines, and markers of oxidative stress and antioxidant status.  Following I/R injury, 
expression of the inflammatory cytokines TNF-α and IL-1β were markedly upregulated in the 
renal cortex (Figure 4.8A-B).  Treatment with sildenafil or BAY 58-2667 reduced expression of 
both markers to near sham control levels.  Furthermore, mRNA expression of the macrophage 
marker F4/80 and the macrophage chemokine MCP-1 were upregulated 6-fold and 50-fold, 
respectively, 6 d after I/R, indicating profound macrophage infiltration (Figure 4.8C-D).  Neither 
sildenafil nor BAY 58-2667 reduced the expression of these markers.  Antioxidant status of the 
renal cortex was assessed by measurement of gene expression of catalase and the mitochondrial 
antioxidant manganese superoxide dismutase (MnSOD).  At 6 d after I/R, catalase and MnSOD 
levels were suppressed to ~20% of control levels.  Treatment with sildenafil and BAY 58-2667 
appeared to modestly increase these expression levels, however, these changes were not 
significant (Figure 4.9A,B).  Interestingly, despite having no significant effects on antioxidant 
status, sildenafil and BAY 58-2667 reduced 8-OH-dG levels (a marker of oxidative DNA 
damage) in the renal cortex back to sham control levels (Figure 4.9C).  These data demonstrate 







Figure 4.8: BAY 58-2667 reduces renal inflammatory cytokine expression. .  Renal cortical 
mRNA expression of TNFα (A), IL1β (B), MCP-1 (C) and F4/80 (D) were assessed by qPCR. * 
indicates significant difference from sham (p<0.05), # indicates significant difference from 







Figure 4.9: BAY 58-2667 reduces renal oxidative damage.  Renal cortical mRNA expression 
of catalase (A) and MnSOD (B) were measure by qPCR.  Renal 8-OH-dG levels were assessed 
by ELISA. * indicates significant difference from sham (p<0.05), # indicates significant 






BAY 58-2667 stimulates renal eNOS expression.   
 Previous reports have demonstrated that pharmacological induction of cGMP can cause 
the upregulation of eNOS expression and NO production through a positive-feedback loop [361]. 
Additionally, eNOS expression and activity have been shown to be inhibited following I/R injury 
[362].  Furthermore, eNOS has been demonstrated to have an important role in MB [233, 270, 
271].  We examined renal eNOS gene expression following I/R and the effects of sildenafil and 
BAY 58-2667 on its expression.  eNOS expression was reduced to ~60% of controls at 6 d after 
I/R (Figure 4.10A).  Treatment with sildenafil restored eNOS expression to sham levels, while 
BAY 58-2667 increased eNOS to 2-fold of sham controls.  To determine the effect of BAY 58-
2667 on renal cGMP levels both through its induction of GC activity and its effect on eNOS 
expression, we measured cGMP in the kidney via ELISA (Figure 4.10B).  No changes were 
observed in cGMP levels following renal I/R vs. sham controls.  Furthermore, treatment with 
sildenafil did not significantly increase renal cGMP.  BAY 58-2667 did increase cGMP 
significantly over sham levels, but not I/R+vehicle levels, however, cGMP levels in all groups 








Figure 10: BAY 58-2667 promotes recovery of renal eNOS expression, but has no effect on 
renal cGMP.  Renal cortical mRNA expression of eNOS (A) was measured by qPCR.  Renal 
cGMP levels were measured by ELISA. * indicates significant difference from sham (p<0.05), # 
indicates significant difference from I/R+vehicle (p<0.05), n = 7-12 for qPCR, n=5-9.  










 Mitochondria are dynamic organelles whose content, structure and function are regulated 
by the balance of mitochondrial degradation by mitophagy, mitochondrial fission and fusion 
processes, and the generation of new mitochondria through the process of mitochondrial 
biogenesis (MB) [125].  Mitochondrial function is required for the maintenance of normal 
cellular function, and is vital for tissue structural and functional repair following injury.  
Mitochondrial dysfunction is prominently observed in an array of both acute and chronic 
conditions including diabetes and metabolic syndrome, neurodegeneration, cardiovascular 
disease, and acute kidney injury (AKI) [153, 363-365].  Following renal ischemia-reperfusion 
(I/R)-induced AKI, renal tubular mitochondria undergo a number of pathological changes 
including loss of membrane potential, Ca2+-induced swelling, and activation of the mitochondrial 
permeability transition [153, 156, 345].  These mitochondrial disturbances lead to tissue ATP 
depletion, release of apoptotic mediators and production of reactive oxygen species, furthering 
renal tissue damage.  Furthermore, mitochondrial homeostasis following renal I/R injury remains 
persistently disrupted evidenced by disturbances in mitochondrial fission/fusion proteins, 
elevated mitophagy and suppressed mitochondrial biogenesis [126, 161].  Due to the energetic 
requirements of renal repair, this persistent mitochondrial dysfunction could limit renal recovery 
following AKI.  Thus, induction of the generation of new, more functional mitochondria through 
the activation of MB could accelerate renal recovery. 
 Previous studies by our laboratory with inducers of MB including SRT1720, formoterol 
and LY 344-864 have shown restoration of renal mitochondrial content and function, and 
acceleration of renal functional recovery [148, 150, 218].  Additionally, cGMP has a well-
characterized role in the regulation of MB.  Induction of cGMP using PDE5 inhibitors has been 
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shown to protect against or promote recovery from AKI [149, 314, 354, 355].  Treatment of mice 
with sildenafil after folic acid-induced AKI stimulated the recovery of mitochondrial gene 
expression and mtDNA content, and reduced tubular injury evidenced by decreased Kim-1 
expression.  cGMP levels can also be regulated by controlling their generation by guanylyl 
cyclases (GCs).  GCs are activated primarily through G-protein coupled membrane receptors or 
by naturetic peptides.  Recent work has led to the development of novel small molecule GC 
stimulators (activated reduced GC) and activators (activate oxidized GC).  In these studies, we 
examined the ability of BAY 41-2272, a GC stimulator, and BAY 58-2667, a GC activator, to 
stimulate MB in vitro and in vivo and to promote recovery renal and mitochondrial recovery after 
I/R-induced AKI.   
 Treatment of rabbit renal proximal tubular cells (RPTC) with BAY 41-2272 stimulated 
mitochondrial uncoupled OCR (FCCP-OCR) at concentrations of 1-10 µM, while BAY 58-2667 
increased FCCP-OCR at concentrations of 1 nM – 10 µM.  No changes were observed in basal 
oxygen consumption (Figure 4.1).  Due to the high oxidative potential of these cells, a change in 
basal oxygen consumption is rarely observed with induction of MB.  Increases in FCCP-OCR 
alone are indicative of increased mitochondrial content or function.  We then treated naïve mice 
with BAY 41-2272 (0.1-1 mg/kg) and BAY 58-2667 (0.01-0.1 mg/kg) to assess their in vivo 
efficacy.  BAY 58-2667 increased renal cortical expression of mitochondrial genes and proteins, 
and mtDNA copy number (Figure 4.2).  Interestingly, BAY 41-2272 had no effect on renal MB 
signaling.  The failure of BAY 41-2272 to induce MB could indicate that GC in the renal cortex 
is primarily present in the oxidized (or heme-free) form preventing the interaction of GC 
stimulators, but not activators.  Due to the high levels of oxidative metabolism in the renal cortex 
this is likely a region that experiences relatively high levels of oxidative stress, perhaps leading 
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to GC oxidation.  Further studies are needed to characterize the oxidative state of GC in the renal 
tubular epithelium.   
 Due to the efficacy of BAY 58-2667 in naïve mice, we tested its ability to promote 
mitochondrial and renal recovery after I/R-induced AKI in mice.  MB is potently and chronically 
suppressed following renal I/R injury, thus reactivation of MB signaling could accelerate renal 
recovery.  Mice were treated with BAY 58-2667 (0.1 mg/kg) at peak injury (24 h after I/R) to 
evaluate its role in renal recovery.  Additionally, another group of mice were treated with the 
PDE5 inhibitor sildenafil due to its known role in the activation of MB and its ability to promote 
renal recovery in other models of AKI.  Daily treatment with either sildenafil or BAY 58-2667 
from 24-144 h promoted recovery of renal function evidenced by reduced BUN, and reduced 
tubular injury markers, Kim-1 and NGAL (Figure 4.3).  Additionally, BAY 58-2667 reduced 
histological scores for renal tubular necrosis (Figure 4.4).  Due to the delay in treatment, these 
changes in renal function and damage markers are indicative of a promotion of renal recovery, 
rather than a blunting of renal injury.   
 As previously described, mitochondrial function is critically important for renal repair.  
MB signaling has previously been shown to be persistently reduced, and vital for renal recovery.  
Mice treated with BAY 58-2667 demonstrated recovery of expression of PGC-1α, NRF-1 and 
several mitochondrial and nuclear-encoded mitochondrial genes, as well as mtDNA content 
indicating a reactivation of MB (Figure 4.5).  Furthermore, protein expression of PGC-1α was 
induced over sham control levels promoting the recovery of COX1 protein expression, and renal 
function evidenced by renal cortical ATP levels (Figure 4.6).  These data clearly demonstrate the 
ability of the GC activator BAY 58-2667 to promote MB in the injured kidney.  Restoration of 
renal cortical ATP levels provides the energy necessary to power renal tissue repair mechanisms.     
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 Recent work has elucidated the link between AKI and the development of CKD and 
ESRD [10, 74, 356].  Previously believed to be unique and independent disease states, AKI and 
CKD are now described on a continuum of renal dysfunction.  Following an acute renal insult, 
activation of renal repair processes regenerate the renal tubular epithelium and restore renal 
function.  However, failure of these processes can lead to tubular atrophy, secretion of pro-
fibrotic signals, proliferation of resident or infiltrating myelofibroblasts, and ultimately chronic 
renal dysfunction [73].  We examined the effects of BAY 58-2667 treatment on early fibrotic 
development 144 h after I/R.  Mice treated with BAY 58-2667 showed reduced expression of the 
fibrotic markers COL1A2 and αSMA (Figure 4.7).  Urinary output was monitored as polyuria is 
observed early during CKD.  BAY 58-2667 did not reduce urine output back to control levels; 
however, as cGMP is a crucial signal for naturesis, GC activation alone likely stimulates urine 
output making interpretation of this result difficult.  Previous work has shown that NO-cGMP 
signaling is reduced in experimental models of renal fibrosis, and induction of cGMP using the 
GC stimulator BAY 41-2272 reduces fibrotic development [366, 367].  The efficacy of BAY 41-
2272 in these models and the failure of BAY 41-2272 to induce MB in the renal cortex suggests 
a MB-independent mechanism for suppression of renal fibrosis.  However, other studies have 
demonstrated the potential of BAY 41-2272 to stimulate MB in other tissues.  Differences in 
dosing and timing of assessment of mitochondrial endpoints could yield different results, thus 
MB may still play a role in fibrotic suppression. 
 Mitochondrial function is closely linked with tissue inflammation and oxidative stress 
[360].  Mitochondrial dysfunction can lead to the release of inflammatory mediators, including 
mtDNA, and the production of reactive oxygen and nitrogen species.  Contrarily, inflammatory 
signals can negatively impact mitochondrial function, and ROS can lead to damage of 
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mitochondrial proteins and lipids.  Thus, activation of any one of these components can 
negatively impact the others creating a vicious cycle of elevated inflammatory signaling, 
compromised mitochondrial function and increased oxidative cellular damage.  Due to the role of 
mitochondria in inflammation and oxidative stress, we measured inflammatory gene expression 
and markers of oxidative stress in I/R mice following treatment with BAY 58-2667.  Expression 
of the inflammatory cytokines TNF-α and IL-1β were potently induced following renal I/R, and 
treatment with both sildenafil and BAY 58-2667 reduced expression of these inflammatory 
signals (Figure 4.8).  BAY 58-2667 additionally reduced renal oxidative damage assessed by 8-
OH-dG levels independent of effects on antioxidant mechanisms (Figure 4.9).  These data 
demonstrate that BAY 58-2667 has beneficial effects on renal recovery after I/R by reducing 
inflammatory signaling and oxidative stress.  This effect could be a result of generation of better 
functioning mitochondria and thus reduced release of inflammatory mediators and ROS from 
dysfunctional mitochondria, or a direct effect of cGMP-induction on inflammatory or oxidative 
signaling.  As cGMP has a well-known effect on vascular function and permeability [368], the 
positive effects observed in this study are likely caused by a mixed effect on renal tubular 
mitochondria, endothelial cells and resident inflammatory cells.   
 Previous work has shown that under certain conditions cGMP can promote its own 
generation through a positive feedback mechanism leading to enhanced production of NO via 
eNOS [361].  eNOS expression and activity has been shown to be disrupted in a number of acute 
conditions including I/R injury [369-371].  In our studies, we observed that eNOS expression 
was suppressed 6 d after I/R and that treatment with sildenafil promoted its recovery to control 
levels.  BAY 58-2667 stimulated eNOS expression to 2-fold of control levels indicating a greater 
potency for GC activators vs. PDE inhibitors for this response (Figure 4.10).  In addition to 
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potentially enhancing NO-cGMP-induced MB, induction of eNOS expression could have 
beneficial effects on vascular homeostasis.  Assessment of renal cGMP levels via ELISA 
demonstrated that cGMP was unchanged following treatment with BAY 58-2667.  However, this 
measurement was performed in tissue 24 h after the last dose of drug.  Induction of cGMP via 
BAY 58-2667 is likely a transient response causing activation of more prolonged downstream 
signals.  Induction of cGMP can lead to activation of PDEs through a negative feedback loop.  
Further studies are needed to evaluate acute changes in renal cGMP and associated signaling 
cascades.   
 Overall these studies demonstrate that induction of renal cGMP levels using the guanylyl 
cyclase activator BAY 58-2667 promotes recovery of renal function and structure, and limits 
fibrotic progression through activation of mitochondrial biogenesis, and reduction in renal 
inflammation and oxidative stress.  These studies highlight the therapeutic potential for GC 
















Urinary ATP synthase subunit β is a novel biomarker of renal mitochondrial 










Although the importance of mitochondrial dysfunction in acute kidney injury (AKI) has 
been documented, noninvasive early biomarkers of mitochondrial damage are needed.  We 
examined urinary ATP synthase subunit β (ATPSβ) as a biomarker of renal mitochondrial 
dysfunction during AKI.  Mice underwent sham surgery or varying degrees (5, 10, or 15 min 
ischemia) of ischemia/reperfusion (I/R)-induced AKI.  Serum creatinine, BUN, and neutrophil 
gelatinase-associated lipocalin were elevated only in the 15 min I/R group at 24 h.  Immunoblot 
analysis of urinary ATPSβ revealed two bands (full length ∼52 kDa and cleaved ∼25 kDa), both 
confirmed as ATPSβ by LC-MS/MS, that increased at 24 h in 10- and 15-min I/R groups.  These 
changes were associated with mitochondrial dysfunction evidenced by reduced renal cortical 
expression of mitochondrial proteins, ATPSβ and COX1, proximal tubular oxygen consumption, 
and ATP.  Furthermore, in the 15-min I/R group, urinary ATPSβ was elevated until 72 h before 
returning to baseline 144 h after reperfusion with recovery of renal function.  Evaluation of 
urinary ATPSβ in a nonalcoholic steatohepatitis model of liver injury only revealed cleaved 
ATPSβ, suggesting specificity of full-length ATPSβ for renal injury.  Immunoblot analyses of 
patient urine samples collected 36 h after cardiac surgery revealed increased urinary ATPSβ 
levels in patients with postcardiac surgery-induced AKI. LC-MS/MS urinalysis in human 
subjects with AKI confirmed increased ATPSβ.  These translational studies provide evidence 
that ATPSβ may be a novel and sensitive urinary biomarker of renal mitochondrial dysfunction 





Acute kidney injury (AKI) is a significant clinical problem in hospitalized patients that is 
increasing in prevalence[372].  Furthermore, rates of adverse complications, mortality, and 
treatment costs are positively correlated with the severity of renal dysfunction[6].  Mitochondrial 
disruption is a key event promoting the progression of tubular cell injury/death during surgery, 
trauma, sepsis, ischemia/reperfusion (I/R), and drug/toxicant-induced AKI [152-154, 160, 163, 
373].  Mitochondria play a major role in Ca2+ homeostasis, reactive oxygen species generation 
and redox balance, cellular proliferation, and apoptosis in AKI.  Mitochondrial dysfunction is 
also a component of many chronic diseases including diabetes, neurodegeneration, and aging 
[163, 373]. 
Ischemia is a common pathophysiologic mechanism in many forms of AKI.  Ischemic 
insult occurs when there is a reduced blood flow to the kidney which may occur after drug or 
toxicant exposure or as a component of vascular disease, sepsis, or volume depletion and 
hypotension [22, 27].  Mitochondrial damage is a major contributor to the tubular cell injury 
observed in the initiation and progression of ischemic AKI [22, 27, 152-154].  Following 
restoration of blood flow after ischemia, production of reactive oxygen and nitrogen species 
within the mitochondria is dramatically increased.  Oxidative damage to mitochondrial proteins 
and lipids causes dysfunction of respiratory complexes, membrane depolarization, ATP 
depletion, and release of apoptotic proteins contributing to cellular injury and death. 
Current organ injury biomarkers do not focus on mitochondrial dysfunction, and tests for 
mitochondrial integrity are limited to invasive procedures including muscle biopsies, organ ATP 
measurements, or respiratory measurements in isolated mitochondria [374].  While the importance 
of mitochondrial dysfunction during AKI in animals has been well documented [126, 149, 218, 
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275], similar data in humans is sparse as the availability of renal tissue for mitochondrial analysis 
is limited.  Consequently, there is a significant need for early, specific and non-invasive biomarkers 
of mitochondrial dysfunction in AKI.  Identification and validation of these markers could 
elucidate novel targets and mechanisms of renal mitochondrial dysfunction in AKI, and enable the 
development of new therapies.   
We have previously reported that after I/R and glycerol-induced AKI, a time-dependent 
loss of renal cortical mitochondrial proteins including ATP synthase subunit β (ATPSβ), a 
component of the electron transport chain (ETC), was indicative of renal mitochondrial 
dysfunction [126, 148, 161, 218]. Mitochondrial and renal function fail to fully recover after injury 
suggesting that mitochondrial function is a key component of the renal repair process.  Thus, 
biomarkers of renal mitochondrial dysfunction may be a suitable proxy for monitoring 
mitochondrial and renal function in patients after AKI. In this study we validated urinary ATPSβ 












Mouse renal I/R-induced AKI model 
   Eight-week-old male C57BL/6 mice (25–30 g) were divided into naïve, sham or I/R 
groups. Mice in the I/R group were subjected to bilateral renal pedicle clamping as described 
previously [148, 161]. Briefly, the renal artery and vein were isolated and blood flow was 
occluded with a vascular clamp for 5, 10, or 15 min.  Mice were placed in metabolic cages 6 h 
after I/R until 24 h for 18 h urine collections.  Urine was collected using a chilled collection 
system and protease inhibitors were added immediately after collection to prevent protein 
degradation.  Mice were euthanized 24 h after surgery, at which time serum was collected and 
kidneys harvested for biochemical and histological analyses.  For time course studies, urine, 
serum and kidneys were collected at 72 and 144 h.  Renal function was monitored by serum 
creatinine and BUN using kits (BioAssay Systems, Hayward, CA) per the manufacturer’s 
instructions. Urinary NGAL was measured by immunoblot and normalized to a standard sample. 
Renal tissues were fixed in 4.5% buffered formalin, dehydrated, and embedded in paraffin. For 
general histopathology, sections were stained with hematoxylin and eosin (H&E). All procedures 
involving animals were performed with approval from the IACUC in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals.  
Mouse nonalcoholic steatohepatitis model 
Male C57BL/6 mice (8–9 weeks) were fed a liquid diet ad libitum containing 35% of 
calories from fat using corn oil with 0.5% (w/v) cholesterol for 5 months.  Control mice were fed 
normal chow (Teklad Global 18% Protein rodent diet) containing 6.2% fat (18% of calories from 
fat) ad libitum.  The fatty acid compositions in each diet were as follows: 16% saturated, 31% 
monounsaturated, 53% polyunsaturated in the nonalcoholic steatohepatitis (NASH) diet, and 
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32% saturated, 41% monounsaturated and 27% polyunsaturated for the control diet.  Mice were 
placed in metabolic cages for 24 h for urine collection.  Blood was collected under pentobarbital 
anesthesia (80 mg/kg, ip).  Liver function was assessed by serum ALT determined using kits 
from Pointe Scientific (Lincoln Park, MI). For general histopathology, sections were stained with 
H&E. 
 
Human urine samples 
 We used a subset of human urine samples from a recent study with published details of 
sample collection, processing, informed consent, and inclusion/exclusion criteria [375]. Urine 
samples were obtained as part of NIDDK-funded multicenter trial (NIH #DK080234) to identify 
prognostic urine markers from cardiac surgery patients who developed AKI.  Protease inhibitors 
were added to each urine sample, and the supernatant was collected after centrifugation at 1,000 
x g, and aliquots were frozen at -80 °C. Samples were shipped to the MUSC site on dry ice and 
kept frozen until use. Corresponding data including patient demographics, baseline chemistry 
measurements, urine collection and maximum values for serum creatinine, electrolytes, surgery 
type, cardiopulmonary bypass time, preexisting diseases, dialysis status, days to discharge and 
mortality status were provided (Table 1). Samples were also collected from patients who had 
cardiac surgery but did not develop AKI. These samples were collected by the MUSC CTSA 
Biobank and are linked to medical record numbers which provided subject demographic and 
clinical information.  
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Table 5.1: Sample clinical characteristics from cardiac surgery patients with AKI or no 
AKI.  Data are shown as median (interquartile range), n (%), or mean ± SD (n = 16 per group). 








Unless stated otherwise, all chemicals and biochemicals were purchased from Sigma 
Chemical Co. (St. Louis, MO).  Rabbit polyclonal anti-NGAL and mouse monoclonal anti-
ATPSβ were purchased from Abcam Inc. (Cambridge, MA); mouse monoclonal anti-COX1 was 
purchased from Life Technologies (Carlsbad, CA); and the loading control glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was obtained from Fitzgerald International Inc. (Acton, 
MA).  Anti-rabbit and anti-mouse secondary antibodies conjugated with horseradish peroxidase 
were obtained from Pierce (Rockford, IL). All LC-MS/MS reagents were LC-grade pure and 
purchased from Waters (Milford, MA).  Protein-A agarose beads used in the 
immunoprecipitation protocol were purchased from Roche (Indianapolis, IN). 
Oxygen consumption in isolated tubular segments 
   Proximal tubules were isolated from fresh kidneys as previously described [32]. Briefly, 
renal cortical tissue was homogenized in Hanks Buffered Salt Solution (HBSS) containing 
collagenase (Worthington Biochemical Corp., Lakewood, NJ) and Soybean Trypsin Inhibitor 
(Sigma-Aldrich, St. Louis, MO).  Tubules were incubated on a rocker at 37 oC for 30 min.  
Following digestion, horse serum was added and samples were vortexed for 30 s to inactivate 
collagenase.  Samples were centrifuged at 200 x g for 5 min, the pellet was washed with HBSS 
and centrifuged at 200 x g again. Tubules were resuspended in RPTC culture media [149] and 
further diluted in media for respirometic analysis.  Tubules were transferred to an XF-96 
polystyrene cell culture plate (Seahorse Biosciences, North Bellerica, MA) and basal and FCCP-
uncoupled oxygen consumption rate (OCR) were assessed in triplicate using the Seahorse XF96 
Extracellular Flux Analyzer as previously described  [284].  OCR was normalized to protein, 
assessed by BCA (Sigma-Aldrich, St. Louis, MO), using bovine serum albumin as the standard. 
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Renal ATP levels 
   ATP was isolated from fresh kidneys as previously described [307].  Briefly, renal 
cortical tissue was homogenized in phenol-TE. DEPC water and chloroform were added and the 
suspension was vortexed.  Samples were centrifuged at 10,000 x g for 5 min at 4 oC.  The upper 
layer was diluted 1:100 in DEPC water and ATP was measured using the ATP Determination Kit 
(Invitrogen, Carlsbad, CA).  ATP levels were normalized to tissue wet weight. 
Renal and urinary immunoblots 
 Immunoblots using mouse renal cortical tissue were performed as previously described 
[376, 377]. Urine samples from mice and humans were thawed and homogenized in 1 volume of 
protein lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4; 1 mM EDTA; 1 
mM EGTA; 2 mM sodium orthovanadate; 0.2 mM phenylmethylsulfonyl fluoride; 1 mM 
HEPES, pH 7.6; 1 μg/ml leupeptin; and 1 μg/ml aprotinin) using a Polytron homogenizer. The 
homogenate was stored on ice for 10 min and then centrifuged at 1,000 x g for 2 min at 4 °C. 
The supernatant was collected and total urinary protein was determined as described above. 
Equal amounts of protein (10 μg) were separated on 4 to 20% gradient SDS-polyacrylamide gels 
and transferred to nitrocellulose membranes. Membranes were blocked either in 5% dried milk 
(for NGAL) or BSA in TBST (for all other antibodies) and incubated with 1:1,000 dilutions of 
anti-NGAL, anti-ATPSβ, anti-COX1 and anti-GAPDH overnight at 4 °C. After incubation for 2 
h at room temperature with secondary antibodies (1:2,000) conjugated with horseradish 
peroxidase, membrane proteins were detected via chemiluminescence. Renal proteins were 
quantified and normalized with GAPDH. Urinary proteins were quantified and normalized to a 
standard sample and corrected to total urinary protein. 
156  
ATPSβ immunoprecipitation 
 Immunoprecipitation was performed according to the method described by Abcam Inc. 
(Cambridge, MA). Briefly, mouse urine samples from the 15 min I/R (severe injury) group were 
homogenized in lysis buffer with protease inhibitor cocktail and then centrifuged to remove cell 
debris.  Lysates were pre-cleared  to reduce non-specific binding during the 
immunoprecipitation.   Briefly, a non-ATPSβ mouse IgG1antibody (50 µL) was added to urine 
lysates and incubated on ice for 1 h.  Protein-A agarose bead slurry (100 µL) was added and 
samples were incubated for 30 min at 4 oC with gentle agitation.  Samples were centrifuged and 
the supernatant saved for immunoprecipitation.  Protein concentration of the pre-cleared 
supernatant was determined by BCA as described above.  A 500 ug aliquot of pre-cleared protein 
was incubated with 10 µg mouse monoclonal anti-ATPSβ (Abcam Inc., Cambridge, MA) 
overnight at 4 oC with gentle agitation. Protein complexes were mixed with protein-A agarose 
bead slurry (70–100 µl) on ice and incubated overnight at 4 °C under rotary agitation. After 
incubation, samples were centrifuged and the supernatant was collected and washed in lysis 
buffer three times via centrifugation at 4o C. The final supernatant was removed and 25–50 µl of 
2x loading buffer was added. Samples were boiled at 95–100 °C for 5 min, centrifuged and the 
supernatant was separated by SDS-PAGE. The gel was stained with Coomassie blue and bands 
were excised for LC-MS/MS-based peptide identification as previously described [378].  
Urinary ATPSβ identification with LC-MS/MS 
 Frozen urine aliquots were thawed at 37 °C for 10 min and centrifuged for 10 min at 
1,000 x g and 4 °C. Total urinary protein and creatinine values were measured. Sample volume 
used for trypsin digestion and subsequent proteomic analysis was calculated by normalizing total 
urinary protein to both urine volume and urine creatinine to eliminate biological variability. LC-
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MS/MS analysis including ATPSβ peptide identification and normalization of spectral counts 
with internal standard HIV gp160 protein for each sample was performed as previously 
described [375, 377]. 
Data and statistical analysis 
Data are expressed as means ± SEM for all experiments.  Multiple comparisons of 
normally distributed data were performed by one-way ANOVA, as appropriate, and group means 
were compared using a Student-Newman-Keuls post-hoc test.  Single comparisons were 
analyzed using the Student’s t-test where appropriate.  The criterion for statistical differences 

















Urinary ATPSβ correlates with the degree of renal injury following I/R-induced AKI in 
mice 
Mice were subjected to sham or I/R surgery by bilateral renal pedicle ligation for 5, 10, or 
15 min corresponding to mild, moderate, and severe injury, respectively.  BUN and serum 
creatinine were increased only in mice with severe injury at 24 h after reperfusion (Figure 5.1A, 
5.1B).  Correlated with renal functional loss, mice in the severe injury group exhibited extensive 
proximal tubular necrosis throughout the corticomedullary region characterized by eosinophilic 
tubules with karyolytic nuclei (Figure 5.2).  No histological renal damage was observed in mice 
after sham or mild I/R injury, whereas minimal proximal tubular vacuolization was observed in 
moderately injured mouse kidneys (Figure 5.2).  Urinary NGAL, a renal tubular damage 
biomarker, was detected in severely injured mice only at 24 h (Figure 5.1C).  Thus, this model 
demonstrates three distinct groups for evaluation with varying degrees of renal injury and 
functional loss. 
Using these groups, we evaluated urinary ATPSβ as a biomarker of renal mitochondrial 
dysfunction during I/R-induced AKI and correlated levels to the severity of renal dysfunction.  
We identified full length (∼52 kDa) and cleaved fragments (∼25 kDa) of urinary ATPSβ protein 
via immunoblot (Figure 5.1D).  Normalized to total urinary protein, full length ATPSβ increased 
in mice after moderate and severe injury (Figure 5.1E).  When normalized to total protein, 
expression of the cleaved fragment increased in mice only after severe injury (Figure 5.1F).  The 
proposed full length and cleaved fragment of ATPSβ were immunoprecipitated from urinary 
protein isolates (Figure 5.1G) and fragments were confirmed to be ATPSβ by LC-MS/MS 
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analysis via identification of the peptide sequence VVDLLAPYAK, which is specific to the 
ATPSβ N-terminal region. 
 
Increases in urinary ATPSβ are associated with renal mitochondrial protein loss and 
reduced mitochondrial function 
We recently reported that renal mitochondrial disruption, including ATPS
for at least 6 days after I/R-induced AKI [126, 148, 161, 218].  Confirming that renal cortical 
mitochondrial proteins decreased in conjunction with increased urinary ATPSβ, we observed that 
renal COX1 decreased following moderate or severe injury, while ATPSβ decreased in the 
severe injury group at 24 h (Fig. 2A-C).  Thus, moderate or severe renal damage is associated 
with the loss of renal cortical COX1 and ATPS and increased urinary ATPSβ.  
The loss of mitochondrial proteins has been reported to cause a reduction in 
mitochondrial function [148, 379].  Mitochondrial function was evaluated by assessment of basal 
and FCCP-uncoupled OCR in isolated proximal tubular segments.  FCCP-uncoupled OCR, a 
mitochondrial stress test, was reduced 50% in mild, moderate and severe injury groups at 24 h 
compared to sham controls (Fig 3A).  Basal respiration was not reduced in any group.  To 
evaluate whether the observed decreases in OCR manifest as reduced renal energy content, renal 
cortical ATP levels were measured.  ATP levels were reduced 30-40% following mild, moderate 
or severe I/R-induced AKI (Fig. 3B).  These multiple mitochondrial markers demonstrate renal 





Figure 5.1: Urinary ATP synthase subunit β (ATPSβ) is increased in mice following I/R-
induced AKI.  Male C57BL/6 mice (8–10 weeks old) were subjected to no surgery, sham, or 
renal I/R (5, 10, or 15 min) surgery.  Mice were euthanized at 24 h after reperfusion, and blood, 
urine, and kidneys were collected. BUN (A), serum creatinine (B), and urinary neutrophil 
gelatinase lipocalin 2 (NGAL) (C) protein expression were measured as indicators of renal 
function and damage.  Urinary ATPSβ were measured via immunoblot (D).  The ATPSβ full 
length and cleaved fragments were quantified via densitometry (E, F) and normalized to a 
standard sample and total urinary protein.  To validate the immunoblot results, ATPSβ was 
immunoprecipitated from urinary isolates, purified via gel electrophoresis and analyzed by LC-
MS/MS.  A representative Coomassie gel for immunoprecipitated-urinary ATPSβ with mouse 
monoclonal anti-mitochondrial ATPSβ antibody is shown (G). Data are expressed as mean ± SE 







Figure 5.2: Representative renal histology from various ischemia times.  Kidneys were 
collected from mice with no surgery, or 24 h after sham surgery or 5, 10 or 15 min of ischemia 
and fixed in formalin.  Sections were stained with H&E for assessment of morphology.  Images 




Figure 5.3: Renal cortical mitochondrial protein expression is reduced after I/R-induced 
AKI.  Mouse renal cortical protein expression of ATP synthase subunit β (ATPSβ) and COX1 
(A) was measured by immunoblot and quantified via densitometry (B, C) at 24 h after sham 
surgery or ischemia.  Expression was normalized to glyceraldehyde 3-phosphate dehydrogenase 








Figure 5.4: Mitochondrial function is reduced after mild, moderate, or severe I/R-induced 
AKI.  Basal and FCCP-uncoupled oxygen consumption rate (OCR) was measured in freshly 
isolated mouse renal proximal tubules 24 h after sham surgery or 5, 10, or 15 min of ischemia 
followed by reperfusion (A).  Rates were normalized to protein. ATP levels were determined and 












Urinary ATPSβ levels are a marker of renal functional recovery after I/R-induced AKI 
We then examined urinary ATPSβ over time after AKI. Urinary full-length and cleaved 
ATPSβ remained elevated 72 h after severe injury and returned to baseline at 144 h. (Fig. 5.5A-
C).  Renal function partially recovers 144 h after severe renal injury in this model [126, 148, 161, 
218] and the return of ATPSβ to baseline is consistent with this partial recovery of renal 
function.   
 
Urinary full-length ATPSβ is specific for renal mitochondrial dysfunction 
ATPSβ is a ubiquitously expressed component of the ETC; thus extra-renal sources of 
ATPSβ in the urine cannot be excluded.  To assess the specificity of urinary ATPSβ for renal 
mitochondrial dysfunction, we evaluated its presence in the urine of mice with NASH.  Mice 
exhibited liver damage and dysfunction evidenced by histological changes (ie, fat accumulation) 
and a rise of serum ALT (Figure 5.6A, 5.6B).  No change in serum creatinine was observed 
suggesting that renal function was not disrupted (Figure 5.6C).  Urinary immunoblot analysis 
detected the cleaved ATPSβ fragment; however, no full-length protein was detected (Figure 
5.6D).  These data provide evidence that the full-length fragment may specifically arise from 
renal mitochondrial dysfunction, whereas the cleaved fragment may arise from renal or nonrenal 







Figure 5.5: Urinary ATP synthase subunit β (ATPSβ) expression time course in mice after 
I/R-induced AKI.  Mice were subjected to sham surgery or bilateral renal pedicle ligation for 
17 min.  Urine was collected at 72 and 144 h after reperfusion.  Urinary ATPSβ protein 
expression was evaluated by immunoblot (A).  The ATPSβ full length and cleaved fragments 
were quantified via densitometry (B, C) and normalized to a standard sample and total urinary 





Figure 5.6: Cleaved  urinary ATP synthase subunit β (ATPSβ) but not full-length is 
elevated in a NASH model.  C57BL/6 mice were fed a high fat/high cholesterol diet for 5 
months to induce NASH.  Controls were fed a normal chow diet.  Liver damage was assessed 
histologically by hematoxylin and eosin (H&E) staining (A).  Liver (B) and renal (C) function 
were assessed by serum ALT and creatinine, respectively.  Data are expressed as mean ± SE.  















Urinary ATPSβ levels are increased in human patients that developed postcardiac surgery 
AKI 
To assess ATPSβ as a renal mitochondrial dysfunction biomarker in humans, we 
analyzed urine collected from patients 36 h after cardiac surgery who either developed AKI or 
did not.  Patient demographic and clinical parameters were collected (Table 5.1). Baseline and 
postsurgical renal function were evaluated by serum creatinine and patients who developed AKI 
showed a 2-fold increase in serum creatinine over baseline indicating severe injury (Figure 
5.7D). We identified full length (∼52 kDa) and cleaved fragments (∼25 kDa) of urinary ATPSβ 
protein in patients who developed AKI (Figure 5.7A). Normalization of full length and cleaved 
urinary ATPSβ to total protein revealed increased full-length ATPSβ in AKI patients (Figure 
5.7B), but no changes were observed in cleaved ATPSβ levels (Figure 5.7C). To validate 
immunoblot results, we conducted LC-MS/MS-analysis which confirmed increases in the same 















Figure 5.7: Urinary ATP synthase subunit β is elevated in human patients following 
cardiac surgery-induced AKI.  ATPSβ protein expression was measured via immunoblot in 
urine collected 36h after cardiac surgery in patient with either no AKI or AKI (A). The full 
length and cleaved fragments were quantified via densitometry (B, C) and normalized to total 
urinary protein. Renal function was assessed by serum creatinine (D). LC-MS/MS analysis from 
urine of AKI patients after cardiac surgery revealed a fragmentation pattern consistent with the 
tryptic peptide VVDLLAPYAK, unique for human ATPSβ (E). Data are expressed as mean ± SE 





Mitochondria have been characterized as central mediators of the pathophysiology of AKI 
resulting from a variety of insults including drug/toxicant exposure, ischemia-reperfusion injury 
and sepsis [152-154, 160, 163, 373].  Persistent disruption of mitochondrial dynamics, function 
and biogenesis has been well documented in animal models of renal injury [126, 148, 149, 161, 
218, 275].  However, due to the limitations in the availability of renal tissue, little is known about 
the role of mitochondrial dysfunction in human AKI.  Therefore, non-invasive biomarkers of renal 
mitochondrial dysfunction are needed to enhance our understanding of the role of mitochondria in 
the initiation and recovery from AKI.  To this end, we examined urinary levels of ATPSβ as a 
potential biomarker of renal mitochondrial dysfunction in a mouse model of I/R-induced AKI and 
in humans who developed AKI following cardiac surgery.   
Mice underwent varying degrees of renal ischemia (5, 10 or 15 min) followed by 
reperfusion.  These groups were characterized as representative of mild, moderate and severe renal 
injury by renal histology and by markers of renal function and damage including serum creatinine, 
BUN and renal NGAL expression (Fig. 1A-C; Suppl. 1).  Immunoblot analysis demonstrated a 
full-length and cleaved form of ATPSβ in the urine of mice following moderate or severe renal 
injury (Fig. 1D-F).  The observed increase in urinary ATPSβ after severe injury may arise from 
necrosis and epithelial cell sloughing into the tubular lumen due to profound renal injury consistent 
with observed increases in urinary NGAL [22, 27].  Interestingly, full-length urinary ATPSβ was 
also elevated after moderate injury in the absence of increases in serum creatinine and urinary 
NGAL, indicating mitochondrial dysfunction prior to renal dysfunction (Fig. 1A-C; Suppl. 1).  
Thus, full-length urinary ATPSβ increases with moderate and severe renal damage and this 
increase precedes elevations of other renal injury markers. In contrast, urinary cleaved ATPSβ 
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increased only after severe injury.  While immunoblot analysis is appropriate for biomarker 
discovery, use of this method for quantification of urinary proteins is neither as sensitive nor 
quantitative as ELISA, thus we are likely missing changes in urinary ATPS. 
At 52-56 kDa, ATPSβ falls around the cutoff for glomerular filtration.  Thus, ATPSβ 
may be filtered, and extra-renal sources cannot be excluded.  However, the potential that urinary 
ATPSβ originates from an extra-renal source during AKI is low as levels are similarly elevated 
after moderate and severe injury despite significant differences in creatinine and NGAL levels 
between these groups (Fig. 1B).  These results provide evidence that sub-lethal damage to 
mitochondria in the absence of necrotic cell death may result in the release of ATPSβ; however, 
the exact mechanism of release is still unclear. 
To validate renal specificity, we measured urinary ATPSβ in a mouse model of NASH 
that exhibited liver injury without an increase in serum creatinine.  We detected no full-length 
ATPSβ in the urine from these mice; however, the cleaved fragment was detected (Fig. 5).  
These data support the idea that full-length ATPSβ is a specific marker for renal mitochondrial 
damage, while the cleaved fragment may arise from renal and extra-renal sources.  We 
hypothesize that the cleaved fragment is freely filtered due to its small size, while full-length 
ATPS is not filtered as it is near the size exclusion limit for filtration, and its carries a 
significant negative charge at physiological pH.  Our data from cardiac surgery patients also 
supports this hypothesis, as we observed both the cleaved fragment in AKI and no AKI samples, 
while only full-
be of renal or extra-renal origin in these patients (heart, liver, vasculature, etc.).  
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We have previously demonstrated a time dependent decrease in renal cortical 
mitochondrial protein expression following various forms of AKI in rodent models.  In this study 
we observed a decrease in renal cortical expression of COX1 24 h after reperfusion in mice with 
moderate or severe renal injury, and ATPSβ in mice with severe injury (Fig. 2). Furthermore, 
mitochondrial function was compromised 24 h after mild, moderate or severe I/R injury as 
assessed by isolated proximal tubule OCR and renal cortical ATP (Fig. 3).  Reduction of renal 
mitochondrial function appears to precede the 1oss of renal mitochondrial proteins and 
elevations in urinary ATPSβ in this model, although this may be due the sensitivity of 
immunoblot analysis. Overall, these results confirm renal mitochondrial dysfunction occurs with 
increased urinary ATPSβ.   
Evaluation of urinary ATPSβ levels at 72 and 144 h after I/R in mice revealed a recovery 
of ATPSβ levels to near control levels at 144 h after injury (Fig. 4).  This recovery mirrors the 
partial recovery of renal function as measured by serum creatinine in this model indicating that 
urinary ATPSβ may serve as a marker of renal functional recovery [148, 161].  Interestingly, the 
recovery of ATPSβ precedes the recovery of renal cortical expression of mitochondrial proteins 
observed in this model.  We postulate that this result may be due to either 1) the remaining 
mitochondria are functionally intact and are not shedding mitochondrial proteins, or 2) the severe 
reduction in mitochondrial number, evidenced by reduced renal cortical expression, creates an 
artificially low expression of shed mitochondrial proteins in the urine.   
To examine the translational potential of urinary ATPSβ, we measured levels in the urine 
of human patients 36 h after cardiac surgery (Fig. 6).  Urinary excretion of ATPSβ increased in 
patients that developed AKI following surgery as compared to those that did not. These human 
data suggest that increased urinary ATPSβ in AKI patients predicts renal mitochondrial 
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dysfunction compared to subjects without AKI. Additional analyses are needed to correlate 
changes in ATPSβ with other renal functional markers and patient outcomes.  A large group of 
well-characterized samples in subjects with mild to moderate AKI, and AKI from other etiologies 
will enable us to elucidate confounding variables and enhance the predictive power of ATPSβ in 
human AKI.  However, as human renal cortical samples (e.g. biopsies) are not readily available it 
will be difficult to directly link urinary ATPSβ with renal mitochondrial function. 
These studies provide evidence that urinary ATPSβ increases in mice subjected to I/R-
induced AKI and that this increase correlates with renal mitochondrial dysfunction. Furthermore, 
urinary ATPSβ has translational potential for detection of renal mitochondrial dysfunction in post-
operative AKI in humans. There are no current reports of non-invasive biomarkers of renal 
mitochondrial dysfunction after AKI with the exception of urinary cytochrome c in drug-induced 
AKI [380]. However, use of cytochrome c is limited due to rapid, transient changes in tissue 
expression and poor renal specificity. Thus, our studies offer evidence that urinary full-length 
ATPSβ may be the first sensitive and specific translational biomarker of renal mitochondrial 
dysfunction in AKI.  However, additional validation is needed to ascertain its pre-clinical and 
clinical applicability.  Characterization of ATPS as a biomarker of renal mitochondrial disruption 
and the roles of miRNAs and proteolytic/autophagic pathways in the regulation of ATPSβ and 
















Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and 










Recent studies demonstrate the importance of mitochondrial dysfunction in the initiation 
and progression of acute kidney injury (AKI); however, no biomarkers exist linking renal injury 
to mitochondrial function and integrity.  To this end, we evaluated urinary mitochondrial DNA 
(UmtDNA) as a biomarker of renal injury and function in humans with AKI following cardiac 
surgery.  mtDNA was isolated from urine of patients following cardiac surgery and quantified via 
qPCR.  Patients were stratified into no AKI, stable AKI and progressive AKI groups based on 
Acute Kidney Injury Network (AKIN) staging.  UmtDNA was elevated in progressive AKI 
patients, and was associated with progression of patients with AKI at collection to higher AKIN 
stages. To evaluate the relationship of UmtDNA to measures of renal mitochondrial integrity in 
AKI, mice were subjected to sham surgery or varying degrees of ischemia followed by 24 h 
reperfusion.  UmtDNA increased in mice after 10-15 min ischemia and positively correlated with 
ischemia time.  Furthermore, UmtDNA was predictive of AKI in the mouse model.  Finally, 
UmtDNA levels were negatively correlated with renal cortical mtDNA and mitochondrial gene 
expression.  These translational studies demonstrate that UmtDNA is associated with recovery 
from AKI following cardiac surgery by serving as an indicator of mitochondrial integrity.  
Therefore, UmtDNA may serve as valuable biomarker for the development of mitochondrial 








Acute kidney injury (AKI) is a serious clinical problem, particularly among surgical and 
critically ill patients [6, 381].  Despite advances in diagnosis and patient management, incidence 
of AKI continues to increase and outcomes continue to be poor.  An expanding array of risk 
factors for AKI and expanded use of nephrotoxic drugs have contributed to its increased 
incidence and prevalence.  AKI is associated with high levels of short and long term mortality, 
and increases patient risk of progression to chronic kidney disease (CKD) and end stage renal 
disease (ESRD) [10, 382, 383].  Survivors of AKI, particularly those with ESRD requiring 
dialysis, are plagued by a variety of chronic sequelae contributing to decreased quality of life and 
increased utilization of healthcare resources. 
Cardiac surgery requiring cardiopulmonary bypass (CPB) is a common cause of AKI in 
humans.  Estimates of incidence of AKI in patients following cardiac surgery are as high as 
30%[384, 385].  Furthermore, AKI is one of the most significant negative predictors of patient 
outcome in this population [386, 387].  Despite the high incidence and severity of CPB-induced 
AKI, methods for early detection following surgery remain poor.  Additionally, there are no 
effective therapeutic strategies to prevent or promote recovery from AKI in these patients [1, 
388, 389].  These facts highlight the need to better understand mechanisms of CPB-induced AKI 
and to develop novel diagnostic tools and therapies.   
Renal injury following CPB is multifactorial and poorly understood; however, ischemia-
reperfusion (I/R) injury is believed to play a significant role [390, 391].  Poor renal perfusion due 
to reduced cardiac output, increased systemic inflammation, hemodynamic alterations, volume 
depletion and perioperative administration of nephrotoxic drugs, contribute to I/R-induced renal 
injury following cardiac surgery [392, 393].  Mitochondrial damage and dysfunction is a key 
pathophysiological component of renal tubular injury during both the initiation and recovery 
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phases of ischemic AKI [154, 156].  Organ reperfusion following ischemia leads to rapid 
opening of the mitochondrial permeability transition pore (MPTP) causing mitochondrial 
membrane depolarization, increased production of reactive oxygen and nitrogen species, and 
release of apoptotic proteins.  Oxidative damage of mitochondrial respiratory complexes and 
subsequent reduction in mitochondrial function contributes to tissue ATP depletion inhibiting 
energy-dependent cellular repair mechanisms [12].  Additionally, generation of new, functional 
mitochondria through the process of mitochondrial biogenesis (MB) is persistently suppressed 
following renal injury in mice [126, 148].   
These reports highlight mitochondria as an intriguing diagnostic and therapeutic target 
for AKI in animals; however, correlative data in humans is limited due to limited availability of 
renal tissue for analysis.  Current assays for mitochondrial function including tissue ATP and 
oxygen consumption measurements require invasive tissue biopsies [374].  Due to the profound 
role of mitochondria in tissue repair, biomarkers of mitochondrial dysfunction following CPB 
may serve as better prognostic measures of AKI progression and recovery compared to existing 
biomarkers, enabling modification of patient management and development of new 
mitochondrial-targeted therapies for AKI.   To this end, we conducted proof of concept 
experiments that examine the efficacy of urinary mitochondrial DNA (UmtDNA) as a predictive 
biomarker of AKI development and progression in humans with CPB-induced 
AKI.   Furthermore, we validated UmtDNA as a biomarker of renal mitochondrial integrity in a 
mouse model of renal I/R injury.  Fragments of mtDNA, referred to as mtDNA damage 
associated molecular patterns (DAMPs), are released into circulation following injury [281, 394].  
Released mtDNA can modulate oxidative and inflammatory injury at distant sites through 
activation of Toll-like receptor signaling [395].  While numerous studies have evaluated serum 
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and plasma levels of mtDNA as predictors of injury and disease progression, no reports exist of 


















Human urine samples 
 Human urine samples were obtained from a NIDDK-funded multicenter trial (DK080234) 
with the goal of identification of prognostic urine biomarkers of cardiac surgery-induced AKI.   
Patients were enrolled prior to undergoing cardiac surgery to determine baseline renal function. 
Urine was collected approximately 1 d following cardiac surgery (mean = 1.26, median = 1).   
Urine was collected from both patients who developed AKI and those that did not.  Following 
collection, protease inhibitors were added to urine samples.  Urine was centrifuged at 1,000 x g to 
remove intact cells and cellular debris, and supernatants were collected and kept frozen at -80oC 
until analysis. Urine supernatant was used rather than total urine as inclusion of the pellet would 
lead to the assessment of both soluble mtDNA and mtDNA contained in cells (including 
lymphocytes and damaged proximal tubular epithelial cells) that have been released into the urine.     
Animals and treatment  
Eight-week-old male C57BL/6 mice (20-25 g) were subjected to sham or I/R surgery by 
bilateral renal pedicle clamping for 5, 10 or 15 min. as described previously [148, 161].  Urine was 
collected for a period of 18 h from 6-24 h post-surgery. Mice were euthanized at 24 h after surgery, 
and blood and kidneys were collected for analysis.  Renal function was evaluated by measurement 
of urine volume and BUN (Bioassay Systems, Hayward, CA).   All procedures involving animals 
were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals.  
Quantitative reverse transcription polymerase chain reaction 
   Total RNA was extracted from mouse renal cortex using TRIzol reagent (Life 
Technologies, Carlsbad, CA).  cDNA was synthesized via reverse transcription (RT) using the 
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iScript Advanced cDNA synthesis kit (Bio-Rad, Hercules, Ca) with an input of 1 µg RNA.  
Quantitative polymerase chain reaction (qPCR) analysis was performed using SsoAdvanced 
SYBR Green Supermix (Bio-Rad) at a concentration of 1x with primers at a concentration of 750 
nM (Integrated DNA Technologies, Coralville, IA).  mRNA expression was calculated using the 
2-ΔΔCT method normalized to β-actin.  Primer sequences for PGC-1α, cytochrome c oxidase 
subunit 1 (COX1), and NADH dehydrogenase [ubiquinone] 1β subcomplex subunit 8 (NDUFB8) 
were described previously [149, 150]. 
Renal mtDNA content 
   qPCR was used to determine the relative quantity of mtDNA in mouse renal cortical 
tissue samples.  DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, 
CA).  Total DNA (5 ng) was used for analysis.  Mitochondrial-encoded NADH dehydrogenase 1 
(ND1) was used to measure mitochondrial copy number and was normalized to nuclear-encoded 
β-actin.  Primers used for ND1 and β-actin were described previously [396]. 
Isolation and quantification of urinary mtDNA 
   Human and mouse urine supernatants were concentrated using Amicon Ultracel-30k 
centrifugal filters (EMD Millipore, San Diego, CA).  DNA was isolated and purified from the 
concentrate using a Viral RNA Mini Kit (Qiagen, Valencia, CA).  Total DNA concentration was 
determined using the Quant-iT PicoGreen dsDNA reagent (Life Technologies, Carlsbad, CA).  
qPCR was used to determine UmtDNA content with a template input of 0.3-5 ng of total DNA. 
For human urine, absolute values of mtDNA and nDNA were determined by calculation from a 
standard curve of total DNA isolated from HK2 cells.  Primer sequences for human ND1and β-
actin were as follows: ND1, sense 5’-ACACTAGCAGAGACCAACCG-3’ and antisense 5’-
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GAAGAATAGGGCGAAGGGGC-3’; and β-actin, sense 5’-TAAAGCGGCCTTGGAGTGTG-
3’ and antisense 5’-GAACACGGCTAAGTGTGCTG-3’.  For mouse urine, absolute ND1 levels 
were determined by calculation from a standard curve of total DNA isolated from mouse kidney 
ranging from 0.1-10 ng.  Primer sequences for mouse ND1 were: sense 5’-
TCCGAGCATCTTATCCACGC-3’ and antisense 5’-GTATGGTGGTAACTCCCGCTG-3’. 
Mouse UmtDNA levels were corrected for urine creatinine (Bioassay Systems, Hayward, CA). 
Data and statistical analysis 
Data are expressed as means ± SEM for parametric data, or median ± IQR for non-parametric data. 
Multiple comparisons of normally distributed data were analyzed by one-way ANOVA and group 
means were compared using a Newman-Keuls post-hoc test.  Non-parametric data were analyzed 
using a Kruskal-Wallis test followed by a Dunn’s test for multiple comparisons.  Single 
comparisons were analyzed via a Mann-Whitney U-test where appropriate. Receiver operator 
characteristic (ROC) curve analysis was used to test the predictive ability of UmtDNA for AKI 
development and progression in mice and humans.  Optimal cutoffs were by minimizing the 
geometric distance from the point representing 100% sensitivity and 100% specificity.  Linear 
regression analyses were performed on multiple variables and correlations were determined by 
calculation of Spearman Rank order coefficients.  The criterion for statistical differences was p < 
0.05 for all comparisons.  
 
RESULTS 
UmtDNA is associated with AKI progression following cardiac surgery 
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To assess UmtDNA as a biomarker of renal dysfunction in humans, UmtDNA levels 
were measured by qPCR in urine collected as a component of an NIDDK-funded multicenter 
trial (NIH #DK080234) to determine prognostic biomarkers of AKI following cardiac surgery 
[375].  Samples were collected through the Southern Acute Kidney Injury Network (SAKInet) 
consortium.  The patient cohort included both patients who developed AKI and those who did 
not develop AKI following surgery.  Patients were enrolled before surgery for baseline 
measurements and urine was collected approximately 1 d following surgery (mean collection 
time = 1.26 d, median collection time = 1 d). Table 6.1 shows the demographic and clinical 
characteristics of the subjects.   Renal function was evaluated at collection and during follow-up 
by serum creatinine, and patients were staged using the Acute Kidney Injury Network (AKIN) 
criteria.  The urine mtDNA/nDNA ratio was not elevated in patients with AKI (AKIN 1 at the 
time of collection) (median=147, IQR 102-610) vs. no AKI (AKIN 0) (median=202, IQR 59-
604), and no differences were observed in UmtDNA levels between healthy or any AKIN stage 








     
                                                   AKI Status 
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Patient demographics No AKI Stable AKI Progressive AKI P-value 
Total patients 17 59 31  
Female 3 (18 %) 13 (22 %) 15 (48 %) 0.02 
Black 3 (18 %) 16 (27 %) 6 (19 %) 0.59 
Age (years) 65 ± 16 66 ± 11 68 ± 12 0.66 
Weight (kg) 81 ± 28 93 ± 20 85 ± 28 0.11 
History     
CHF 6 (36 %) 14 (24 %) 11 (35 %) 0.42 
Prev. cardiac surgery 2 (12 %) 9 (15 %) 10 (32 %) 0.10 
Diabetes mellitus 8 (47 %) 20 (34 %) 14 (45 %) 0.45 
COPD 2 (12 %) 3 (5 %) 4 (13 %) 0.39 
Peripheral vascular disease 0 (0 %) 6 (10 %) 1 (3 %) 0.22 
Stroke 0 (0 %) 4 (7 %) 2 (6 %) 0.55 
Surgical parameters     
CABG 16 (94 %) 42 (71 %) 23 (74 %) 0.15 
Valve replacement 4 (24 %) 22 (37 %) 15 (48 %) 0.23 
Bypass 14 (82 %) 46 (78 %) 27 (87 %) 0.57 
Bypass Time 117 ± 49 139 ± 65 150 ± 90 0.31 
Outcomes     
Baseline creatinine 1.3 ± 0.4 1.2 ± 0.3 1.3 ± 0.5 0.41 
Collection creatinine 1.4 ± 0.4 2.0  ± 0.7 1.8 ± 0.8 0.0083 
Max creatinine  1.4 ± 0.4 2.1  ± 0.8 2.9 ± 1.5 <0.0001 
RRT 1 (6 %) 1 (2 %) 5 (16 %) 0.031 
Mortality 1 (6 %) 1 (2 %) 7 (23 %) 0.0029 
Days to discharge 6.8 ± 2.6 9.3 ± 8.6 15.1 ± 11.4 0.0031 
Days to max creatinine 5.6 ± 4.5 2.3 ± 1.7 4.1 ± 2.6 <0.0001 
Table 6.1: Patient demographics and clinical characteristics of cardiac surgery 
patients. No AKI (AKIN 0 throughout follow-up), Stable AKI  (≥ AKIN 1 at 
collection, collection AKIN = maximum AKIN), Progressive AKI ((≥ AKIN 1 at 
collection, maximum AKIN > collection AKIN). CHF, congestive heart failure; COPD, 
chronic obstructive pulmonary disease; CABG, coronary artery bypass graft; RRT, 
renal replacement therapy.  P-values were determined using the Chi-Square test or 
ANOVA, as appropriate. 
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Figure 6.1: Urinary mtDNA copy number is not correlated with AKIN stage following 
CPB-induced AKI in humans.  Patients were stratified into no AKI or AKI (AKIN 1+) groups 
by AKIN stage at collection (A) or maximum AKIN stage (B).  Patients were further stratified 
into healthy, no AKI (AKIN 0), or AKIN stage 1, 2 or 3 by collection AKIN stage (C) or 
maximum AKIN stage (D). Data are expressed as median +/- IQR. Single comparisons were 
performed via Mann-Whitney U-test.  Multiple comparisons were performed using a Kruskal-







To assess the efficacy of UmtDNA in predicting worsening of AKI, patients were 
classified into 3 groups based on disease progression: no AKI (AKIN 0 throughout follow-up), 
stable AKI (≥ AKIN 1 at collection, maximum AKIN > collection AKIN), or progressive AKI (≥ 
AKIN 1 at collection, maximum AKIN > collection AKIN).  Patients with AKIN 0 at collection 
that subsequently developed AKI were excluded from the progressive AKI group, although no 
patients displaying this behavior were observed in the cohort.  UmtDNA was elevated in patients 
with progressive AKI (median = 353, IQR 187 - 1053) vs. no AKI (median = 118, IQR 26 – 
517), or stable AKI (median = 104, IQR 50 – 340) (Figure 6.2A).  
ROC curve analysis was performed to assess UmtDNA as a predictive test for AKI 
progression. There was no difference between no AKI and stable AKI patients (AUC=0.53, 
p=0.73) (Figure 6.2B).  Elevated UmtDNA was a fair predictor of progressive AKI compared to 
no AKI (AUC=0.72, p=0.012) (Figure 6.2C) and stable AKI patients (AUC=0.72, p=0.0008) 
(Figure 6.2D).  Evaluation of the primary endpoint of AKI progression in patients with 
established AKI at collection (stable vs. progressive AKI) revealed an optimal cutoff at 207 at 
which the test had a sensitivity and specificity of 71% and 71%, respectively.  A cutoff of 899 
yielded the highest positive likelihood ratio (LR+ = 3.0).  Seventeen of eighty-nine AKI patients 
had urinary mtDNA/nDNA ratios greater than 899, of which eight met the outcome of 
progressive AKI.  The sensitivity and specificity of the test using this cutoff was 36% and 88%, 
respectively.  The lowest negative likelihood ratio was achieved at a cutoff of 52 (LR- = 0.08).  
Sixteen patients had urinary mtDNA/nDNA ratios less than 52, of which fifteen did not meet the 
outcome of progressive AKI.  Using this cutoff, the test had a sensitivity and specificity of 97% 




Figure 6.2: Urinary mtDNA copy number is associated with progression of renal 
dysfunction from collection in patients with CPB-induced AKI.  Urine was collected from 
patients following CBP.  Urinary mtDNA levels were measured via real time qPCR for ND1, 
and corrected to the nuclear control gene β-actin.  Patients were stratified into 3 groups based on 
collection and maximum AKIN staging: no AKI (n=17), stable AKI (n=63) and progressive AKI 
(n=31) (A).  Data are expressed as median +/- IQR. Multiple comparisons were performed using 
a Kruskal-Wallis test followed by Dunn’s test.  *p<0.05 vs. No AKI, #p<0.05 vs. stable AKI. 





UmtDNA does not correlate with existing markers of renal damage and dysfunction 
following cardiac surgery 
 To evaluate the performance of UmtDNA as an indicator of renal function, we compared 
UmtDNA with serum creatinine in the cohort.  Correlation analysis of UmtDNA revealed no 
correlation with maximum serum creatinine (Figure 6.3A) (r=0.0733, p=0.4533), or maximum % 
change in serum creatinine from baseline (Figure 6.3B) (r=-0.0013, r=0.9894).  Due to the 
limited sensitivity of serum creatinine as a marker of renal injury, we compared UmtDNA levels 
to levels of urinary angiotensinogen, a marker demonstrated to perform as well as urinary KIM-1 
and NGAL as an indicator of renal damage and progression [375, 397].   UmtDNA was not 
correlated with urinary angiotensinogen levels following CPB (Figure 6.3C) (r=0.0681,  
p=0.4877).  Furthermore, UmtDNA did not correlate with bypass time (Figure 6.3D) (r=0.0370, 
p=0.7053), days to maximum creatinine (Figure 6.3E) (r=0.0190, p=0.8467), or days to 












Figure 6.3: Urinary mtDNA copy number is not correlated with degree of CPB-induced 
AKI in humans. Urinary mtDNA/nDNA was not correlated with maximum serum creatinine 
(A), maximum % change in serum creatinine from baseline (B), urinary angiontensinogen levels 
(C), cardiopulmonary bypass time (D), days to maximum creatinine (E) and days to discharge 
(F) (n=111 for all analyses).  Linear regression was performed and Spearman’s Rank order 

















UmtDNA is elevated in mice after I/R-induced AKI and correlates with ischemia time 
 To explore the biological correlates of UmtDNA in the kidney, we used a mouse model 
of renal I/R injury.  Mice were subjected to sham surgery (n=12) or bilateral renal pedicle 
ligation for 5 (n=4), 10 (n=9) or 15 min (n=11) corresponding to mild, moderate and severe renal 
histological damage [398].  Mice that produced no or insufficient urine for detection of 
UmtDNA (n=6) were excluded from further analyses.  BUN was elevated at 24 h only in the 15 
min I/R group, and no difference was observed in urine output between all groups (Figure 6.4A, 
6.4B).  Total output of UmtDNA over the course of an 18 h collection period increased in the 10 
or 15 min I/R groups (Figure 6.4C).  UmtDNA was not normalized to nDNA due to undetectable 
levels of urinary β-actin in mice.  Normalization of UmtDNA to urine creatinine demonstrated an 
increase vs. sham only in the 10 min I/R group (Figure 6.4D).  UmtDNA correlated with time of 
ischemia (r=0.63, p<0.0001); however it did not correlate with renal function assessed by BUN 
(Figure 6.5A, 6.5B) (r=0.17, p=0.33).  Correction of UmtDNA levels for urine creatinine did not 










Figure 6.4: Urinary mtDNA levels are increased in mice following renal I/R.  Male C57BL/6 
mice underwent sham surgery or ischemia (5, 10 or 15 min) followed by reperfusion.  Mice were 
placed in metabolic cages from 6-24 h after reperfusion for urine collection.  Blood was collected 
and mice were euthanized 24 h after reperfusion.  Renal function was evaluated by BUN (A) and 
18 h urine output (B).  Urinary mtDNA levels were measured by qPCR for ND1 and are 
expressed as total urinary output in 18 h (C) and urinary output corrected for urinary creatinine 
levels (D).  Data are expressed are mean +/- SEM.  # indicates statistical significance at p<0.05; 








Figure 6.5: Total urinary output of mtDNA is correlated with degree of ischemia, but not 
BUN.  Urinary mtDNA levels expressed as total urinary output per 18 h were correlated with 
BUN levels (A) or ischemia time (B) (n=36).  Linear regression was performed and Spearman’s 



















Figure 6.6: Urinary mtDNA levels corrected for urinary creatinine are a marker of renal 
injury in mice.  Urinary mtDNA levels expressed as total urinary output corrected for urinary 
creatinine were not correlated with BUN (A) but were correlated with ischemia time (B) (n=36).  
Linear regression was performed and Spearman’s Rank order coefficients were calculated. ROC 
curves were constructed for urinary output of mtDNA corrected for urinary creatinine comparing 
sham mice (n=12) to all mice that had underwent I/R (n=24) (C) or mice reaching a cutoff value 







UmtDNA is predictive of AKI development in mice after I/R 
 ROC curve analysis was performed to assess the ability of UmtDNA to predict AKI 
development in mice following renal I/R.  UmtDNA was predictive of AKI development in mice 
undergoing any degree of ischemia vs. sham control mice (AUC=0.88, p=0.0003) (Figure 6.7A).  
An optimal cutoff of 2.8 ng mtDNA/18 h yielded a sensitivity and specificity of 88% and 83%, 
respectively.   
 Several non-responders (no increase in BUN) were observed in the renal I/R group; 
therefore, mice were reclassified into no AKI and AKI groups based on an increase of >2 SD 
above our historical sham surgical BUN level (mean +/- SD = 24.0 +/- 9.7 mg/dL, BUN cutoff ≥ 
43.4 mg/dL).  Mice with BUN levels below this cutoff were excluded from this analysis.  ROC 
curve analysis demonstrated predictive power for AKI vs. no AKI using UmtDNA in mice after 
renal I/R (AUC=0.80, p=0.011) (Figure 6.7B).  The optimal cutoff for this analysis was also 
determined to be 2.8 ng/18 h with a sensitivity and specificity of 77% and 83%, respectively.  No 
differences were observed when analyses were performed corrected for urine creatinine (Figure 










Figure 6.7: Total 18 h urinary output of mtDNA is a biomarker of renal injury following 
I/R in mice.  ROC curves were constructed for total 18 h urinary output of mtDNA comparing 
sham surgical mice  (n=12) to all mice that underwent I/R (n=24) (A) or only mice with BUN >2 


















Renal mitochondrial gene expression and mtDNA copy number are negatively correlated 
with UmtDNA levels 
 Renal cortical mtDNA copy number and mRNA expression of PGC-1α, COX1 and 
NDUFB8 were assessed via qPCR and correlated to 18 h urinary output of mtDNA.  Renal 
cortical mtDNA copy number decreased following I/R, and was negatively correlated with 
UmtDNA output (r=-0.45, p=0.039) (Figure 6.8A).  Additionally, mRNA expression of PGC-1α, 
COX1 and NDUFB8 decreased after I/R and their expression was also negatively correlated with 
UmtDNA output (PGC-1α: r=-0.48, p=0.034; COX1: r=-0.45, p=0.046; NDUFB8: r=-0.66, p 
=0.0015) (Figure 6.8B-D).  Analysis performed using UmtDNA corrected for urine creatinine 















Figure 6.8: Total 18 h urinary output of mtDNA correlates with reductions in renal 
mtDNA copy number and mitochondrial gene expression. Urinary mtDNA levels expressed 
as total urinary output per 18 h were correlated with relative renal mtDNA copy number (A), 
PGC-1α (B), COX1 (C) and NDUFB8 (n=36).  Renal mtDNA and mRNA expression were 
corrected to the nuclear gene β-actin.  Linear regression was performed and Spearman’s Rank 













Figure 6.9: Urinary mtDNA levels corrected for urine creatinine correlate with a reduction 
of renal mitochondrial DNA copy number and mitochondrial gene expression in mice. 
Urinary mtDNA levels expressed as total urinary output corrected for urinary creatinine were 
correlated with relative renal mtDNA copy number (A), PGC-1α (B), COX1 (C) and NDUFB8 
(n=36). Renal mtDNA and mRNA expression were corrected to the nuclear gene β-actin.  Linear 









 Complete recovery from renal injury is dependent on a rapid and sustained activation of 
critical tissue repair processes, particularly of the renal proximal tubule [12, 399, 400].  
Following injury, a coordinated tissue repair response is activated promoting recovery of sub-
lethally injured cells, clearance of necrotic cells and debris, and re-establishment of an intact, 
polarized and functional renal epithelium.  Repair of the renal tubular epithelium is highly 
energy dependent, thus mitochondrial function is crucial to the structural and functional recovery 
of the kidney.  Due to the significant role of mitochondria in renal repair and recovery, 
biomarkers of renal mitochondrial function and integrity may be valuable prognostic tools of 
AKI progression.   While the role of mitochondrial dysfunction in AKI in animals is clearly 
established, practical limitations of existing assays of mitochondrial function involving renal 
biopsy have limited our ability to study the link between mitochondrial dysfunction and renal 
injury in humans [12, 126, 148, 153, 156, 161, 401].   
In the present study, we examined UmtDNA copy number as marker of renal injury in a 
cohort of patients who developed AKI following cardiac surgery.  We found that UmtDNA was 
associated with an increased risk of worsening AKI following initial sample collection, and that 
UmtDNA is mildly predictive of AKI progression by ROC analysis (Figure 6.2).  The power of 
these studies is limited by a small cohort size, and the practical limitations of stratification of 
patient data according to serum creatinine.   AKI progression was based on an increase in AKIN 
stage as determined by serum creatinine from collection baseline.   As serum creatinine is a poor 
early indicator of renal damage/dysfunction, it is possible that some patients classified as AKIN 
0-1 at collection had more severe renal damage, potentially affecting the predictive value of 
UmtDNA for AKI progression in this cohort.  Therefore, UmtDNA may simply serve as an 
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indicator of varying degrees of renal damage rather than a biological indicator of renal repair, 
recovery or progression.  However, stratification of patients by AKIN stage at collection or 
maximum AKIN stage revealed no differences in UmtDNA between any groups suggesting that 
UmtDNA is not significantly associated with degree of renal damage, and notable increases in 
days to maximum creatinine and days to discharge occurred in the progressive AKI group (Table 
6.1).  This data suggests differences in recovery between these groups rather than initial injury; 
however, practical limitations of serum creatinine still temper these conclusions.  Larger scale 
studies are needed in patients with AKI of various degrees and from multiple etiologies in order 
to validate the predictive power of UmtDNA.  In this study we determined LR+ and LR- values to 
serve as maximum and minimum cutoff values to stratify patients into low and high risk groups.  
Analysis of our data set using the cutoffs demonstrated that risk of AKI progression could be 
evaluated with reasonable confidence.  These cutoffs value could be used for patient screening 
for enrollment into future larger scale studies with AKI progression as an endpoint.   
 Traditional markers of renal dysfunction including serum creatinine and BUN have 
limited to no ability to predict progression of disease following CBP-induced AKI [402].  These 
limitations have led to the development of new renal injury markers with enhanced predictive 
power over existing clinical markers [403, 404].  However, the prognostic value of even these 
newer markers, including KIM-1 and NGAL, is still relatively weak [405, 406]. A recent study 
by Arthur et al. examined the ability of a panel of renal biomarkers including KIM-1, NGAL, L-
FABP and IL-18 to predict the progression of AKI following cardiac surgery using a different 
subset of SAKInet patients than used in our study [407].  From this study, IL-18 was determined 
to be the best predictor of AKI progression (AKIN 1 to AKIN 2/3 or death) with an AUC of 
0.74.  While our definition of AKI progression differed slightly from that of this study, the 
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predictive performance of UmtDNA compared favorably (AUC = 0.72, stable vs. progressive 
AKI).  Interestingly, in contrast to many of the markers assessed in the study by Arthur et al., 
UmtDNA failed to correlate with traditional markers of renal damage and dysfunction (Figure 
6.3) even in the acute injury phase. We compared UmtDNA levels to another candidate 
biomarker of AKI and AKI progression, urinary angiotensinogen.  Urinary angiotensinogen has 
been shown to a be a strong predictor of AKI progression in ICU patients [375].  Furthermore, 
urinary angiotensinogen measured on the first day of hospitalization predicted future 
development of AKI in patients with decompensated CHF with extremely high accuracy, and 
was superior to the performance of urinary NGAL [397].  Interestingly, UmtDNA was not 
correlated with urinary angiotensinogen in our cohort.  These data may suggest that UmtDNA, a 
potential surrogate marker of renal mitochondrial integrity, is a biomarker of different cellular 
processes than urinary angiotensinogen and other candidate markers, and perhaps represents a 
more direct indicator of renal repair.   The mechanistic relevance of UmtDNA levels in the status 
of renal mitochondria and renal repair processes warrants further investigation. Furthermore, 
failure of UmtDNA to correlate with urinary angiotensinogen could be useful in the development 
of a prognostic biomarker panel, as non-correlated biomarkers are superior for use in 
combinatorial predictive models such as a multivariable logistic regression models or 
classification trees [407]. 
 As human renal cortical samples (e.g. biopsies) from AKI patients are not readily available 
we chose to explore the physiological link between UmtDNA and renal mitochondrial integrity in 
a mouse model of renal I/R.  Our lab has demonstrated that mitochondrial homeostasis is 
persistently disrupted following I/R-induced AKI in rodents, and this persistent mitochondrial 
disruption is associated with an incomplete renal repair process [126, 161].  Mice were subjected 
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to varying degrees of ischemia (5, 10 or 15 min) followed by reperfusion for 24 h.  UmtDNA levels 
increased in mice with moderate (10 min ischemia) or severe (15 min ischemia) renal injury 
(Figure 6.4), and correlated with degree of ischemia (and histological grade), but not renal function 
as assessed by BUN (Figure 6.5).  These data differ from results from human cardiac surgery 
patients as no correlation was observed with bypass time during cardiac surgery.  However, bypass 
time, while often a reasonable indicator of surgical complexity, is likely a poor surrogate marker 
of degree of ischemia or renal injury in humans due to heterogeneous patient characteristics and 
surgical parameters.  UmtDNA levels were found to be associated with renal injury in mice (Figure 
6.7). Of note, when mice without detectable renal injury by BUN were excluded, the predictive 
power of UmtDNA decreased in our studies.  This is likely due to poor performance of BUN as a 
marker of renal injury.  Based on data from figure 6.4, UmtDNA levels fail to correlate with BUN 
indicating that UmtDNA is not an indicator of renal function, but more likely a better indicator of 
degree of renal damage or progression in these mice.  Limitations of BUN as a true marker of renal 
damage are likely leading to exclusion of mice that are truly injured, thus reducing the observed 
predictive power of UmtDNA.    Overall, these data demonstrate that mouse I/R provides a 
reasonable model of the UmtDNA response observed in human patients following CBP, and 
provided a platform for examination of renal cortical mitochondrial parameters.  
 We evaluated mouse renal cortical mtDNA copy number and mRNA expression of PGC-
1α, COX1 and NDUFB8 (genes involved in mitochondrial biogenesis) as markers of 
mitochondrial integrity and biogenesis following renal I/R.  Correlation of renal mtDNA copy 
number and mitochondrial genes with total UmtDNA output demonstrated negative correlations 
indicating that UmtDNA is reflective of renal mitochondrial disruption following I/R (Figure 
6.8).  Normalization of UmtDNA to urine creatinine showed modest improvements in these 
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correlations (Figure 6.9).  Normalization to urine creatinine, commonly used to quantitate urine 
albumin, has been used inconsistently in biomarker evaluations.  Systematic evaluation of the 
performance of urinary biomarkers as an absolute concentration, corrected for urine creatinine or 
as total urinary excretion, demonstrated improved predictive power of biomarkers when 
corrected to creatinine [408] however, we observed no substantial improvement in predictive 
power of UmtDNA when corrected for urine creatinine in our studies.   
   Correlations of UmtDNA with mitochondrial gene expression suggest that the predictive 
power of UmtDNA for AKI progression may arise from its ability to predict the degree of renal 
mitochondrial damage and disruption, which could inhibit renal repair processes.  However, we 
cannot definitively conclude that UmtDNA is a marker of renal repair or recovery.  Correlation of 
suppression of mitochondrial gene expression to elevations of UmtDNA fails to causally link 
mitochondrial integrity to recovery from AKI.  Future mechanistic studies are needed to examine 
how modulation of UmtDNA levels correlates with renal repair and functional recovery after AKI.  
Additionally, regulation of renal mtDNA and mitochondrial mRNA expression is subject to 
complex regulatory processes.  Changes in these indicators may not be truly reflective of 
mitochondrial damage or disruption.  However, many previous studies have clearly demonstrated 
mitochondrial damage and dysfunction as key pathophysiological components of the initiation and 
recovery from I/R-induced AKI.   Significant structural alterations, loss of mitochondrial 
membrane integrity, and decreases in mitochondrial function have been previously demonstrated 
in multiple models of renal injury [345, 398, 409]. 
Past reports of urinary markers of renal mitochondrial dysfunction are limited to urinary 
cytochrome c which is elevated following drug-induced AKI [380].  Cytochrome c is a poor renal 
biomarker as it is only transiently elevated following injury and thus likely serves as a better 
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predictor of degree of renal damage rather than recovery and disease progression.  Our group 
recently published that urinary levels of the protein ATP synthase subunit β serve as a biomarker 
of CPB-induced AKI; however, it’s predictive value in this study was not assessed [398].  These 
studies provide preliminary evidence of UmtDNA as a novel biomarker reflective of AKI 
progression linked to renal mitochondrial integrity.  The mitochondrial and energy dependence of 
renal repair processes and renal recovery make UmtDNA a promising tool for exploration of the 
role of mitochondrial damage and dysfunction in human renal disease and the development of new 

































 Sublethal and lethal injury to the renal proximal tubular cells of the kidney contributes to 
renal dysfunction following AKI [22, 27].  Following injury, the renal proximal epithelium has 
the capacity to repair itself through the activation of renal cell proliferation and repair processes.  
These repair processes are highly energy dependent, and thus rely on proper mitochondrial 
function for the supply of ATP.  However, mitochondrial dysfunction is a common 
pathophysiological mechanism of various forms of AKI characterized by mitochondrial 
depolarization, reduced ATP output, increased oxidative stress, mitochondrial fragmentation and 
the suppression of mitochondrial biogenesis, thus limiting renal recovery [22, 156, 293, 410].  
Therefore, re-activation of mitochondrial biogenic signaling pathways to generate new, 
functional mitochondria may serve as a novel therapeutic target for the promotion of renal 
recovery following AKI. 
 Cellular models of oxidant-induced proximal tubular injury using the model oxidant tert-
butyl hydroperoxide (TBHP), demonstrated that mitochondrial biogenesis was induced following 
injury, and vital to the recovery of cellular function [204].  Furthermore, activation of 
mitochondrial biogenesis through the overexpression of PGC-1α, the master regulator of 
mitochondrial biogenesis, accelerated recovery of renal proximal tubular cells (RPTC) following 
TBHP-induced damage [207].  This data suggested that activation of mitochondrial biogenesis 
through the induction of the transcriptional coactivator PGC-1α could promote recovery of renal 
tubular cells.  Thus, the need existed to identify pharmacological activators of PGC-1α-
dependent mitochondrial biogenesis.   
Use of high throughput respirometry allowed for the identification and evaluation of 
several classes of compounds that could induce mitochondrial biogenesis in RPTC including the 
SIRT1 activators, resveratrol and SRT1720 [162, 284], isoflavones [244], the 5-
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hydroxytryptamine IIB receptor agonist, DOI, and the long acting β2-agonist, formoterol [219].  
Further studies with SRT1720 and formetrol demonstrated their ability to induce mitochondrial 
gene and protein expression and mitochondrial function in RPTC [162, 219].  Additionally, 
treatment of RPTC with SRT1720 following oxidant damage with TBHP accelerated recovery of 
mitochondrial protein expression, uncoupled mitochondrial respiration and cellular ATP levels.  
Furthermore, treatment of mice following renal I/R injury with either SRT1720 or formoterol 
accelerated renal functional recovery through the activation of mitochondrial biogenic signaling, 
perhaps by enhancing the bioenergetic surplus needed for renal repair [148, 218].  These results 
provided strong evidence that pharmacological activation of mitochondrial biogenesis is a viable 
approach to stimulate renal recovery. 
Exploration of additional druggable targets for the induction of mitochondrial biogenesis 
led us to explore the role of cyclic nucleotides, and pharmacological modulators of renal cyclic 
nucleotides levels.  cAMP is a well-characterized inducer of PGC-1α transcription through its 
activation of protein kinase A and subsequent phosphorylation of cAMP response element-
binding protein (CREB).  This signaling pathway was identified in early work examining the 
signaling pathways involved in the cold induction of PGC-1α expression.  Cold exposure causes 
the release of norepinephrine, activation of the sympathetic autonomic nervous system and 
increased levels of cAMP through Gs-receptor activation.   
cAMP and cGMP levels are regulated both by their production, primarily through G-
protein coupled receptors, and their degradation by phosphodiesterases (PDEs) to their non-
cyclic forms, AMP and GMP.  Inhibition of PDEs using various class specific inhibitors can lead 
to the accumulation of cAMP and/or cGMP and promote activation of their downstream 
signaling pathways.  Due to the well-characterized role of cAMP in mitochondrial biogenesis, 
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we explored the efficacy of the PDE3 (degrades both cAMP and cGMP) inhibitors, cilostamide 
and trequinsin, and the PDE4 (degrades only cAMP) inhibitors, rolipram and Ro 20-1724.  
Treatment of RPTC for 24 h demonstrated a dose-dependent increase in mitochondrial 
uncoupled OCR with the PDE3 inhibitors, cilostamide and trequinsin, while no change was 
observed in uncoupled OCR with either rolipram or Ro 20-1724, indicating a potential 
specificity of the mitochondrial biogenic response for cGMP in RPTC (Figure 2.1).  
Additionally, cilostamide and trequinsin caused dose-dependent increases in the expression of 
PGC-1α, and the mitochondrial genes NDUFβ8 and COX1 in RPTC (Figure 2.2).  Furthermore, 
mitochondrial gene expression and mtDNA copy number were increased in the renal cortex of 
mice 24 h after treatment with either cilostamide or trequinsin (Figure 2.5).   
In order to explore the specificity of the activation of mitochondrial biogenesis in RPTC 
for either cAMP or cGMP, we measured the induction of cAMP and cGMP via ELISA in RPTC 
(Figure 2.3).  The PDE3 inhibitors, cilostamide and trequinsin, demonstrated rapid and potent 
inductions of both cAMP and cGMP levels, while the PDE4 inhibitor, rolipram, induced only 
cAMP, and the PDE5 (degrades only cGMP) inhibitor, sildenafil, increased only cGMP levels.  
Furthermore, treatment with the cell permeable cyclic nucleotide analogs, 8-Br-cAMP and 8-Br-
cGMP, revealed that only 8-Br-cGMP induced mitochondrial uncoupled OCR and mitochondrial 
gene expression in RPTC.  This data provided strong evidence that the mitochondrial biogenic 
response was cGMP-specific in renal tubular cells.   
cGMP has previously been characterized as an inducer of mitochondrial biogenesis in 
other model systems.  The nitric oxide (NO) mimetic DETA-NO, 8-Br-cGMP, and the guanylyl 
cyclase stimulator, BAY 41-2272, all were shown to stimulate mitochondrial biogenesis and 
increase mitochondrial function after 6 d treatment in U937 monocytes, L6 myoblasts, and PC12 
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neurosecretory cells [233].  Vardenafil, a long-acting PDE5 inhibitor, stimulated mitochondrial 
biogenesis in cultured adipocytes [232].  Treatment with naturetic peptides, activators of 
membrane bound guanylyl cyclases, induced muscle mitochondrial content and function and fat 
oxidation in diabetic mice [239].   Finally, caloric restriction was demonstrated to induce 
expression of endothelial nitric oxide synthase (eNOS) and subsequently mitochondrial 
biogenesis, and eNOS-knockout mice demonstrated reduced mitochondrial content and 
metabolism, and increased weight gain [271].   
Treatment of RPTC with the PDE5 inhibitor sildenafil increased mitochondrial 
uncoupled OCR and mitochondrial gene expression (Figure 2.4).  Additionally, mice treated with 
sildenafil showed increased mitochondrial gene expression, mtDNA content and renal ATP 
levels 24 h after treatment (Figure 2.6).  To determine the efficacy of sildenafil in a model of 
AKI, renal injury was induced in mice via bolus injection of folic acid.  Mitochondrial gene 
expression and mtDNA content were rapidly and potently suppressed following injury; however, 
treatment with sildenafil promoted the recovery of mitochondrial markers, and furthermore, 
reduced renal tubular injury demonstrated by reduced renal cortical expression of Kim-1 (Figure 
2.7).  These data provide strong support for the efficacy of induction of cGMP through inhibition 
of cGMP regulatory PDEs as a novel approach to induce mitochondrial biogenesis and accelerate 
renal recovery following AKI.   
Increasing evidence suggests that failed renal recovery after AKI is a significant risk 
factor for the progression to chronic kidney disease (CKD) and end stage renal disease (ESRD) 
[10, 74, 356].   Due to the energetic demands of renal repair, compromised mitochondrial 
function could play a significant role in the inability of the renal tubular epithelium to fully repair 
after AKI.  Pharmacological stimulation of mitochondrial biogenesis and recovery of renal 
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bioenergetics could enhance renal recovery and limit the development of renal fibrosis and CKD 
progression.   
To evaluate this hypothesis, we first examined the chronic effects on mitochondrial 
biogenesis in a folic acid-induced model of renal injury.  Treatment of mice with high dose folic 
acid caused a rapid AKI with peak injury at 24 h after injection, characterized by elevations in 
serum creatinine, BUN, urinary glucose levels and renal cortical NGAL expression (Figure 3.1).  
These biomarkers recovered over the course of 14 d after injection.  However, during this 
recovery phase, kidneys demonstrated signs of fibrotic development and progression to early 
CKD (Figure 3.5).  Renal expression of the growth factor TGFβ was elevated, as well as the 
fibrotic markers αSMA and COL1A2.  Marked collagen deposition was demonstrated by 
picrosirius red staining and polarized microscopy.  Furthermore, mice demonstrated progressive 
increases in urinary output and decreases in urine osmolality all indicative of CKD development.  
Correlated with the apparent failure of renal repair and fibrotic development was a persistent 
suppression of mitochondrial gene expression, including PGC-1α, Tfam, COX1, NDUFβ8, and 
ATPSβ, and mtDNA copy number (Figure 3.3).  These data support a potential role for the 
suppression of mitochondrial biogenesis and persistent mitochondrial dysfunction in the failure 
of renal repair.   
We hypothesized that stimulation of mitochondrial biogenesis using the PDE5 inhibitor, 
sildenafil, could promote recovery of these mitochondrial parameters and slow the progression of 
renal fibrosis.  Mice were treated daily beginning at 24 h after folic acid for a period of a 1 wk.  
Sildenafil failed to promote recovery of renal mitochondrial gene expression and mtDNA content 
(Figure 3.7).  Furthermore, sildenafil failed to limit the progression of renal fibrosis in this 
model.   Failure of sildenafil to promote recovery in FA-induced CKD could be the result of 
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attenuation of the mitochondrial biogenic response to chronic PDE inhibition, and/or chronic 
inhibitory signals that cannot be overcome by exogenous activation of mitochondrial biogenic 
signaling.  The fibrotic response observed following folic acid administration is quite potent, and 
perhaps the failure of sildenafil was model dependent.  
Due to the lack of efficacy of cGMP modulation in the folic acid model, we chose to 
evaluate the effect of cGMP-induced mitochondrial biogenesis following renal I/R injury.  
Additionally, we sought to examine the efficacy of activation of cGMP production through 
guanylyl cyclase (GC) stimulation by the GC stimulator, BAY 41-2272, or the GC activator, 
BAY 58-2667.  Treatment of RPTC with either BAY 41-2272 or BAY 58-2667 caused a dose-
dependent increase in mitochondrial uncoupled OCR, indicating that these compounds are 
affecting mitochondrial content or function (Figure 4.1).  Injection of mice with BAY 58-2667 
(10-100 µg/kg) increased renal cortical mitochondrial gene and protein expression and mtDNA 
copy number, however, BAY 41-2272 (0.1-1 mg/kg)  had no effect (Figure 4.2).  BAY 41-2272, 
classified as a GC stimulator functions by activating GC through interaction with its reduced 
heme moiety.   In contrast, BAY 58-2557, a GC activator, increases GC activity without 
interacting with the heme moiety and thus can activate the oxidized form of GC.  BAY 58-2667 
can activate GC synergistically with nitric oxide.  The ability of BAY 58-2667, but not BAY 41-
2272 to stimulate mitochondrial biogenesis could thus be due to the ability to activate oxidized 
or non-heme containing GC.  As the proximal tubule is highly dependent upon oxidative 
phosphorylation for energy, it also is subject to high levels of oxidative stress.  Even basal levels 
of ROS in the renal cortex could potentially cause depletion of the reduced pool of GC limiting 
its ability to be activated by its endogenous activator, nitric oxide, or BAY 41-2272 and other 
GC stimulator compounds.   
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We then evaluated the ability of BAY 58-2667 to promote the recovery of renal and 
mitochondrial function following I/R-induced AKI.  Mice were treated daily beginning at 24 h 
after I/R (time of maximal renal dysfunction) with BAY 58-2667 (100 µg/kg) or saline vehicle 
until 144 h post I/R.  Sildenafil was used as a positive control at a dose of 1 mg/kg.  Mice treated 
with BAY 58-2667 or sildenafil showed accelerated recovery of renal function to sham surgical 
levels by 144 h, while I/R + vehicle mice failed to recover renal function (Figure 4.3).  
Additionally, renal mRNA and protein levels of the renal tubular injury markers, Kim-1 and 
NGAL, were also recovered following treatment with BAY 58-2667.  Furthermore, levels of 
renal tubular necrosis were reduced in mice treated with BAY 58-2667 vs. I/R controls (Figure 
4.4).  Expression of PGC-1α and NRF1, the mitochondrial-encoded genes, ND1 and COX1, and 
the nuclear-encoded mitochondrial gene, ATPSβ, all reduced following renal I/R, were increased 
in mice treated with BAY 58-2667, indicating a recovery of mitochondrial biogenic signaling 
(Figure 4.5).  These signaling changes led to an increase in the mitochondrial proteins, PGC-1α 
and COX1, and an increase in mitochondrial function evidenced by increased renal ATP levels 
(Figure 4.6).    BAY 58-2667 blunted the progression of fibrosis indicated by reduced COL1A2 
and αSMA expression (Figure 4.7).  BAY 58-2667 also had positive effects in reducing renal 
inflammatory markers and oxidative DNA damage (Figure 4.8, 4.9).  Finally, BAY 58-2667 
recovered expression of renal cortical eNOS levels above sham controls, while tissue cGMP 
levels at the time of measurement were unchanged (Figure 4.10).  These data strongly indicate 
that activation of GC promotes recovery following renal I/R through positive effects on 
mitochondrial content and function, reduced inflammation and oxidative stress.   
Evaluation of the efficacy of mitochondrial targeted therapies, including stimulators of 
mitochondrial biogenesis, in humans, requires the ability to assess mitochondrial content and 
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function using non-invasive assays.  Current methods of measuring mitochondrial function in 
humans are restricted to invasive tissue assays.  Therefore, we evaluated two new urine 
biomarkers of renal mitochondrial integrity, urinary ATP synthase subunit β and urinary 
mtDNA, in mouse renal I/R injury and in humans following cardiac surgery.   
ATPSβ is a subunit of the ATP synthase located in the inner mitochondrial membrane.  
ATPSβ was found to be elevated in the urine of rats following I/R or glycerol-induced AKI (data 
not shown).  We evaluated urinary ATPSβ levels further using a mouse I/R model.  Varying 
degrees of renal injury were induced in mice by clamping of the renal pedicle for periods of 5, 10 
or 15 min, indicative of mild, moderate or severe renal histological injury (Figure 5.2).  ATPSβ 
was detected in the urine via immunoblot, and revealed 2 prominent bands – a full length band of 
~50 kDa and a cleaved band of ~25 kDa, both of which were elevated after moderate or severe 
I/R, preceding the elevation of traditional biomarkers of renal injury (Figure 5.1).  Elevation of 
urinary ATPSβ was associated with decreases in renal cortical expression of ATPSβ, and the 
complex I protein, COX1 (Figure 5.3).  Furthermore, changes in urinary ATPSβ were associated 
with mitochondrial dysfunction evidenced by reduced renal tubular FCCP-uncoupled OCR and 
renal cortical ATP levels (Figure 5.4).  Measurement of urinary ATPSβ over a time course 
following renal I/R demonstrated continued elevation of both the full length and cleaved 
fragments at 72 h after I/R.  Both recovered to sham control levels by 144 h after I/R mirroring 
the recovery of renal function in these mice (Figure 5.5).  Assessment of urinary ATPSβ in a 
non-kidney injury model, the NASH model of liver injury, revealed that only the cleaved ATPSβ 
fragment was detected in the urine (Figure 5.6).  This data indicates that the cleaved fragment is 
not specific for renal injury, but perhaps the full length fragment is renal specific.  Mitochondrial 
damage in non-renal tissue could result in the systemic release of ATPSβ.  Due to the smaller 
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size of the cleaved fragment, it is likely freely filtered at the glomerulus.  The larger fragment is 
near the size exclusion limit for filtration, and is also relatively highly charged, which would 
limit its ability to be filtered.  The potential specificity of the full length band for renal injury 
highlights its potential as a renal biomarker.  Lastly, urinary ATPSβ was measured in human 
patients following cardiac surgery.  Patients who developed AKI had higher urinary expression 
of the full length ATPSβ, but not the cleaved form (Figure 5.7).  This further suggests that the 
full length form is renal specific as the cleaved form could originate from other tissues injured 
during cardiac surgery including the heart and vasculature.   
mtDNA is released into circulation from mitochondria in response to tissue injury [411].  
Recognition of mtDNA by toll-like receptor 9 (TLR9) leads to activation of inflammatory 
signaling cascades [412].  Thus, mtDNA could serve as an indicator of sterile inflammation 
resulting from tissue injury.  Several studies have examined plasma mtDNA levels following 
multiple pathologies, however, no studies have evaluated urinary mtDNA (UmtDNA) as either a 
marker of systemic or renal-specific injury [281, 413].  We evaluated UmtDNA as a biomarker 
of renal mitochondrial dysfunction and AKI progression/recovery in a mouse model of renal I/R 
and in cardiac surgery patients.  Measurement of UmtDNA levels in patients following cardiac 
surgery demonstrated that UmtDNA was not diagnostic of AKI or AKIN stage (Figure 6.1).  
However, UmtDNA levels were shown to be predictive of AKI progression.  Elevated UmtDNA 
levels were a fair predictor of progressive AKI (increase in AKIN stage following collection) vs. 
stable AKI (no change/reduction in AKIN stage after collection (Figure 6.2).  Furthermore, 
UmtDNA levels were not associated with other biomarkers of renal dysfunction and injury.  No 
correlation was observed with maximum creatinine levels, max % change in creatinine or urinary 
angiontensinogen levels.  Additionally, UmtDNA was also not correlated with cardiac bypass 
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time, days to maximum creatinine or days to discharge (Figure 6.3).  Failure of UmtDNA to act 
as a diagnostic marker of AKI and the lack of correlation with existing biomarkers of renal 
damage and dysfunction suggest that it is a marker of a unique biological process.  Due to the 
role of mitochondria in tissue recovery, perhaps it is serving as a better predictive indicator of 
renal repair and recovery.  Its ability to predict AKI progression further supports this hypothesis.   
In order to further evaluate the biochemical significance of urinary mtDNA we used a 
mouse model of renal I/R with varying degrees of ischemia.  Mice undergoing 10 or 15 min of 
ischemia followed by reperfusion were found to have elevated UmtDNA levels at 24 h after 
injury (Figure 6.4).  Total 18 h output of UmtDNA was found to be significantly correlated with 
time of ischemia, but again failed to correlate with renal function assessed by BUN (Figure 6.5).  
UmtDNA levels were demonstrated to be predictive of AKI development in mice by ROC curve 
analysis (Figure 6.7).  Correction of UmtDNA had no effect on these results (Figure 6.6).  Most 
importantly, UmtDNA levels were found to be negatively correlated with renal mitochondrial 
gene expression and renal mtDNA copy number (Figure 6.8, 6.9).  These data indicate that 
UmtDNA is serving as a biomarker of renal mitochondrial integrity and mitochondrial biogenic 
signaling in the kidney. 
The above described studies demonstrate the importance of mitochondrial function in 
renal repair and recovery.  Disruption of mitochondrial function after AKI can result in 
incomplete repair, fibrotic development and ultimately progression to CKD.  Activation of MB 
may serve as a valuable therapeutic strategy to promote the recovery of mitochondrial content 
and function after AKI.  Induction of cGMP through the use of phosphodiesterase inhibitors or 
guanylyl cyclase activators may be a valuable therapeutic strategy to activate mitochondrial 
biogenic signaling in the setting of AKI.  Furthermore, use of new biomarkers of renal 
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mitochondrial integrity, urinary ATPSβ and urinary mtDNA, will assist in the evaluation of these 
mitochondrial targeted therapies in human patients. 
Unanswered questions  
Mitochondrial function and tissue bioenergetics are increasingly recognized as important 
components of nearly all disease states, thus modulation of tissue mitochondrial content and 
oxidative metabolism has become an attractive target for drug development.  However, there 
remains a significant number of unanswered questions in regards to both safety and efficacy of 
this therapeutic strategy.  For example, could whole body activation of MB have unintended, 
negative consequences, including increased systemic oxidative stress and inflammation?  Will 
MB prior to an injury, surgery or toxic drug treatment, prevent organ dysfunction or increase 
organ dysfunction due to the presence of “more” dysfunctional mitochondria?  Additionally, 
what treatment strategies are required for the persistent enhancement of mitochondrial content 
and function in the setting of acute and chronic disease (i.e., avoidance of receptor 
desensitization or activation of antagonistic pathways)?  Consideration of these critical questions 
will hasten the development of MB compounds and enhance their applicability to human disease.  
Efforts to improve mitochondrial function in various disease states have targeted all 
aspects of mitochondrial homeostasis, including mitochondrial degradation through activation or 
suppression of mitophagy, mitochondrial dynamics through modulation of fission/fusion 
proteins, and mitochondrial synthesis through regulation of MB. Pharmacological modulation of 
any of these processes for therapeutic effect in a diseased organ creates the possibility of 
disruption of mitochondrial homeostasis in off-target tissues.  For example, blocking 
mitochondrial fission protects against MPTP opening and apoptotic cell death in heart [414].  
However, activation of mitofusin 2 (MFN2), a pro-fusion mitochondrial protein, can block 
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proliferation in multiple cell types, including astrocytes and vascular smooth muscle cells [415, 
416].  Loss of cellular proliferation and tissue plasticity could prove problematic in the setting of 
injury due to impairment of angiogenesis and other critical tissue repair processes.     
We can gain some insight into the safety of MB as a therapeutic strategy by examination 
of FDA-approved compounds subsequently identified as effectors of MB or mitochondrial 
function.  There are examples of drugs that have subsequently been shown to affect 
mitochondria, including minocycline, rosiglitazone, cyclosporine A, sildenafil, captopril, 
formoterol, and others [143, 148, 149, 417, 418].  Many of these agents have been demonstrated 
to exert their effect in animal models at least in part through induction of MB in the diseased 
tissue.  For instance, studies suggest that a component of the beneficial effects of captopril, an 
angiotensin converting enzyme inhibitor used extensively in treatment of hypertension and 
congestive heart failure, is through activation of MB in the heart [417].  This provides evidence 
of the chronic administration of a mitochondrial biogenic agent in a patient population with 
significant systemic comorbidites, suggesting the relative safety of MB as a therapeutic strategy. 
Despite significant promise as a therapy for an array of disease states, no specific activators of 
MB currently exist for treatment of a human disease.  A great deal of work remains to develop 
more potent and specific agents for induction of MB, evaluate safety of MB in diverse patient 
populations, and to ultimately optimize dosing strategies for treatment of both acute and chronic 
conditions to maximize efficacy and avoid refractory responses.  
 
Future directions 
Both phosphodiesterase inhibition and guanylyl cyclase activation appear to be promising 
therapeutic strategies for the stimulation of mitochondrial biogenesis in AKI.  Future studies will 
216  
seek to further characterize the mitochondrial biogenic response through the determination of the 
downstream signaling pathways linking cGMP to mitochondrial biogenesis.  This will include 
examination of the activity of cGMP-dependent protein kinase (PKG) and its downstream 
phosphorylation targets, as well as characterization of the effects of cGMP on known regulators 
of MB including AMPK and SIRT1.  Furthermore, in order to validate the role of NO-cGMP in 
the activation of MB and renal recovery, AKI studies could be performed using eNOS, GC 
and/or PKG knockout animals with the goal of demonstrating a clear mechanistic link between 
reduction of renal cGMP and impaired renal recovery.   
Mitochondrial biogenesis is potently and persistently suppressed following AKI; 
however, the mechanisms of its suppression remain unclear.  We believe that the suppression is 
an acute adaptive response to reduce mitochondrial generation in the setting of mitochondrial 
insult, thus limiting the production of ROS by damaged mitochondria.  This adaptive response 
becomes maladaptive in the chronic setting by limiting energy-dependent tissue repair processes.  
To further explore the mechanisms of suppression of mitochondrial biogenesis, we performed 
short term I/R experiments in mice.  Mice underwent 18 min of ischemia followed by 
reperfusion and tissues were collected at 1 and 3 h after I/R.  PGC-1α expression was reduced to 
~30% of sham control levels at 3 h after I/R, but was not changed at 1 h (Figure 7.1).  Expression 
of the mitochondrial transcription factor Tfam was also suppressed at 3 h.   mtDNA copy number 
was decreased to ~50% of sham control levels as early as 3 h (Figure 7.2).  Evaluation of the 
mitochondrial-encoded mitochondrial genes, COX1 and ND1, found that both were suppressed 
at 3 h after I/R (Figure 7.3).  Finally, the nuclear-encoded mitochondrial genes, NDUFβ8, 














Figure 7.1. PGC-1α and Tfam are suppressed 3 h after I/R injury.  mRNA expression was 
assessed by qPCR.  Data are expressed are mean +/- SEM.  * indicates statistical significance at 















Figure 7.2. mtDNA copy number is suppressed at 3 h after I/R.  mtDNA content was 
assessed by qPCR.  Data are expressed are mean +/- SEM.  * indicates statistical significance at 














Figure 7.3. Mitochondrial-encoded mitochondrial genes are suppressed at 3 h after I/R.  
mRNA expression was assessed by qPCR.  Data are expressed are mean +/- SEM.  * indicates 










Figure 7.4. Nuclear-encoded mitochondrial genes are suppressed at 3 h after I/R.  mRNA 
expression was assessed by qPCR.  Data are expressed are mean +/- SEM.  * indicates statistical 









 This data indicates that the suppression of mitochondrial biogenesis is a potent, early 
response after I/R injury.  The signal causing the suppression is also persistent evidenced by 
continued reduction of renal mitochondrial biogenic signaling as late as 144 h after I/R.  This 
rapid and persistent signal suggests that acute and chronic inflammation may be a mediator of 
the response.  Examination of renal TNF-α levels demonstrated a 2.4-fold increase in expression 
by 3 h after I/R (Figure 7.5).  From the BAY 58-2667 studies, TNF-α remains highly elevated in 
renal cortex at 144 h after I/R demonstrating that the signal is persistent.  Previous studies have 
suggested TNF-α as a negative regulator of PGC-1α [280, 419, 420].  Furthermore, TNF-α is 
known to cause suppression of eNOS expression and eNOS-dependent MB [234, 421].   
 In addition to inflammatory signals, microRNAs represent a novel potential regulator of 
mitochondrial biogenesis after AKI.  Following renal I/R, expression of mir-494, a negative 
regulator of Tfam expression inducible by TNF-α, and mir-696, identified as a negative regulator 
of PGC-1α in muscle, were upregulated as early as 1 h after injury (Figure 7.6) [422-424].  These 
microRNAs could be targeted therapeutically using antagomir-based strategies or inhibition of 
microRNA processing.  While upregulation of these microRNAs is an interesting finding, further 
studies are needed to characterize their roles in AKI-induced suppression of MB.  Additionally, 
each is just one in what is likely a larger cascade of mitochondrial-targeted microRNA changes 








Figure 7.5. Renal cortical TNF-α is upregulated at 3 h after I/R.  mRNA expression was 
assessed by qPCR.  Data are expressed are mean +/- SEM.  * indicates statistical significance at 














Figure 7.6. Renal mir-494 and mir-696 are upregulated after I/R.  microRNA expression was 
assessed by qPCR.  Data are expressed are mean +/- SEM.  * indicates statistical significance at 



















 Results with urinary ATP synthase β and urinary mtDNA demonstrated each as 
promising biomarkers of renal mitochondrial dysfunction in AKI.  Further validation studies are 
needed for each including evaluation in larger patient populations with varying degrees and 
etiologies of renal injury.  For urinary ATPSβ, the goal is to develop an ELISA or luminex-based 
assay for rapid and sensitive detection for use in point-of-care settings.  Our results demonstrated 
that the full length form of ATPSβ appeared specific for renal mitochondrial disruption.  While 
this result requires further validation, assay development will require identification of antibodies 
that can specifically detect the full length vs. the cleaved fragment of ATPSβ.  We have begun 
procedures to develop new antibodies for ATPSβ with the goal of increasing sensitivity and 
specificity vs. commercially available antibodies.  A sampling of the immunoblot results from 
antibodies produced against the ATPSβ recombinant protein in mice are shown below (Figure 
7.7).  The left lane in each blot is a sham control urine, while the right lane is urine from mouse 











Figure 7.7. Sample of new ATPSβ antibody clone immunoblot results.  Each blot represents a 














 Urinary mtDNA was shown to be predictive marker of AKI progression that was 
correlated with suppression of renal mitochondrial biogenic signaling.  As mtDNA is released in 
response to mitochondrial injury, perhaps it serves as signal to resident cells to suppress 
mitochondrial biogenesis.  Thus, mtDNA could serve as a biostatic mechanism signaling to other 
cells to limit mitochondrial production to reduce further oxidative cellular damage.  To evaluate 
this hypothesis, we first sought to determine if mtDNA is released in response to oxidant injury.  
Treatment of TKPTS cells with H2O2 demonstrated a dose-dependent release of mtDNA into the 
tissue culture medium, which was associated with reduction in cellular mtDNA content and 
PGC-1α mRNA expression (Figure 7.8).  Once released from a damaged cell, mtDNA can signal 
to other cells by binding and activating TLR9.  To determine if TLR9 activation is involved in 
suppression of MB, we treated TKPTS cells with the TLR9 ligands, ODN1585, ODN1826 and 
ODN2395, and exogenous mtDNA (Figure 7.9).  Activation of TLR9 by ODN1826 and 
ODN2395 caused a dose-dependent decrease in expression of ND1, NDUFβ8 and PGC-1α.  
ODN1585 and exogenous mtDNA isolated from mouse kidney reduced ND1 expression, but had 
no effect on expression of the other two genes.  Further evaluation of these effects are needed at 
different times and doses, as well as assessment of the requirement for fragmentation or 








Figure 7.8.  mtDNA is released after oxidant injury and is associated with suppression of 
cellular mtDNA content and PGC-1α expression.  TKPTS cells were treated with increasing 
doses of H2O2 for 24 h.  mtDNA and nDNA were assessed in tissue culture media by qPCR.  




Figure 7.9. Effect of TLR9 agonists on mitochondrial gene expression in TKPTS cells.  
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